Ultrafast Microfluidic Immunoassays Towards Real-time Intervention of Cytokine Storms by Song, Yujing





A dissertation submitted in partial fulfillment 
 of the requirements for the degree of  
Doctor of Philosophy  
(Mechanical Engineering) 




Professor Katsuo Kurabayashi, Chair  
Professor Jianping Fu  
Assistant Professor Yongqing Li 
Assistant Professor Benjamin H. Singer 



































Writing a Ph.D. thesis is truly a gratitude time for me to sincerely thank all the support and 
people around me in the past six years which probably one of the best periods in my life, during 
which I won four tennis trophies, ran two full marathons within 3h30m, and was selected as 
Precision Health Scholar at U-M. First of all, I want to express my greatest appreciation to my 
advisor and life-long mentor, Prof. Katsuo Kurabayashi for his guidance and support during my 
entire graduate school time. In Dr. Kurabayashi’s lab, I got a chance to have amazing 
collaborations with clinical doctors and researchers and was able to apply my engineering research 
to the “Front Line” of saving patients’ lives during the global pandemic period COVID-19 which 
I can never imagine to have in other places. I was deeply influenced by Dr. Kurabayashi’s strong 
emphasis on encouraging free discoveries in the lab, respecting student’s ideas, and cultivating the 
student’s leadership to drive their projects. I enjoyed my time in his office when we brainstormed 
research ideas for the next step or future proposals on his whiteboard. In addition, I would like to 
thank all my committee members: Profs. Muneesh Tewari, Jianping Fu, Benjamin H. Singer, and 
Yongqing Li for all the valuable discussions and inputs for my research. A phone call with Dr. 
Singer every day during the COVID-19 period to discuss the patient’s data and conditions is one 
of the most memorable times for me. I would like to thank all my clinical collaborators: Profs. 
Sung Won Choi, Monalisa Ghosh, David Frame, Lenar Yessayan, David Humes, Drs. Scott 
Denstaedt, Erin Sandford, Yuzi Tian, Christopher Flora.  
Secondly, I would like to express my strong gratitude to my exceptional lab mates and 
fellow-students for their great guidance and support. These people are: Drs. Pengyu Chen, Meng-
 iii 
Ting Chung, who are both my mentors for overall research; Dr. Robert Nidetz, who is my mentor 
for the cleanroom fabrication; Drs. Young Geun Park, Bo-Ram Oh, Byunghoon Ryu, Mengxi Wu, 
Andrew Kozminski; Ms. Christina Rice; Mr. Brian Berger, Andrew Stephens, Nicolas Mesyngier. 
Lastly, many thanks to Mr. Keisuke Goto, Qingtian Yin, Shiuan-Haur Su, and outstanding 
undergraduate students: Zelin Linghu, Zhenhui Liu, Jingyang Zhao, Tao Cai, Yuxuan Ye who 
spent days and nights with me in the lab to make our device work! 
Thirdly, I would like to thank all the friends around me, amazing undergraduate students 
in the heat transfer class that I was GSI for, and those tennis leagues that I played for: USTA, 
KOTEF, Overseas Chinese tennis clubs in Ann Arbor and Novi. I strongly believe tennis and 
research are the “game changers” of my life. Without them, Ann Arbor would just be a long cold 
winter place in my memory. I also feel thankful for my funding resources like U-M Precision 
Health, Cancer Research Institute, NSF, and NIH. 
Finally, it is time for me to express my deepest love and thank to my parents Baomin Song, 
Jing Lyu, and my girlfriend/fiancee Tianying Lan. Their unconditional support is my greatest 
motivation to pursue a Ph.D. degree and make up my mind being on the frontline to fight against 
COVID-19 pandemic. My mom, Jing, who used to be the frontline head nurse back in 2003 for 
SARS patients in Beijing, is the role model that I am truly proud of. She provided me with valuable 
knowledge and experience on personal protection in handling COVID-19 patient samples. She, 
together with Dr. Min-Sheng Su (my labmate Shiuan-Haur’s dad) shipped us crucial protection 
gears overseas. My girlfriend Tianying, my life-long soulmate, who accompanies me with love, 
understanding, and patience, is my strongest support to face any obstacles in my life.    








Table of Contents 
 
Acknowledgements ii 
List of Figures ix 
List of Tables xix 
List of Appendices xx 
Abstract xxi 
 
Chapter 1. Introduction 1 
1.1 Introduction and Research Background                1 
 1.1.1 Cytokines: Key Clinical Targets                                                                              1 
 1.1.2 Current Challenges to Precision Medicine in Critical Care of Acute Illness          3 
 1.1.3 Rapid, Sensitive, Accurate Biomarker Analysis             5 
1.2 Motivation and Objectives                 6 
1.3 Scopes of the Thesis                  9 
1.4 Thesis Outline                  12 
Chapter 2. Literature Review 15 
2.1 ELISA Immunoassay Technology               15 
2.2 Microfluidic Cytokine Immunoassay Devices             17 
2.3 Single-Molecule Digital Counting Assays              20 
2.4 Label-Free Plasmonic Biosensors               22 
 v 
Chapter 3. Rapid Single-molecule Digital Detection of Protein Biomarkers for Near-real-
time Monitoring of Systemic Immune Disorders 28 
3.1 Introduction to the Study                28 
3.2 Materials and Methods                30 
 3.2.1 Materials                 30 
 3.2.2 Finite Element Analysis of Transient Digital Assay            31 
 3.2.3 Definition of the Pre-equilibrium State             32 
 3.2.4 Device Fabrication and Assembly              34 
 3.2.5 Antibody Conjugation to Magnetic Beads             35 
 3.2.6 Mouse CLP Preparation and Sample Collection            36 
 3.2.7 Patient Blood Sample Collection and Preparation            36 
 3.2.8 PEdELISA Assay                37 
 3.2.9 Data Analysis and Image Processing              38 
 3.2.10 Statistics                 42 
3.3 Results                  42 
 3.3.1 Design of PEdELISA platform              42 
 3.3.2 Theoretical study of “quench-and-snapshot” measurement           46 
 3.3.3 Analytical validation of the assay              51 
 3.3.4 Longitudinal biomarker profile measurement for septic mice          56 
 3.3.5 Near-real-time monitoring of post-CAR-T cell infusion CRS          58 
3.4 Discussion                  61 
Chapter 4. Machine Learning-Based Cytokine Microarray Digital Immunoassay Analysis
 65 
 vi 
4.1 Introduction to the Study                65 
4.2 Materials and Methods                68 
 4.2.1 Materials                 68 
 4.2.2 Antibody Conjugation to Magnetic Beads             68 
 4.2.3 Microfluidic Chip Fabrication and Spatial-Spectral Encoding          69 
 4.2.4 Patient Blood Sample Collection and Preparation            71 
 4.2.5 14-plex PEdELISA assay               71 
 4.2.6 Training of the Dual-pathway Convolutional Neural Network          73 
 4.2.7 Statistics                 75 
4.3 Results and Discussion                75 
 4.3.1 Multiplexed Digital Immunoassay with CNN Image Processing          75 
 4.3.2 PEdELISA Microarray Platform Performance            79 
 4.3.3 Multiplex Pre-equilibrium Cytokine Detection            85 
Chapter 5. A Digital Protein Microarray for COVID-19 Cytokine Storm Monitoring 92 
5.1 Introduction to the Study                92 
5.2 Materials and Methods                94 
 5.2.1 Materials                 94 
 5.2.2 Antibody Conjugation to Magnetic Beads             95 
 5.2.3 PEdELISA Cartridge Fabrication and Patterning            95 
 5.2.4 Design of programmed fluidic handling and low-cost optical scanning modules 97 
 5.2.5 Control and characterization of 2D optical scanning module          99 
 5.2.6 Programmed PEdELISA Assay and Imaging           100 
 5.2.7 Pragmatic study of rapid cytokine measurement in COVID-19        101 
 vii 
 5.2.8 Statistics               102 
5.3 Results and Discussion              102 
Chapter 6. AC Electroosmosis-enhanced Nano-plasmofluidic Detection of Ultra-low-
Concentration Cytokine                                                                                                            111 
6.1 Introduction to the Study              111 
6.2 Materials and Methods              114 
 6.2.1 Materials               114 
 6.2.2 Device Layout and Fabrication            115 
 6.2.3 Experimental Setup and ACE-LSPR Imaging Technique         118 
 6.2.4 Modeling of Electrical Double Layer            119 
 6.2.5 ACEO Flow Visualization and Particle Image Velocimetry Analysis       121 
 6.2.6 ELISA Correlation Test             123 
 6.2.7 T-Test for 5min Initial Slope Analysis           124 
6.3 Results and Discussion              125 
 6.3.1 Theoretical Study of ACE-LSPR            125 
 6.3.2 Experimental Validation of ACE-LSPR           130 
 6.3.3 Clinical Demonstration of ACE-LSPR           134 
Chapter 7. Conclusions and Future Work 137 
7.1 Thesis Summary               137 
 7.1.1 Rapid Single-molecule Digital Detection of Protein Biomarkers for Near-real- 
  time Monitoring of Systemic Immune Disorders          138 
 7.1.2 Machine Learning-Based Cytokine Microarray Digital Immunoassay Analysis 
                  139 
 viii 
 7.1.3 A Digital Protein Microarray for COVID-19 Cytokine Storm Monitoring       141 
 7.1.4 AC Electroosmosis-enhanced Nano-plasmofluidic Detection of Ultra-low-  
  Concentration Cytokine             142 
7.2 Future Work                143 
 7.2.1 System Automation and Platform Translation          144 




List of Figures 
 
Figure 1.1 (A) Dynamic immune cellular response under pathogen attacks into immune system. 
http://jama.jamanetwork.com/article.aspx?articleid=2279715. (B) A complex cytokine 
communicating network while addressing inflammatory response. www.genecopoeia.com, Data 
Source: KEGG, BioCarta               -p.2 
 
Figure 1.2 Concept of personalized immunomodulatory therapy for systemic inflammatory disease 
enabled by rapid cytokine-based immune status monitoring. This concept is analogous to 
feedback-loop system control theory used in system engineering that controls the behavior of a 
dynamical system with an input.           -p.10 
 
Figure 1.3 Principle of nanoparticle/nanostructure based localized surface plasmon resonance.  
               -p.11 
 
Figure 2.1 Blood barcode chip for microfluidic ELISA assay that involves (A) plasma separation 
from a finger prick of blood and (B) sandwich immunoassay of plasma proteins on DNA-coded 
barcode arrays in a microfluidic channel. Adopted from Fan et al.       -p.18 
 
Figure 2.2 Image of the portable diagnostic system consisting of a microfluidic control system 
(box on the left), a fluoresce USB microscope , a dELISA microfluidic chip (center), and a laptop 
computer (rignt).Adopted from Piraino et al.          -p.21 
 
Figure 2.3 Integrated micro droplet dELISA platform. (A) Schematic of the assay chip (top and 
bottom views) (B) Photograph of the disposable assay chip. (C) Droplet generator encapsulating 
microbeads. (D) Fluorescence micrograph of the droplets. (E) Schematic of the platform with a 
mobile phone, three light sources, and the disposable chip. Adopted from Yelleswarapu et al.  
                  -p.22 
 
Figure 2.4 (A)-(B) SPR sensing introducing gold nanoparticles to enhance the SPR signal to 
increase sensitivity (C) Modified characteristics of metal thin film layer to improve SPR sensing 
capability.               -p.25 
 
Figure 2.5 (A) A single silver nanoparticle-based nanoplasmonic biosensor for immunoassay 
detection. (B) Fiber-optics based rapid, sensitive LSPR biosensing platform.          -p.26 
  
Figure 3.1 Schematic concept of instantaneous single-molecule binary counting of pre-equilibrium 
protein binding events. The combination of pre-equilibrium reaction quenching with single 
molecular counting can theoretically achieve an assay with a near-zero incubation time without 
losing linearity.              -p.29 
 x 
Figure 3.2 Theoretical binding kinetics of bead surface adsorption process. The pre-equilibrium 
state is determined by the time constant τ based on the Langmuir model.        -p.33 
 
Figure 3.3 Dual-plex PEdELISA assay encoded using (a) 2.8 µm-diameter superparamagnetic 
beads first dyed with Alexa Fluor (AF) 488 and then conjugated with capture antibodies against 
TNF-α or MCP-1 and (b) 2.8 µm-diameter non-color superparamagnetic beads conjugated with 
capture antibodies against IL-6 or Il-2. Image of arrayed microwells in (c) bright field, (d) AF 488 
channel, (e) QuantaRed (Qred) channel, and (f) three-channel (bright field + AF 488 + Qred) 
overlay modes . (g) MATLAB code-processed bright field image to determine the overall bead 
filling rate with filled (+) and empty (–) wells. (h) Sorted microwell intensity histogram. (i) Bead 
and microwell counting across 100 arrays of microwells. (j) MATLAB code-processed two-
channel (AF 488 + Qred) overlay image for dual-color digital counting (dark green square: AF488-
dyed bead, blue circle: non-color bead with Qred emission, light green diamond: AF488-dyed bead 
with Qred emission). Snapshot of Qred image showing enzyme active Qred "On" microwell spots 
with the presence of bead-bound analyte molecules (e.g., TNF-α and IL-2) at (k) 100 pg/mL, (i) 
20 pg/mL, and (m) 4 pg/mL.                -p.39 
 
Figure 3.4 (A) Two-step ultrafast, dual-plex PEdELISA process for pre-equilibrated assay system, 
including short (15–300sec) two-color magnetic bead incubation for the formation of antibody-
antigen-antibody immune-complexes (Step 1), buffer exchange, quick (30sec) avidin-HRP 
labeling (Step 2), and 6-repeated rinsing within 96-well low-retention tubes. (B) Digitization 
process that involves trapping of magnetic beads into on-chip microwell arrays, loading of HRP 
fluorescence substrate (QuantaRed), and sealing of beads with fluorocarbon oil. Digital signal 
readout by automated image scanning and counting of fluorescently activated “On”-state 
microwells. The two-layer (microwell layer, micro-chamber layer) PDMS-based microfluidic 
detection chip which contains a total of 5.376 million d=3.8 µm microwells can handle 16 samples 
per scanning. CapAb: capture antibody. DeAb: detection antibody.                -p.43 
 
Figure 3.5 Finite element analysis of biomolecular interactions in the 2-step PEdELISA process. 
(A) Schematic of the theoretical sphere, namely the “reaction volume,” used for modeling work, 
whose quantity is equal to the total sample volume divided by the number of beads. Reagent mass 
transport and binding kinetics are considered at the surface of a single magnetic bead placed in its 
center for half of the geometry due to symmetry. (B) Step1: immune-complex formation process 
involving the conjugation between target antigen molecules, capture antibodies immobilized on 
the bead surface, and detection antibodies freely floating in the reaction volume. (C) Step 2: avidin-
HRP labeling process involving the conjugation of avidin-HRP with the biotinylated detection 
antibodies. The average number of targets (i.e., capture antibody-antigen-detection antibody 
immune-complexes) formed per bead, λ, is calculated as a function of the Step 1 incubation time 
and the analyte concentration at (D) Kd = 10
-10 M and (E) Kd = 10
-9 M. The model predicts that the 
PEdELISA readout linearly increases with the analyte concentration when λ is small (< 0.1). By 
accounting for the experimentally obtained noise floor, the LOD value can be theoretically 
determined for a given value of the Step 1 incubation time. (F) Predicted kinetics of the second 
step of the PEdELISA process. The fraction of the formation of HRP enzyme-labeled antibody-
antigen-antibody immune-complexes is presented for three representative HRP concentrations of 
1 pM, 10 pM, and 100 pM.            -p.47 
 xi 
Figure 3.6 Impact of detection antibody (DeAb) concentration, number of magnetic beads per 
sample, capture antibody binding site density (Bd), and mass transport on immune complex 
formation kinetics of PEdELISA assay. Here the assay signal output is determined by the average 
number of targets (capture antibody-antigen-detection antibody immune-complexes) formed per 
bead as a function of the Step 1 incubation time for different antibody-to-antigen on-rate 
association constant values: (b) kon = 10
4 M-1s-1, (c) kon = 10
5 M-1s-1, (d) kon = 10
6 M-1s-1, and (e) 
kon = 10
7 M-1s-1.              -p.50 
 
Figure 3.7 PEdELISA assay medium tests for 1x ELISA buffer, 10%, 25%, and 50% fetal bovine 
serum (FBS) spiked with 100 pg/mL of (A) IL-6, (B) TNF-α, (C) MCP-1, and (D) IL-2. All the 
tests were performed with the total assay incubation time of 5min+30s. (E) Signal-to-noise ratio 
(SNR) of IL-6, TNF-α, MCP-1, and IL-2 measurements in different media. The SNR value 
represents the ratio of the spike-in signal to the background (negative control) signal. The serum 
was diluted using the 1x ELISA buffer to prepare the 10%, 25%, and 50% serum media. In general, 
a larger surface blocking effect, perhaps, owing to the presence of albumin, was observed for serum 
media, which resulted in a slightly lower spike-in signal and background noise compared to the 
ELISA buffer. However, there is no significant difference in the SNR value between the different 
media groups (P>0.05 n=5-8, one-way ANOVA).              -p.52 
 
Figure 3.8 Characterization and optimization of PEdELISA assay. PEdELISA standard curves for 
the four cytokines: (A) IL-6, (B) MCP-1, (C) TNF-α and (D) IL-2, with the Step 1 incubation time 
varying from 60 sec to 300 sec and the Step 2 incubation time fixed at 30 sec. Due to the extreme 
under-labeled nature of the assay, the 15-sec and 30-sec assays were performed by merging the 
Step 1 and Step 2 process into a single step by mixing all required reagents. The LOD was 
determined by concentration from the reagent blank’s signal + 3σ (dotted line).         -p.53 
 
Figure 3.9 Correlation between PEdELISA and conventional sandwich ELISA tests for the four 
cytokines using spike-in recombinant proteins in 25% fetal bovine serum: (A) 15-sec PEdELISA 
incubation time (R2=0.92), (B) 300-sec PEdELISA incubation time (R2=0.97). The ground truth 
is plotted in dotted line with scattered pre-determined spike-in concentrations.         -p.54 
 
Figure 3.10 Theoretical (line) and experimental (scatter) LOD of PEdELISA as a function of the 
Step 1 incubation time for four cytokines.           -p.55 
 
Figure 3.11 Dual-plex PEdELISA specificity determined for combinations of (a) IL-6 and MCP-
1 (b) TNF and IL-2 with a 5-min incubation process. Only one type of cytokine was spiked-in into 
each medium and signals were measured for both probes in the dual-plex PEdELISA assay. 
Considering the relatively weak antibody-antigen affinity of MCP-1, the spike-in concentration of 
MCP-1 was set to be 5 times higher than those of the other three cytokines.        -p.55 
 
Figure 3.12 Fine-time monitoring of CitH3 on living mice (M1-4) with cecal ligation puncture 
(CLP). (A) CLP and mouse blood collection procedures. To induce different septic shock severity, 
the cecum was punctured and ligated at 100%, 75% and 50% of its total length. Around 15 µL of 
tail blood was collected at 0, 1, 5, 10, 15, 20 hr time points until the mouse’s death. (B) Correlation 
between PEdELISA and conventional sandwich ELISA for the CitH3 assay using a 10% sham 
 xii 
mouse serum spiked with recombinant peptide (C) longitudinal CitH3 profiles of the four mice: 
100%, 75%, 50% ligation, and sham over their lifetimes.         -p.57 
 
Figure 3.13 Near-real-time molecular monitoring of multi-cytokines of hematological cancer 
patients under CAR-T cell therapy. (A) Timeline of the hematological cancer patients received 
CAR-T cell therapy. Daily blood draw in general started five days before the infusion for baseline 
collection until the patient was discharged. For the real-time monitoring, the sample was first 
processed within 45 min of blood draw to extract serum and then tested by the PEdELISA within 
an hour. The data typically became available for clinicians within 2-3 hours from the initial point 
of patient blood collection. The initial onset of CRS and the development of neurotoxicity of three 
patients were labeled along the timeline. (B) Good agreement (R2=0.96) between 300-sec 
PEdELISA and ELISA was found for measurements of selected unknown CAR-T patient samples 
at different time points for four cytokines. Time-series profiles of CRS and CRES grade, IL-6, 
MCP-1, TNF-α, and IL-2 for (C) Patient A (grade 4 severe CRS), (D) Patient B (grade 2 mild 
CRS) and (E) Patient C (grade 0-1 very mild-CRS). Day 0 represents the day of CAR-T cell 
infusion. Data before Day 0 represents the baseline. The dotted line represents the time point when 
anti-cytokine drug tocilizumab (Anti-IL-6R), infliximab (Anti-TNF-α) were administered. The 
shaded region marks the period that the patient was received dexamethasone (corticosteroid).  
These data do not account for a time lag of a few hours (or occasionally 8-12 hours) between the 
points of CRS grade recording and blood draw.          -p.59 
 
Figure 3.14 Group comparison (non-CRS vs CRS) of the three CAR-T cell therapy patients for 
(A) IL-6, (B) MCP-1, (C) TNF-α, and (D) IL-2. The statistical analysis between the two data 
groups was performed by one-way ANOVA comparing means with the Tukey test. IL-6 
(P<0.001), MCP-1 (P<0.001) and IL-2 (P=0.0059) levels were significantly higher in CRS 
condition than in non-CRS condition. TNF- α level was not significant (P=0.142). Note that the 
data include those obtained at the time points when CRS-suffering patients were put on steroids or 
immunosuppressive agents (tocilizumab, infliximab).         -p.61 
 
Figure 4.1 Multiplexing the digital immunoassay by constructing a PEdELISA microarray chip 
based on the concept of microfluidic spatial-spectral encoding: (A) Trapping beads into microwells 
of the arrayed biosensing patterns on the multi-array biosensor layer. Mixtures of fluorescently 
encoded beads of Ncolor colors are loaded to the microfluidic channels on the bead settling layer. 
(B) Peeling off the bead settling layer from the multi-array biosensor layer, and attaching the 
sample loading layer on the multi-array biosensor layer. The 90º orientation of the sample loading 
channels permits each channel to contain an array of biosensing patters of Narray types. Loading 
serum samples to the channels of the sample detection layer with pipettes. The chip arrangement 
yields a total of Ncolor×Narray plex for the analysis of each sample.        -p.70 
 
Figure 4.2 Training process of the dual-pathway convolutional neural network (CNN) with 
semantic segmentation. (A) The data library was carefully pre-selected based on 3000 
representative images (32×32 pixels) to pre-train the CNN. The images were first labeled based 
on global thresholding and segmentation (GTS) and then manually modified based on human 
supervision. (B) The pre-trained CNN was then used to label a new data library which contains 
around 200 larger images (256×256 pixels) to further improve the feature extraction and 
classification accuracy.            -p.74 
 xiii 
Figure 4.3 Concept of CNN processed PEdELISA microarray analysis. Microfluidic spatial-
spectral encoding method used for multiplexing digital immunoassay. Fluorescence color-encoded 
magnetic beads coated with different capture antibodies are pre-deposited into the array of 
hexagonal-shaped biosensing patterns in the microfluidic detection channel. The locations of the 
biosensing patterns are physically separated from each other. This arrangement yields Ncolor×Narray 
measurement combinations determining the assay plexity, Nplex, where Ncolor is the total number 
of colors used for encoding beads deposited in each biosensing pattern, and Narray is the total 
number of the arrayed biosensing patterns in each detection channel. In this study, Ncolor=2 (non-
fluorescent and Alexa Fluor® 488: AF488) and Narray=8.        -p.77 
 
Figure 4.4 A convolutional neural network-guided image processing algorithm for high throughput 
and accurate single molecule counting. Two neural networks were run in parallel, reading multi-
color fluorescence image data, recognizing target features versus defects, and generating an output 
mask for post data processing. The brightfield image was analyzed using a Sobel edge detection 
algorithm. The images were finally overlaid to determine the fraction of enzyme active beads 
emitting QuantaRedTM signal (Qred+ beads) to total beads for each color label. The unlabeled scale 
bars are 25 μm.              -p.79 
 
Figure 4.5 Fraction of AF-488 encoded beads invading the channel to be loaded with non-color 
coded beads before and after the bead flushing test assay (P=0.550). On average, only 0.087% of 
the trapped beads were misplaced in the channel for the both cases. The result was obtained from 
the fluorescence images of 160 independent microwell sites. The harsh assay conditions with a 
washing buffer flow rate of 40uL/min and a duration of 15 min caused negligible physical crosstalk 
between the beads.               -p.80 
 
Figure 4.6 Algorithm comparison between the global thresholding segmentation (GTS) and the 
convolutional neural network (CNN). In GTS, an optimized global threshold value is 
predetermined based on the intensity histogram of the image to be processed (shown by the black 
dash line). The CNN method does not require the predetermination of the threshold value.    -p.82 
  
Figure 4.7 Image processing by convolutional neural network (CNN) and global thresholding and 
segmentation (GTS) methods (A) representative images causing false signal counting (red dot: 
Qred+ microwell, green dot: AF-488-colored bead, yellow dot: recognized spot to be counted). (i) 
The circle represents an area covered by an aqueous reagent solution that is spread over multiple 
microwell sites due to poor confinement during the oil sealing process. GTS counts potentially 
false and unreliable signal spots from the area. CNN removes the area from counting. (ii) Image 
defocusing causes GTS to merge two signal spots from a pair of the neighboring Qred+ microwells 
in the circle and to count it as a single signal spot. (iii) Secondary illumination of microwell sites 
due to optical crosstalk in the circle results in their false counting by GTS. (iv) GTS fails to label 
and count microwell sites holding dim AF-488-colored beads.  Error analysis of CNN and GTS 
methods on (B) Qred-channel (C) AF488-channel and (D) brightfield images. (E) Tests assessing 
the impact of optical crosstalk on the accuracy of CNN and GTS using dual-color IL-1α and IL-
1β detection by spiking (i) IL-1α:1ng/mL IL-1β:1ng/mL (ii) IL-1α:1ng/mL IL-1β:1pg/mL (iii) IL-
1α:1pg/mL IL-1β:1ng/mL (iv) IL-1α:1pg/mL IL-1β:1pg/mL (v) IL-1α:1pg/mL IL-1β:1pg/mL 
assay in single plex for validation. All assays were performed in fetal bovine serum buffer.    -p.83 
 xiv 
Figure 4.8 Arrangement of a panel of 14 cytokine detection for CAR-T cytokine release syndrome 
detection test. The two cytokines labeled with the black and green fonts on each row were detected 
in the sample detection channels (1, 2, 3, and 4) vertical to the row using non-color (black) and 
AF-488 (green) encoded beads, respectively.          -p.86 
  
Figure 4.9 PEdELISA microarray analysis. (A) Assay standard curves for 14 cytokines from 
0.16pg/mL to 2500pg/mL in fetal bovine serum (FBS). Three independent tests with two on-chip 
repeats were performed using recombiant proteins (error bar = standard deviation: σ). (B) Assay 
specificity test with FBS “all-spike-in,” “single-spike-in,” and “no-spike-in” (negative) samples. 
The analyte concentration of 500pg/mL used for spiking FBS is the optimal value to assess both 
false positive and negative signals. The limit of detection (LOD), limit of quantification (LOQ), 
and standard root mean square coefficient of variance (RMS CV) of each cytokine were cacluated 
from these data and summarized in Table 4.1.          -p.87 
 
Figure 4.10 14-plex cytokine measurements in longitudinal serum samples from CAR-T patients 
who were diagnosed (A) grade 1-2 CRS (B) no CRS. Day 0 represents the day of CAR-T cell 
infusion. Data before Day 0 represents the baseline. The shaded region marks the period that the 
patient was diagnosed with grade 1-2 CRS. For better visualization, the data was organized and 
separately plotted based on the cytokine level from high to low.        -p.90 
 
Figure 5.1 Fabrication of the disposable PEdELISA microfluidic cartridge. The cartridge contains 
two PMMA layers top (venting) and bottom layer (substrate), a thin PDMS layer (200 µm) which 
contains fL-sized microwell arrays for digital assay, and a PET thin film (120 µm) with 
microfluidic channels fabricated by laser cutting.          -p.96 
 
Figure 5.2 PEdELISA assay platform comprising two modules: (A) programmed fluidic handling 
module with Arduino controlled linear rail and multi-channel pipettes. (B) Customized low-cost 
2-axis fluorescence scanning module with a consumer-grade CMOS camera.      -p.99 
 
Figure 5.3 (A) User-interface of the Universal Gcode Sender for automated PEdELISA assay 
image scanning (B) Characterization of the bi-directional motion control accuracy by repetitively 
scanning and imaging the designated microarray on the cartridge. Less than 5 µm bidirectional 
repeatability was achieved.             -p.99 
 
Figure 5.4 PEdELISA microarray assay platform for COVID-19 patient cytokine storm profiling. 
(A) Schematic and photo image of the assay system in a biosafety cabinet. The platform comprises 
a cartridge holding a disposable microfluidic chip (inset), an automated fluidic dispensing and 
mixing module, and a 2D inverted fluorescence scanning module. (B) The 4-step assay procedure 
includes (i) automated injection and subsequent on-chip mixing of serum and a detection antibody 
solution with capture antibody-coated magnetic beads pre-deposited in microwell arrays, which is 
accompanied by a short incubation (8-min) and followed by washing (2-min), (ii) HRP enzyme 
labeling (1-min), followed by washing (5-min), (iii) fluorescence substrate loading and oil sealing 
(2-min), and (iv) x-y optical scanning and imaging (12-min). (C) Data analysis using a 
convolutional neural network-guided image processing algorithm for high throughput and accurate 
single-molecule counting that corrects image defects and accounts for signal intensity variations. 
Both the fluorescence substrate channel (Qred CH) and brightfield channel (BF CH) are analyzed 
 xv 
to calculate the average number of immune-complexes formed on each bead surface. The 
unlabeled scale bars are 25 μm.          -p.104 
 
Figure 5.5 PEdELISA assay characterization. (A) Assay specificity test with “all-spike-in,” 
“single-spike-in,” and “no-spike-in” (negative) of recombinant cytokine standard at 200 pg/mL in 
fetal bovine serum (FBS) buffer. (B) Daily COVID-19 patient assay standard curves for four 
cytokines from 0.32 pg/mL to 1000 pg/mL in FBS (10 curves for each cytokine obtained over 10 
workdays). The data points were fitted with four-parameter logistic (4PL) curves. The black dotted 
line represents the signal level from a blank solution. The blue dotted line shows 3σ above the 
blank signal, which is used to estimate the limit of detection (LOD) for each cytokine. (C) Linear 
correlation (R2=0.99, P<0.0001) between rapid measurements of fresh samples and retrospective 
measurements of stored samples (1 freeze-and-thaw at -80 °C) in quadruplicate for 5 representative 
COVID-19 patients. (D) Good agreement (R2=0.95, P<0.0001) observed between single-plex IL-
6 ELISA and multiplex PEdELISA measurements for 16 COVID-19 patients. The inset shows the 
circled region.            -p.105 
 
Figure 5.6 (A) Timeline of daily near-real-time COVID-19 cytokine measurement. (B) Statistical 
group analysis of patients that are dosed/undosed with Tocilizumab. Significant elevations of IL-
6 levels were observed after the treatment of Tocilizumab (P<0.0001). (C)-(D) Correlation of 
cytokine IL-6 to Ferritin and C-Reactive Protein (CRP), standard clinical inflammatory 
biomarkers. Ferritin does not correlate well with IL-6 (R2 = 0.01, P=0.71). CRP correlates with 
IL-6 (R2 =0.41, P=0.018) better, but the IL-6 levels were widely distributed for patients with high 
levels of CRP.            -p.109 
 
Figure 6.1 (A) Schematic and principle of AC electroosmosis-enhanced localized surface plasmon 
resonance (ACE-LSPR) biofunctional nanoparticle imaging. Pt microelectrodes were first 
patterned on a glass substrate by photolithography and metal lift-off. AuNRs were then deposited 
to form line-shaped sensor pattern between the microelectrodes using a microfluidic patterning 
technique. With 180 out-of-phase AC bias applied to the Pt electrodes, the electrical double layer 
horizontally moves along the electrode surfaces.  The electrical double layer movement generates 
a hydrodynamic rotational flow within the microfluidic channel.  The hydrodynamic flow 
facilitates the transport of the target biomolecules down to the sensing surface and their surface 
binding reaction. (B)-(C) Close views of the analyte-receptor interactions with/without ACEO. A 
large depletion zone is formed and slows down the surface reaction under diffusion-limited 
operation. (D) The binding results in an increase of scattering cross-section and a red shift of the 
plasmon resonance which is converted into the scattering intensity increase by a band-pass filter 
(680/13 nm, shown by the shade). (E) Darkfield image of AuNR line-shaped patterns (shown in 
red) and microelectrodes (black strips in the middle) with a microfluidic flow channel 
perpendicular to them (400 μm, orange dotted line). (F) SEM image showing the zoomed-in view 
of the isolated AuNRs patterned on the glass substrate between the microelectrodes. The size of 
the AuNRs was measured to be ~40 nm in diameter and ~84 nm in length. After the assay, the 
formation of a dense dielectric layer surrounding each AuNR was observed, suggesting the binding 
of antibodies and analytes onto the sensor surface (Inset).       -p.114 
 
Figure 6.2 ACE-LSPR optofluidic device layout. (a) Photo image of the ACE-LSPR optofluidic 
device chip. The scale bar is 1 cm.  (b) Device layout showing the design incorporating three 
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parallel meandering AuNR patterns (yellow) and six parallel sample loading/detection channels 
made of PDMS (blue). Inset: 10x darkfield image of the sensing spot formed at the intersection 
between the AuNR lines and the PDMS channels. Ref: ACEO-Decoupled LSPR Biosensor. -p.115 
 
Figure 6.3 Schematic of the device fabrication process which includes: (A) Pt/Cr microelectrode 
patterning by sputtering and liftoff processes; (B) AuNRs deposition by O2 plasma treatment, 
microfluidic patterning, and thermal annealing; (C) Bioconjugation of AuNR sensor sites with 
anti-IL-1β with EDC/sulfo-NHS linking using 16-Mercaptohexadecanoic acid.               -p.116 
 
Figure 6.4 (A) Schematic of the dark-field microscopy setup used in this study. (B) Illustration of 
the ACE-LSPR biofunctional nanoparticle imaging process. (C) Photo image of the ACE-LSPR 
device mounted on the motorized X-Y stage of the dark-field microscopy setup.    -p.119 
 
Figure 6.5 (A) Fluid velocity field measured by 2D micron resolution particle image velocimetry 
(μ-PIV) analysis. Images of the gold nanorods moving in the 0.001x PBS buffer (σ = 1.59 mS/m) 
were captured at 16.67 frame/s using darkfield microscopy with a focal plane at 40 μm above the 
microelectrode surface. (B) Theoretical and experimental ACEO velocity at x =17.5 μm from the 
center of the microelectrodes at 200Hz. The scattered dots represent experimental values obtained 
by averaging the tracing particles’ x-direction velocity values along the red dotted line in (a) at 𝑉0 
= 1V. The curve represents simulation results at a corrected value of 𝑉0 = 0.613V.   -p.123 
 
Figure 6.6 Initial slope values obtained from analyte binding curves under ACEO for the initial 
slope extraction time of 1 to 8 min. The time period of 5 min was determined as the minimum 
period to obtain the calibration curve. P values were calculated between the initial slope values for 
1 to 7 min and the value for 8 min for the IL-1β concentration at 100 pg/mL, 500 pg/mL, and 1 
ng/mL. *, p-value < 0.05; **, p-value < 0.01; NS, no significant difference.    -p.125 
 
Figure 6.7 2D Finite-element analysis (FEA) simulations on the mass transport and surface 
reaction in the ACE-LSPR optofluidic device. (A) Simulation setup and boundary conditions. The 
ACEO velocity was first characterized by calculating the movement of the electrical double layer 
driven by the tangential component of the electric field using Coulomb’s law. This velocity was 
then coupled with incompressible N-S equation to solve for the flow field, which was subsequently 
integrated with Fick’s law to derive the concentration profile. Finally, the first order Langmuir 
Absorption was adopted as a boundary condition accounting for the surface reaction at the sensor 
surface. (B)-(D) Analyte concentration profiles within microfluidic channel of the device operated 
under ACEO at 𝑉0 = 2𝑉 𝑓 = 200𝐻𝑧, with diffusion only, and with convection flow at 25 μm/s, 
respectively. The ACEO velocity direction and magnitude are shown by the blue arrows. The 
initial concentration for all three cases was set to be 𝑐 𝑐0⁄ = 1. The inlet (left edges) and the outlet 
(right edges) for ACEO and diffusion only cases were defined as open boundaries with no analyte 
replenishment (𝑐 𝑐0⁄ = 1 𝑎𝑡 𝑥 = ∞). (E) Time-course change of binding ratio (BR) for different 
operating conditions. The BR is defined as the ratio of analyte occupations over the entire available 
binding sites. (F) Time-course change of enhancement factor for different channel heights under 
ACEO operation at 𝑉𝑝−𝑝 = 2𝑉 𝑓 = 200𝐻𝑧. Here, the enhancement factor is defined as the BR 
under ACEO over the BR under the condition of diffusion only.        -p.128 
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Figure 6.8 Detection of purified IL-1β in 0.001x PBS buffer. (A) Real-time scattering light 
intensity profiles of the line-shaped ACE-LSPR AuNR sensor patterns at various IL-1β 
concentrations (50 fg/mL to 100 pg/mL). Here, the operation condition at 𝑉𝑝−𝑝 = 4𝑉 𝑓 = 200𝐻𝑧 
was applied after 10-11 min of incubation. (B) Darkfield images showing the mapping of the 
scattering intensities of triplicated sensing patters under conditions with/without ACEO. (C) 
Calibration curves obtained from the intensity mapping in b (left y axis). The LOD was determined 
by the intersection of the fitted calibration curve with 3 standard deviations (3σ) above the mean 
of the background noise. The LOD was calculated to be 158.5 fg/mL (9.1 fM) for “with ACEO” 
and 15.2pg/mL for “without ACEO”. A reduction of LOD by two orders of magnitude was 
achieved. The signal enhancement ratio (right y axis) was calculated by the scattering intensity 
change for the “with ACEO” condition over the “without ACEO” condition. The “without ACEO” 
condition data were obtained from the intensity change of the Ref bar shown in Figure 6.1E. -p.131 
 
Figure 6.9 Detection of IL-1β in human serum. (A) Real-time scattering light intensity profiles of 
the line-shaped ACE-LSPR AuNR sensor patterns presenting enhanced signals for 50% human 
serum matrix (HSM) spiked by IL-1β at concentrations of 1 pg/mL to 10 ng/mL. Here, the 
operation condition at 𝑉𝑝−𝑝 = 1.5𝑉 𝑓 = 1𝑘𝐻𝑧 was applied after an incubation period of 5 min. 
(B) Calibration curves obtained from intensity mapping and 5 min initial slope analysis (shown by 
the inset). The raw data were fitted by a 5-parameter logistic function. (C) Serum IL-1β 
concentrations measured by three different methods for 6 pediatric sepsis patients stratified into 
hyper-inflammatory and mild-inflammatory subgroups. The labels of “ACE-LSPR,” “ELISA,” 
and “5-min Slope” indicate data obtained for the clinical samples by ACE-LSPR signal intensity 
analysis after an incubation period of ~15 min, conventional 96-well plate ELISA, and 5-min initial 
slope-based analysis, respectively. (D) One-tailed paired difference t-test performed for 5-min 
initial slope measurement between the two patient subgroups. The p-value calculated between the 
two patient subgroups is < 0.01.          -p.133 
 
Figure 6.10 Correlation between data obtained from the ACE-LSPR and ELISA for both the 
spiked-in serum samples and patient samples with the IL-1β concentration ranging from 1 to 1000 
pg/mL.             -p.135 
 
Figure 7.1 Preliminary test of the microwell fabrication on clear PMMA sheet using hot embossing 
method. The embossed the microwell diameter is 40 µm.         -p.144 
Figure 7.2 (A) Illustration of PEdELISA microarray disk design for integrated blood plasma 
separation, collection, metering and downstream multiplex PEdELISA analysis. The fabricated 
PEdELISA microarray disk has a multilayer structure consisting of a top vent layer (PMMA), top 
pressure sensitive adhesive layer with microfluidic channels (PSA), middle micro-chamber layer 
for sample storage (PMMA), bottom adhesive layer with microfluidic channels (PSA) and, bottom 
microwell array layer (PMMA). (b) Illustration of integrated laser scanning optics for high-
throughput PEdELISA fluorescence digital counting analysis. The scanning principle is similar to 
that of a conventional CD-type read head.         -p.145 
Figure 7.3 Double blockade of PAD-CitH3 pathway for the treatment of sepsis. PAD citrullinates 
H3 to produce CitH3; CitH3 triggers neutrophil extracellular traps (NETs) cell death (NETosis) to 
release nuclear contents, which forms a “vicious cycle” (left panel). PAD inhibitor with specific 
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monoclonal anti-CitH3 antibody (Ab) for neutralization of circulating CitH3 (double block, right 
panel) can suppress PAD-CitH3 pathway and promote survival. TLR: Toll-like receptor; MPO: 
Myeloperoxidase; MyD88: Myeloid differentiation primary response gene 88; WT: wild type; KO: 
Knockout.            -p.148
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Biomarker-guided precision medicine holds great promise to provide personalized therapy 
with a good understanding of the molecular or cellular data of an individual patient. However, 
implementing this approach in critical care uniquely faces enormous challenges as it requires 
obtaining “real-time” data with high sensitivity, reliability, and multiplex capacity near the 
patient’s bedside in the quickly evolving illness. Current immunodiagnostic platforms generally 
compromise assay sensitivity and specificity for speed or face significantly increased complexity 
and cost for highly multiplexed detection with low sample volume. This thesis introduces two 
novel ultrafast immunoassay platforms: one is a machine learning-based digital molecular 
counting assay, and the other is a label-free nano-plasmonic sensor integrated with an 
electrokinetic mixer. Both of them incorporate microfluidic approaches to pave the way for near-
real-time interventions of cytokine storms. 
In the first part of the thesis, we present an innovative concept and the theoretical study 
that enables ultrafast measurement of multiple protein biomarkers (<1 min assay incubation) with 
comparable sensitivity to the gold standard ELISA method. The approach, which we term “pre-
equilibrium digital enzyme-linked immunosorbent assay” (PEdELISA) incorporates the single-
molecular counting of proteins at the early, pre-equilibrium state to achieve the combination of 
high speed and sensitivity. We experimentally demonstrated the assay’s application in near-real-
time monitoring of patients receiving chimeric antigen receptor (CAR) T-cell therapy and for 
longitudinal serum cytokine measurements in a mouse sepsis model. 
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In the second part, we report the further development of a machine learning-based 
PEdELISA microarray data analysis approach with a significantly extended multiplex capacity 
using the spatial-spectral microfluidic encoding technique. This unique approach, together with a 
convolutional neural network-based image analysis algorithm, remarkably reduced errors faced by 
the highly multiplexed digital immunoassay at low analyte concentrations. As a result, we 
demonstrated the longitudinal data collection of 14 serum cytokines in human patients receiving 
CAR-T cell therapy at concentrations < 10pg/mL with a sample volume < 10 µL and 5-min assay 
incubation. 
In the third part, we demonstrate the clinical application of a machine learning-based digital 
protein microarray platform for rapid multiplex quantification of cytokines from critically ill 
COVID-19 patients admitted to the intensive care unit. The platform comprises two low-cost 
modules: (i) a semi-automated fluidic dispensing module that can be operated inside a biosafety 
cabinet to minimize the exposure of technician to the virus infection and (ii) a compact 
fluorescence optical scanner for the potential near-bedside readout. The automated system has 
achieved high interassay precision (~10% CV) with high sensitivity (<0.4pg/mL). Our data 
revealed large subject-to-subject variability in patient responses to anti-inflammatory treatment for 
COVID-19, reaffirming the need for a personalized strategy guided by rapid cytokine assays.     
Lastly, an AC electroosmosis-enhanced localized surface plasmon resonance (ACE-LSPR) 
biosensing device was presented for rapid analysis of cytokine IL-1β among sepsis patients. The 
ACE-LSPR device is constructed using both bottom-up and top-down sensor fabrication methods, 
allowing the seamless integration of antibody-conjugated gold nanorod (AuNR) biosensor arrays 
with microelectrodes on the same microfluidic platform. Applying an AC voltage to 
 xxiii 
microelectrodes while scanning the scattering light intensity variation of the AuNR biosensors 
results in significantly enhanced biosensing performance. 
The technologies developed have enabled new capabilities with broad application to 
advance precision medicine of life-threatening acute illnesses in critical care, which potentially 
will allow the clinical team to make individualized treatment decisions based on a set of time-








1.1 Introduction and Research Background 
1.1.1 Cytokines: Key Clinical Targets.  
The immune system provides a critical mechanism for a living organism to protect itself 
against invasions of external pathogens due to bacterial and viral infections. Despite the 
conceptually clear role of the immune system, pathways underlying the defense mechanism are so 
complex and yet to be fully understood. The complexity of the immune defense system originates 
from dynamic functional interactions between biomolecules, cells, and organs over time. Among 
these players, cytokines are key biomolecules acting as mediators and modulators of the complex 
functional interactions and responses of the immune system (Figure 1.1) (1-3). They are soluble 
low-molecular-weight proteins secreted by immune cells and responsible for the regulation of host 
defense, tissue homeostasis, cell-to-cell communication, and inflammatory reaction. A tightly 
regulated balance of physiological actions between pro-inflammatory and anti-inflammatory 
cytokines is critically necessary to maintain the optimal immunity function. Systemic 
inflammation, which can be clinically manifested in various forms, including systemic 
inflammatory response syndrome (SIRS), sepsis, acute respiratory distress syndrome (ARDS), and 
auto-immune disorders (e.g., systemic lupus erythematosus), results from excessive production of 
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pro-inflammatory cytokines, such as IL-6 and TNF-. These highly inflammatory responses are 
counteracted by certain anti-inflammatory cytokines, including IL-10, transforming growth factor 
(TGF-), and IL-4, which attempt to restore immunological equilibrium. The multifaceted roles 
of cytokines in maintaining the tightly regulated balance of immunity have attracted enormous 
clinical interest in quantification of these biomolecules and its application for infectious disease 
treatment and drug development (4). Previous studies suggest that quantification of cytokine-based 
immune fingerprints provides a more accurate way of stratifying and diagnosing bacterial 
infections than conventional methods based on symptoms, initial clinical observations, and basic 
laboratory markers (5, 6).  
 
Figure 1.1 (A) Dynamic immune cellular response under pathogen attacks into the immune system. 
http://jama.jamanetwork.com/article.aspx?articleid=2279715. (B) A complex cytokine communicating 
network while addressing inflammatory response. www.genecopoeia.com, Data Source: KEGG, BioCarta 
 
There has been an explosion in the use of immunotherapies for treating autoimmune diseases, 
infection (7), cancer (8), and other immune-related deficiencies (9, 10). Among these therapies, 
cytokine-targeted methods aiming to establish a normal balance of the cytokine network in the 
host have shown great promise for some inflammatory diseases, such as rheumatoid arthritis and 
Crohn’s disease (11, 12). More recently, with the emerging global pandemic of the new 
coronavirus, COVID-19, FDA has approved the use of IL-6 receptor blocking antibodies, such as 
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tocilizumab (Actemra), sarilumab (Kevzara), and siltuximab (Sylvant) that are FDA approved for 
treating various pro-inflammatory conditions manifested by hospitalized critically ill patients with 
COVID-19-induced hypoxia (13). Quantifying cytokines secreted by isolated immune cells or 
circulating cytokines in whole blood allows immune responses to be monitored, providing 
clinically and immunologically useful information related to infectious diseases, cancer, 
autoimmune diseases, allergy transplantation, and drug discovery (14).  Multiplexed detection of 
different cytokines in a single sample has been proven powerful for obtaining a more complete 
picture of immunity owing to the highly networked nature of their functions (15). A recent clinical 
study reveals that among 41 COVID-19 patients with pneumonia with abnormal findings on chest 
CT, distinctly higher plasma levels of 8 cytokines: IL-2, IL-7, IL-10, GSCF, 1P10, MCP1, MIP1A, 
and TNF-  were observed for critically ill patients admitted to an intensive care unit (ICU) than 
for moderately ill non-ICU patients (16). This finding suggests that multiplexed detection of these 
cytokines may provide key information to precisely stratify patients and predict the trajectory of 
their illness levels, thus guiding efficient usages of limited resources of the ICU. 
1.1.2 Current Challenges to Precision Medicine in Critical Care of Acute Illness.  
Barack Obama, the former President of the United States, advocated scientific approaches to 
improving human health in his official statement in 2015 (17). Under his leadership, the country 
announced a research initiative to promote progress toward a new era of precision medicine. 
Precision medicine provides prevention and treatment strategies that take individual variability 
into account, based on large-scale biologic databases, such as proteomics, metabolomics, 
genomics, diverse cellular assays, and even mobile health technology, and computational tools for 
analyzing large sets of data. Cancer diagnosis/oncology is the medical field that has seen great 
benefits from the precision medicine approach since the research initiative. Researchers have 
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sought after the aspirational goal of distinguishing and treating highly specific biologic alterations 
in cancer, such as specific aberrations in gene structure or regulation, transcription, or post-
transcription molecular pathways, to realize personalized therapy and improved outcomes. For 
example, Piccart-Gebhart et al. (18) demonstrated improved outcomes of breast cancer 
chemotherapy by using a monoclonal antibody, Trastuzumab, which targets the single gene 
mutation in the human epidermal growth factor receptor 2 (HER2) gene in breast cancer cells. 
Multiple other breakthroughs and innovations in diagnosis and treatment targeted to specific 
abnormalities have extensively benefitted patients with cancer (19, 20). Thus, a rosy future of 
precision medicine is foreseen with the successful completion of the Human Genome Project (21) 
and molecular subtyping of melanoma on BRAF, RAS, and NF1 mutations (22).  
By contrast, it is notable that critical care medicine has not yet seen a tangible fruit of the 
precision medicine approach. Patients with acute, critical illness constitute a large and growing 
portion of healthcare consumers in the United States, driving over $80 billion in expenditures and 
over 13% of hospital costs (23). Despite the costs, morbidity and mortality of critical illness, 
however, many of the illnesses cared for in the intensive care unit (ICU) remain poorly defined 
without clear disease-specific therapies (24, 25). Apparently, major barriers to precision medicine 
exist in critical care. While testing and therapeutic plans for cancers and other chronic diseases are 
formulated over days to weeks, life-saving treatment for critically ill patients must be delivered in 
minutes to hours. The need for generating phenotype data that are adequately timely for a group 
or cluster of patients with the complexities of multi-morbidity poses significant challenges to 
implementing precision medicine in critical care. Additionally, without particular patterns of gene 
expression or biomarker profiles guiding therapies with a precise prediction of the trajectory of 
life-threatening illness, the current approach is forced to “passively” treat patients only when their 
 5 
symptoms become obviously worsen. Such delays prohibit clinical interventions to prevent the 
development of organ failure and even mortality in the early stage of the illness.  With molecularly 
targeted therapeutics failed, the field of critical care medicine now recognizes an urgent need for 
novel clinical trials designed to embrace and explore the heterogeneity of treatment during phases 
2 and 3 (24, 25). The implementation of precision medicine in critical care surely requires a close 
partnership between medicine and engineering to provide innovative approaches leading to 
reduced costs, increased timeliness of patient screening and treatment, and facilitated data sharing.  
1.1.3 Rapid, Sensitive, Accurate Biomarker Analysis. 
One of the major factors leading to the aforementioned barriers is the lack of technologies 
permitting the timely and accurate acquisition of phenotypical and pathological data of patients. 
For example, the gold standard for the diagnosis of sepsis – a life-threatening illness caused by the 
body’s response to an infection – has traditionally been a combination of physiologic vital signs 
and organ-specific blood parameters coupled with microbial cultures to identify the presence of 
sepsis and source of infection(26). However, a positive culture can take over 48 hours to incubate, 
and false-negative results are common due to the low density of blood bacteria at the early stage 
of infection. Other methods based on nucleic acid amplification also require a sample-to-answer 
time as long as 4–10 hours, and these often suffer poorer sensitivity and specificity than microbial 
cultures(27). A promising alternative method is sampling and analysis of blood circulating protein 
biomarkers that serve as inflammatory-based surrogate indicators of infection-induced 
inflammation, such as cytokines (28, 29). 
Proteins in circulating blood often provide valuable biological signatures for disease diagnosis. 
Immunoassays are powerful techniques for protein biomarker analysis. They take advantage of the 
ability of an antibody developed by nature to recognize and bind a specific protein existing in a 
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complex mixture of macromolecules. The enzyme-linked immunosorbent assay (ELISA) is the 
gold standard biomarker detection method widely used in clinical diagnosis because of its high 
sensitivity and selectivity, but it generally lacks the speed to provide timely data for critical care. 
Continuing efforts have been undertaken to develop ultrafast immunoassays by employing 
methods, such as assay step simplification (30), label-free biosensing (31-35), surface-to-volume 
ratio enhancement (36-38), active protein mixing (39, 40) and molecular pre-concentration (41, 
42). However, if a rapid assay is achieved with a reduced assay incubation time, the measurement 
normally experiences poor sensitivity. For a system with weak antigen-antibody affinity, where 
the protein binding kinetics is solely limited by the surface reaction rate (reaction limited 
regime(43)), there is no effective way to shorten the assay time using the aforementioned methods 
involving active mass transport enhancement by mixing, pre-concentrating, and miniaturizing. 
Additionally, the other methods become impractical owing to increased complexity and 
extensiveness required for nanomaterial synthesis, fabrication, and integration. The absence of a 
rapid immunoassay with high sensitivity prohibits the acquisition of the patient’s accurate “real-
time” biomarker profile information, which is critically needed for precision treatment of acute 
illnesses. Existing immunoassay methods also suffer other impediments, including limited 
multiplexity, the inability to deliver a near-bedside result, and increased complexity and cost 
resulting from sophisticated micro/nanofabrication or circuit designs for reagent mixing and pre-
concentration. All together, these limitations pose major obstacles towards fulfilling the promise 
of biomarker-guided precision medicine in critical care. 
 1.2 Motivation and Objectives  
The absence of rapid, sensitive, and accurate diagnostic methods renders treatment of critically 
ill patients highly empirical with no access to information allowing individualized selection and 
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use of appropriate drugs (44). Indeed, several review papers suggest that the failure of therapy 
could be attributed to the lack of appropriate techniques to monitor circulating blood biomarkers 
and host defense responses across highly heterogeneous patient cohorts during the course of 
disease development (45-49). The current technological gap prohibits the acquisition of the 
patient’s accurate “real-time” biomarker profile information, which is critically needed for 
precision treatment of acute illnesses. This research is motivated by the urgent need for a new 
diagnostic tool for the timely personalized treatment of life-threatening acute illnesses.  
Although critically important biomarkers, such as cytokines, may have high concentrations in 
tissues, their concentrations in the circulation may be low, requiring sensitive and robust 
measurement in addition to speed.  Additionally, approaches to precision medicine in critical 
illness must be flexible.  While assays for some biomarkers, such as the cardiac troponin in 
myocardial infarction (MI), have been refined over decades after obtaining gold-standard evidence 
of their importance, our understanding of biomarkers in complex, heterogeneous conditions in 
critical illness is undergoing rapid evolution (50). The high cost and difficulty of generating 
appropriate assays may lead to a stalemate in precision medicine for acute care: in the absence of 
validated biomarker-driven treatments, there is little market for new assays – but the absence of 
practical assays prohibits the clinical trials needed to study new treatments. In order to facilitate 
prospective clinical trials of biomarker-driven therapy, measurement technologies that can rapidly 
and inexpensively adapt to new analytes are needed. To meet these unmet needs, this thesis work 
aims to develop a novel immunoassay biosensor platform that enables near-the-patient concurrent 
quantification of circulating blood cytokine biomarkers. 
This work is also motivated by the need for fundamental engineering knowledge. To fully 
understand the physics that determines the speed and sensitivity of biomarker analysis, this thesis 
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develops multi-physics models accounting for protein mass transport (forced convection and 
diffusion), protein surface reaction and binding kinetics, and biosensing signal transduction. These 
models guide us for the optimization of new rapid, sensitive immunoassay biosensing approaches 
that involve quenching pre-equilibrated antigen-antibody immune complex formation events, 
counting single-molecule digital signals, and label-free plasmonic protein biosensing with 
electrokinetically enhanced protein mass transport and surface binding.  The models also provide 
a theoretical foundation of the scientific validity of our newly developed assay strategies. These 
strategies are theoretically validated for the biosensing performance that fully meets the stringent 
requirements for biomarker-guided timely and accurate personalized diagnosis and treatment of 
life-threatening acute illnesses. With the theoretically guided optimization, one of the biosensor 
technologies presented in this thesis achieves cytokine biomarker analysis at unprecedented levels 
of detectability with a limit of detection (LOD) of ~1 pg/mL (50fM) and speed leading to a sample-
to-answer time of < 5 min. Another developed technology provides a maximum sensor response 
speed that can be fast enough to shorten the assay reaction incubation time as short as 30 sec, 
which is more than 200 times shorter than that of the conventional ELISA gold standard technique. 
Careful engineering design could achieve the system cost more than 10 times less than that of a 
bulky high-end system incorporating a fully automated robotic machine for sample/reagent 
handling (51).  
Ultimately, the biomarker detection capability demonstrated in this thesis needs to be translated 
into wide clinical use to tailor the biomarker-targeted immunomodulatory therapy. Here, this study 
is motivated to develop biosensor systems that can serve as a broadly used technological platform 
to determine the optimal treatment approach and drug administration timing for a wide spectrum 
of severe life-threatening illnesses, such as sepsis, cytokine release syndrome (CRS), acute 
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respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), 
myocardial infarction (MI), post-cardiac arrest syndrome (PCAS), and trauma-induced acute 
immune disorders. The ability to achieve comprehensive real-time profiling of circulating blood 
biomarkers may open the door to novel clinical trials.  In addition, the technology should find 
wider use owing to its general applicability to assays involving receptor-analyte interactions. The 
receptor types used in this technology may be further extended to a wide variety of antibodies, 
peptides, and oligonucleotides. This will allow this technology to be implemented for other 
biological assays than cytokine profiling, such as protein biomarker analyses, receptor-ligand 
assays, enzyme assays, and DNA assays. Thus, the technology will serve as a general and powerful 
tool in protein expression profiling, gene expression analysis, molecular-level analysis of 
infectious diseases, and human leukocyte antigen (HLA) testing.  
1.3 Scopes of the Thesis 
This thesis perceives the technological gap described above as an exciting opportunity for 
engineering researchers. A new cytokine biosensor technology filling the gap promises to advance 
precision medicine of life-threatening acute illnesses in many ways. For example, this will provide 
the time-changing profile of a panel of cytokine biomarkers in the patient in real-time and allow 
clinicians to determine precisely the timing, frequency, and dose of the drug specifically targeting 
the pathological origin. Here, the cytokine biosensor will play a pivotal role in the feedback system 
tightly regulating the delicate balance of cytokine levels within the immune system (Figure 1.2). 
For sepsis alone, establishing such a biosensor-enabled approach to feedback immune system 
control will save more than 250,000 lives a year in the U.S. In light of this vision, this research 
aims to develop novel biosensor systems enabling near-patient, real-time cytokine profiling with 
high seep, sensitivity, accuracy, and multiplexity while keeping the assay cost low. Towards this 
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end, this thesis work establishes two approaches termed: (1) the “pre-equilibrium digital enzyme-
linked immunosorbent assay (PEdELISA) and (2) the “AC electroosmosis-enhanced localized 
surface plasmon resonance (ACE-LSPR) biofunctional nanoparticle imaging.”  
 
Figure 1.2 Concept of personalized immunomodulatory therapy for systemic inflammatory disease enabled 
by rapid cytokine-based immune status monitoring. This concept is analogous to feedback-loop system 
control theory used in system engineering that controls the behavior of a dynamical system with an input.    
 
The PEdELISA method is a digital immunoassay based on single-molecule counting of 
antigen-antibody immune complexes at an initial state of their formation far from equilibrium, 
namely a “pre-equilibrium state,” for cytokine biosensing.  Digital immunoassay is an emerging 
technique for biochemical analysis of analytes in low abundance. Its single-molecule sensitivity 
originates from binary counting of On/Off signals amplified within various types of small sub-
volume partitions (52-55). Conventional digital immunoassays typically require a long incubation 
time (hours) to ensure a sufficiently high signal-to-noise ratio for sub-fM detection (56, 57). In 
contrast, our approach applies single-molecule counting within a short (30-600s) incubation time 
for a system in which analyte molecules exist more abundantly by capturing a snapshot of pre-
equilibrated reaction at its very early stage. The snapshot approach significantly extends the 
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digitally quantifiable range from fM to clinically relevant sub-nM, which is conventionally 
believed to be far outside the range permitted by single-molecule binary counting. PEdELISA is 
capable of achieving a sandwich immunoassay even for a system at the reaction limit regime nearly 
as fast as point-of-care glucose or pregnancy tests while retaining the regular ELISA-grade 
sensitivity. Here, the single-molecule counting condition is achieved by intentionally quenching 
the immunologic reaction.  
 
Figure 1.3 Principle of nanoparticle/nanostructure-based localized surface plasmon resonance.  
 
In the ACE-LSPR biofunctional nanoparticle imaging technique, we employ a label-free gold 
nanorod (AuNR) plasmofluidic device coupled with AC electroosmosis (ACEO)-driven analyte 
flow. The device overcomes the physical barrier of the conventional diffusion-limited biosensors, 
thus achieving unprecedented sensing performance. Over the past years, researchers have 
perceived localized surface plasmon resonance (LSPR)-based biomolecular binding assay as an 
emerging biochemical analysis technique.  In LSPR, metal nanoparticles/nanostructures in sub-
wavelength size are excited by an external light source to generate surface plasmons in a localized 
space (Figure 1.3). Surface binging of analyte molecules onto the nanostructures yields a shift of 
the resonance in the plasmon-photon coupling. The resonance shift allows LSPR biosensors to 
 12 
quantify the analyte concentration.  This technique holds the great potential to replace current gold 
standard assay (e.g., ELISA) in real clinical applications because of its much more simplified 
procedure eliminating multiple laborious assay processes and sample sparing capability. However, 
such an assay still falls short of meeting speed and sensitivity urgently required for critical care 
medicine. To overcome these limitations, this thesis demonstrates an innovative bioanalytical 
method of coupling ACEO-enhanced analyte transport and analyte-receptor interactions with 
biofunctional nanoparticle imaging. This study theoretically and experimentally proves that the 
electrohydrodynamic enhancement can significantly improve nanoparticle-based plasmofluidic 
analyte detection capability and shows the promise of label-free LSPR biosensing as a powerful 
biochemical analysis approach to low-abundance biomarker detection. 
1.4 Thesis Outline 
Based on the research scope discussed above, this thesis consists of six subsequent chapters as 
follows: 
Chapter 2 - Literature review: This chapter reviews the studies relevant to this thesis which 
mainly focus on ultrafast multiplex immunoassay technique towards near-bedside operation. After 
briefly introducing the gold standard immunoassay technology, the first part reviews the current 
advances of microfluidic cytokine immunoassay devices, and then the second part discusses the 
ultrasensitive single-molecule digital counting assays. Lastly, label-free nano-plasmonic 
immunoassay was reviewed and the current limitation is summarized.  
Chapter 3 - Rapid Single-molecule Digital Detection of Protein Biomarkers for Near-real-
time Monitoring of Systemic Immune Disorders: This chapter presents an innovative concept 
that enables near real-time measurement of multiple protein biomarkers (<1 min assay incubation) 
with comparable sensitivity to the gold standard ELISA method. The approach, which we term 
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“pre-equilibrium digital enzyme-linked immunosorbent assay” (PEdELISA) incorporates the 
instantaneous single-molecule digital counting of pre-equilibrium protein binding events to 
simultaneously realize speed and sensitivity. Here, we developed a theoretical model to validate 
that the 2-step transient assay format of PEdELISA can maintain a linear relationship between the 
analyte concentration and the assay readout regardless of the reaction time and predicted the 
minimum required incubation time for a desired detection limit. We also experimentally 
demonstrated the assay’s application in near-real-time monitoring of protein biomarkers in patients 
manifesting post-chimeric antigen receptor (CAR) T-cell therapy cytokine release syndrome 
(CRS) with ~30 min serum sample to answer time and the longitudinal serum cytokine 
measurement in a mouse septic model. 
Chapter 4 - Machine Learning-Based Cytokine Microarray Digital Immunoassay Analysis: 
This chapter further presents the development of a highly multiplexed microfluidic PEdELISA 
platform by incorporating both spatial-spectral microfluidic encoding and machine learning-based 
autonomous image analysis. This unique approach remarkably reduces errors facing the high-
capacity multiplexing of digital immunoassay at low protein concentrations. As a result, the assay 
has achieved 16-plexed biomarker detection at concentrations < 10pg/mL with a sample volume 
< 10 µL, including all processes from sampling to data analysis within 30 min, while only requiring 
a 5-min assay incubation. Longitudinal data obtained for a panel of 14 serum cytokines in human 
patients receiving CAR-T cell therapy reveals the powerful biomarker profiling capability 
Chapter 5 - An Automated Microarray Digital Assay towards Near-Realtime Personalized 
Intervention of Cytokine Storm among COVID-19 Patients: This chapter demonstrates the 
application of an automated machine learning-based PEdELISA platform for realtime multiplex 
quantification of cytokines from severe COVID-19 patients admitted to the ICU at the University 
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of Michigan Hospital. The low-cost automated platform comprises a 2-part module: an automated 
fluidic dispensing/mixing module that operates inside the biosafety cabinet to minimize the 
exposure of technician to the virus infection, and a 12-12-15 inch compact fluorescence optical 
scanner for the potential near-bedside operation. The PEdELISA platform enabled daily cytokine 
profiling with: high sensitivity (<0.4pg/mL), interassay precision (~10% CV), and near-realtime 
turnaround (10min assay incubation, ~30min total). A cytokine profiling test allowed us to observe 
clear interleukin -6 (IL-6) elevations after receiving tocilizumab (IL-6 inhibitor) while significant 
cytokine profile variability exists across all critically ill COVID-19 patients and to discover a weak 
correlation between IL-6 to clinical biomarkers, such as Ferritin and CRP. 
Chapter 6 - AC Electroosmosis-enhanced Nano-plasmofluidic Detection of Ultra-low-
Concentration Cytokine: In this chapter, we present a label-free nano-plasmofluidic device 
integrated with microelectrodes for rapid analysis of a low-abundance cell signaling protein, 
detected by AC electroosmosis-enhanced localized surface plasmon resonance (ACE-LSPR) 
biofunctional nanoparticle imaging. Applying an AC voltage to microelectrodes for active mixing 
while scanning the scattering light intensity variation of the nano-plasmonic biosensors results in 
significantly enhanced assay performance.  
Chapter 7 - Conclusions and Future Work: The final chapter summarizes the two platforms 
developed in this thesis: The labeled PEdELISA platform and the label-free ACE-LSPR platform 
and their application towards near-realtime intervention of cancer immunotherapy, COVID-19 and 
sepsis induced cytokine storm. In the last section, several ongoing studies are discussed, including 
the building and translation of a fully integrated and automated PEdELSIA system for near-bedside 
ICU patients cytokine profiling, the development of a whole-blood assay system, and the 








This chapter provides a review of previous studies related to this thesis work. The review gives 
insight into the motivations and applications of our research as well as analysis of competing 
technologies. This thesis work aims to develop microfluidic cytokine assay platforms achieving 
the combination of both rapidness and sensitivity. The review has four main sections related to 
this goal: (1) ELISA immunoassay technology as a gold standard of analytical biochemistry 
analysis, (2) microfluidic cytokine assay technologies, (3) digital immunoassay platforms, and (4) 
label-free plasmonic biosensors. Each section details why this review is relevant and discusses 
multiple previous work that studied the topic. The review will summarize the achievements and 
limitations of existing work and describe how to address these problems in this thesis work. 
2.1 ELISA Immunoassay Technology 
Proteins in circulating blood often provide valuable biological signatures for disease diagnosis. 
Immunoassays are powerful techniques for biomarker analysis. They take advantage of the ability 
of an antibody developed by nature to recognize and bind a specific protein existing in a complex 
mixture of macromolecules. The enzyme-linked immunosorbent assay (ELISA) is a widely used 
analytical biochemistry technique, first demonstrated by Engvall and Perlmann in 1971 (58). Now, 
this technique is the gold standard biomarker detection method widely used in clinical diagnosis. 
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The assay detects the presence of antigens in a liquid sample using antibodies specifically binding 
to them. ELISA is a well-established, well-proved immunoassay technique showing high 
sensitivity and selectivity, which has been used as a diagnostic tool in medicine, plant pathology, 
and biotechnology. However, involving sample incubation, detection antibody incubation, and 
labeling reagent incubation processes as well as multiple washing steps, commercial ELISA kits 
usually require a minimum assay time (primarily dominated by the incubation time after sample 
loading) of 3 - 8 hours, bulky optics and instrument in a current centralized clinical laboratory 
setting, and high assay costs as shown in Table 2.1. Certainly, such limited performances and high 
costs prohibit their use for critical care medicine that urgently needs cytokine profile data at a low 
limit of detection (LOD) reaching the 1 -10pg/mL level (59), speed permitting analyte analysis 
with a sample-to-answer time < 30 min and high frequency of test for continuous monitoring of 
the patient’s immune status.  
Table 2.1 Competing immunoassay diagnostic systems (*Total assay time includes analyte 
quantification, data acquisition, and analysis, but does not include sample preparation. Please 
also note that the assay and instrument cost of the commercial system is from their market price 















Luminex $3000 >$40,000 > 4 hours 0.1 -100 25-50 25-65 
Colorimetric 
ELISA 
$200 $5,000 > 4 hours 1-10 100 1 
Quanterix 
SIMOA 
$1000 >$200,000 45 min 0.002 - 1 100 6 
PerkinElmer 
AlphaLISA 
$1200 >$200,000 4 hours 1-100 50-100 4 
Our 
Platform in 
Ch.3, 4, 5 
$50 <$5,000 < 30 min 0.1-5 5-10 16 
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2.2 Microfluidic Cytokine Immunoassay Devices 
Modern advances in microfabrication technologies have driven an increasing number of 
studies to integrate biosensors in a microfluidic platform with sophisticated on-chip fluidic 
channels, chambers, and valves. The microfluidic environment creates a short sample-to-sensor 
distance positioning analyte molecules in close proximity to receptors on the sensor surface. It 
reduces the time required for the molecules to reach the sensor receptors by diffusion. The small 
volume of the microfluidic environment generates strong convection at a small sample flow rate. 
The coupling of diffusion and convection in the microfluidic volume enhances analyte transport, 
and therefore resulting in efficient sample delivery and sample sparing capabilities for cytokine 
analysis (60).  
Researchers have demonstrated several microfluidic immunoassay devices for cytokine 
analysis as summarized in Table 2.2. Performing cytokine immunoassay in a microfluidic platform 
leads to highly efficient sample purification, reagent loading, parallel reagent manipulation, 
parallel signal reading, and multiplexed analyte detection (61, 62). For example, the blood barcode 
chip reported by Fan et al. (63) demonstrates these advantageous microfluidic features. The chip 
achieved multiplexed detection of 12 protein biomarkers, including IFN-γ, TNF-α, IL-2, IL-1α, 
IL-1β, TGF-β1, IL-6, IL-10, IL-12, GM-CSF, MCP-1, and PSA, from 10 μL whole blood samples 
diluted to 90 μL with buffer (Figure 2.1). 
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Figure 2.1 Blood barcode chip for microfluidic ELISA assay that involves (A) plasma separation from a 
finger prick of blood and (B) sandwich immunoassay of plasma proteins on DNA-coded barcode arrays in 
a microfluidic channel. Adopted from Fan et al. (63). 
 















IFN-g, TNF-a, (IL)-2, IL-1a, IL-
1b, (TGF)-b1, 








































































et al. (66) 
Our platform in 
Ch. 3, 4, 6 
IL-6, TNF-α, IL-2, IL-8, IL-
13, IL-1α, IL-1β, IL-10, IL-
















However, the biochemical process applied for these devices essentially remains the same as 
that of the standard ELISA, which involves time-consuming assay steps and an immunocomplex 
formation incubation process (> 1 hour). To speed up the ELISA analysis, recent studies have 
significantly cut down the incubation time for analyte biding (i.e., antigen-antibody immune 
complex formation) on the sensor surface. For example, Sasso et al. (64) demonstrated a 
commercial multiplexed magnetic bead assay (Luminex) for IL-6, and TNF- in a microfluidic 
platform with an incubation time of 10 min. Similarly, Castanheria et al. (61) performed 
microfluidic ELISA to detect IL-1, IL-6, TNF-, and IL-12 simultaneously with an incubation 
time of 10 min. However, if a rapid assay is achieved with a reduced assay incubation time, the 
measurement normally experiences poor sensitivity. Although the LOD value found in the 
literature for the rapid microfluidic immunoassays is ~ 10 pg/mL, it simply means that cytokine 
levels above the value were considered positives. A low value of LOD is often misdealing, not 
guaranteeing reliable analyte measurement. The measurement does not guarantee reliable 
quantification of the analytes. Instead, limit of quantification (LOQ), which is the lower bound for 
the linear range in which a fold change occurs for the detection signal with the varying analyte 
concentration, is a better measure of the assay performance. LOQ values are often found to be 
more than an order of magnitude higher than LOD values for cytokines measured using these rapid 
microfluidic immunoassay devices (61). 
Continuing effort has been undertaken to develop rapid microfluidic immunoassays by 
employing methods, such as assay step simplification (30), label-free biosensing (31-35), surface-
to-volume ratio enhancement (36-38), active protein mixing (39, 40), and molecular pre-
concentration (41, 42). However, for a system with weak antigen-antibody affinity, where the 
protein binding kinetics is solely limited by the surface reaction rate (reaction limited regime (43)), 
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there is no effective way to shorten the assay time using the aforementioned methods involving 
active mass transport enhancement by mixing, pre-concentrating, and miniaturizing. Furthermore, 
implementing active fluid manipulation mechanisms and non-ELISA-based biosensors found in 
these methods requires their integration into a microfluidic platform using sophisticated micro-
/nanofabrication techniques and high-precision operations. This often brings poor repeatability to 
the measurement.   
2.3 Single-Molecule Digital Counting Assays 
Digital assays have attracted much attention from the research community with excitement 
for their ability to detect biomarkers with single-molecule sensitivity. These assays 
compartmentalize biological samples into millions of femtoliter-volumes and interrogate 
biochemical reactions individually. One can find a wide use of digital assays as a platform for the 
ultrasensitive detection of nucleic acids (68-70), proteins (52, 66, 71-75), single cells (76), and 
single exosomes (77) in the literature. Along with the high sensitivity, digital assays show stability 
and robustness, which is highly attractive for POC diagnostics. As such, incorporating the digital 
assay into a microfluidic format has enhanced the performance of immunoassays considerably to 
fulfill all of the following performance criteria: (i) low limit of detection (LOD, subpicomolar), (ii) 
high dynamic range (5 orders of magnitude or better), (iii) multiplexed biomarker analysis (4 or 
more), and (iv) compatible with ultralow volume (<5 μL) samples (78). 
The most well established commercial implantation of an ELISA-based digital assay, 
namely digital ELISA (dELISA), is Quanterix’s Simoa (51). However, this commercial system 
requires very bulky optics and fluid handling components to automate the entire process from 
sampling to data delivering, which leads to a very high instrumentation cost > $200,000 (see Table 
2.1). Some studies have implemented dELISA for cytokine detection with a portable platform 
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suited for bedside diagnosis. For example, Piraino et al. (78) demonstrated multiplexed detection 
of 3 different types of anti-Ebola IgG antibody in human serum at concentrations as low as 0.33 
pg/mL using an integrated microfluidic chip device. They further developed a portable, low-cost 
diagnostic system incorporating the chip with an automated fluidic manipulation unit and a digital 
CMOS camera for POC operation (Figure 2.2). More recently, Yelleswarapu et al. (66) developed 
a smartphone-connected microfluidic platform for miniaturized dELISA detection of GM-CSF and 
IL-6 cytokines using parallel droplet generation/detection channels (Figure 2.3). The research team 
achieved a very low LOD of 0.004-0.007 pg/mL in their measurement. Despite their exciting 
performance and potential, this platform still requires a relatively long sample incubation time > 
60 min, thus leading to a total sample-to-answer time > 2 hours.  In general, the conventional 
digital assays for protein analysis face a similar issue whether they use the bulky commercial 
instrument or the POC platform. Unfortunately, direct implementation of these assays is not 
suitable for realizing precision medicine of critical illnesses.  
 
Figure 2.2 Image of the portable diagnostic system consisting of a microfluidic control system (box on the 
left), a fluoresce USB microscope , a dELISA microfluidic chip (center), and a laptop computer 




Figure 2.3 Integrated micro droplet dELISA platform. (A) Schematic of the assay chip (top and 
bottom views) (B) Photograph of the disposable assay chip. (C) Droplet generator encapsulating 
microbeads. (D) Fluorescence micrograph of the droplets. (E) Schematic of the platform with a 
mobile phone, three light sources, and the disposable chip. Adopted from Yelleswarapu et al. (66). 
 
2.4 Label-Free Plasmonic Biosensors 
Many of immunoassay methods use a fluorescence labeling process involving multiple 
washing steps prior to the analysis. The fluorescence technique is well established in life sciences 
but only provides the end output of the signal readout. As a result, these methods lack the ability 
to observe the time-course evolution of antigen-antibody complex formation processes. For this 
reason, we believe that introducing a label-free, real-time biosensing technique to immune cell 
function analysis will provide another promising approach to significantly advance scientific 
knowledge and disease diagnosis techniques.  
Label-free biomarker analysis has been performed using various types of sensors, including 
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mechanical (microcantilever(79), acoustic wave(80), quartz crystal microbalance mass(81)), 
electrical (electrochemical impedance spectroscopy(82, 83), amperometric detection(83, 84), 
capacitive affinity detection(85), nanoelectronic field-effect transistors(33, 34, 86), optical 
(photonic crystal(87, 88), optical resonator(89, 90)), and plasmonic (surface plasmon 
resonance(91-93), localized surface plasmon resonance (LSPR) (94-99) sensors. Among these 
label-free sensors, plasmonic biosensors (100-106) are particularly advantageous for point-of-care 
(POC) measurements.  
Over the last decade, plasmonic biosensors were extensively studied for various applications. 
As mentioned in the previous chapter, the principle of the plasmonic biosensors depends on the 
interaction of electromagnetic (EM) radiation on a noble metal in contact with surrounding 
dielectric medium.  Coherent oscillations of free electrons near the metal surface called surface 
plasmons (SPs) resonate with incident excitation light frequency. SPs own the evanescence field 
at the boundary area between the metal and dielectric region and this field exponentially decays 
into a dielectric region. The resonance mode of SPs is sensitive to the local refractive index change 
and this change is induced by the adsorption of biomolecules in the metal-dielectric interface 
results in the alteration of the resonant condition of SPs. SP-based biosensing is found in two 
settings: (1) the surface plasmon resonance (SPR) setting, where SPs occur at the interface between 
a thin metal substrate and a dielectric medium; and (2) the localized surface plasmon resonance 
(LSPR) setting, where SPs are excited at the surface of subwavelength sized 
nanoparticle/nanostructure by an external light source (Figure 1.3). 
The most widely used plasmonic biosensing technique for biological and chemical analyte 
detection is label-free SPR biosensing. Especially for the biomolecule sensing (e.g. biomolecule 
quantification), SPR biosensors can overcome the shortcomings of labeling-based conventional 
 24 
techniques, such as long sample preparation time, complex processes, and large sample volume 
requirements, by eliminating tedious labeling processes. However, SPR detection suffers from 
several fundamental limitations while working as a biomolecule detection sensor due to its 
Kretschmann arrangement involving a bulky prism, and yielding a longer surface plasmon decay 
length (d) than the LSPR technique. This SPR arrangement hinders sensor miniaturization and 
integration with other functional systems, such as point-of-care devices. Moreover, the longer 
surface plasmon decay length (d) in SPR is typically on the order of half of the resonance 
wavelength (few hundreds of nm). This feature enables SPR biosensors to provide higher 
sensitivity to a bulk refractive index (RI) change, and is susceptible to background noise coming 
from bulk refractive index fluctuation. The sensitivity of SPR biosensors usually lies between 10-
7 and 10-6 in refractive index unit (RIU) (107, 108) which represents the range of pM-nM detection 
limit for the target analyte detection. However, in clinical studies the small molecule such as 
cytokine molecule concentration falls around range of pM-fM (31). Thus, to overcome the 
sensitivity limitation, some of SPR sensing platforms involved using secondary antibodies or 
compounds to amplify the sensing signal. 
Chou et al. demonstrated an SPR biosensor combined with a secondary antibody as a signal 
enhancer for detecting IL-6 in cell culture medium and achieved a detection limit around 1.3 ng/mL 
(109). Several studies further use nanoparticles to enhance the SPR signal. Martinez-Perdigueroa 
et al. and Law et al. developed a nanoparticle-based SPR biosensor by integrating gold 
nanoparticles and immunoassay technologies into SPR system to detect cytokines (Figure 2.4) 
(110, 111). In both studies, an evanescent field that was extended from the gold film to the gold 
nanoparticles induced plasmonic coupling, drastically enhancing the detection sensitivity. 
Approaches mentioned above introduce a secondary element to enhance the SPR signal and 
 25 
provide better detection limit for the sensing. However, all these methods implemented additional 
assay steps, complicate overall procedures, and diminish the merits of label-free sensing by tagging 
labels to the target molecule.  
 
Figure 2.4 (A)-(B) SPR sensing introducing gold nanoparticles to enhance the SPR signal to increase 
sensitivity (110, 111). (C) Modified characteristics of metal thin film layer to improve SPR sensing 
capability (112). 
 
Battaglia et al. explored alternative SPR excitation methods using fiber-optics to improve the 
sensing performance for SPR detection (93). In the study, IL-1, IL-6 and TNF- in PBS solution 
was detected with fiber-optics and achieved sensitivity around 1 ng/mL, but failed to meet the 
sensitivity level of clinical requirements such as few pg/mL. Furthermore, improvements of the 
sensing capability of SPR biosensors were explored by improving the characteristics of the metal 
thin film layer (Figure 2.4C) or by altering the dielectric surrounding (112). 
Recent advances in nanomaterials and nanofabrication processes open up the potential of 
LSPR plasmonic biosensing techniques for fast, real-time, label-free detection of biological 
species. The evanescence field surrounding LSPR sensors is directly excited by EM illumination 
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by free space optics. As a result, in LSPR, the bulky optics is not required and the system can be 
miniaturized and integrated with other systems. Furthermore, the EM field is highly confined to a 
local area near a metal nanostructure surface; biomolecules attached onto the nanostructure surface 
occupy a large fraction of the evanescence field volume. This leads to a significant change of the 
LSPR signal from the sensing substrate and result into high sensitivity that allows capability to 
detect small molecules.  
 
Figure 2.5 (A) A single silver nanoparticle-based nanoplasmonic biosensor for immunoassay detection 
(113). (B) Fiber-optics based rapid, sensitive LSPR biosensing platform (114). 
 
Huang et al. demonstrated LSPR biosensors detecting TNF-α molecules using a silver 
nanoparticle (113). This biosensing technique offered an ultrasensitive platform which enables 
measuring single molecule level detection. But this sensing mechanism requires long analysis time 
for analyte binding to reach equilibrium, which hinders use of rapid immune diagnosis application. 
For more rapid sensing of cytokine molecules, Chiang et al. and Huang et al. measured IL-1 and 
TNF- by providing few tens of pg/mL detection sensitivity within less than 10 min (114, 115). 
However, in these platforms the fiber probe should be dipped into a large volume of sample for 
signal measurement, which leads to practical limitations in its clinical applications. More recently, 
a) b)
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Chen et al. developed a nanoparticle patterned microarray type of LSPR biosensing device 
detecting multiple cytokine species using few serum cytokine samples in a single device at the 
same time (31). In this study, instead of using a single nanoparticle, the patterned array of 
nanoparticles was used as sensing element and functionalized with six different probe antibodies 
for sensing. This platform allows high throughput analysis of cytokine biomarker in 1 µL serum 
sample to a detection limit around 10 pg/mL within 40 min.   
Despite the recent advancements, the sensitivity of a majority of LSPR biosensors still falls 
short of matching that of ELISA and other non-label-free assay techniques. This warrants further 













Rapid Single-molecule Digital Detection of Protein Biomarkers for Near-real-
time Monitoring of Systemic Immune Disorders 
 
3.1 Introduction to the Study 
The evolution of biomarker-guided precision-medicine therapies targeting specific 
pathological processes has advanced rapidly, based on a greater understanding of genomic, 
molecular, and cellular data of an individual patient (116, 117). However, implementing the 
precision medicine approach in critical care uniquely faces enormous challenges (118). In 
particular, timely diagnosis and treatment of a quickly evolving illness (119-121) require both fast 
and sensitive measurement of biomarkers as well as accessibility near the patient. Numerous 
efforts have been undertaken to develop rapid immunodiagnostics, including assay step 
simplification (30), label-free biosensing (31-35), surface-to-volume ratio enhancement (36-38), 
active analyte mixing (39, 40), and molecular pre-concentration (41, 42). Nonetheless, these 
methods generally sacrifice assay sensitivity and specificity, and face significantly increased 
complexity and cost resulting from sophisticated micro/nanofabrication. For a system with weak 
antigen-antibody affinity, where the protein binding kinetics are solely limited by the surface 
reaction rate (reaction-limited regime (43)), the aforementioned methods involving active mass 
transport enhancement or miniaturization become less effective for shortening the assay time. 
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Digital immunoassays are emerging techniques for biochemical analysis of analytes in low 
abundance. Their single-molecule sensitivity originates from binary counting of On/Off signals 
amplified within various types of small sub-volume partitions (52). The wide use of digital assays 
can be found in the literature as a platform for the ultrasensitive detection of nucleic acids (68, 70), 
proteins (52-54, 122-124), single viruses (125), and exosomes (126). The most well-established 
commercial implantation of an enzyme-linked immunosorbent assay (ELISA)-based digital assay, 
namely digital ELISA (dELISA), is Quanterix’s Simoa (51). However, the high assay and 
instrumentation costs with the current bulky design in optics and fluid handling components 
prevent its application for near-bedside real-time diagnosis. Recently, Yelleswarapu et al. (122) 
developed a smartphone-connected microfluidic platform for miniaturized dELISA detection of 
cytokines using parallel droplet generation/detection methods. Despite the exciting performance 
and potential for point-of-care operation, this platform still requires a long sample incubation time 
> 90 min, thus leading to a total sample-to-answer time > 2 hours. In general, there is lack of a 
platform that can provide near-realtime protein biomarker profiling with a large clinically relevant 
dynamic range from fM to sub-nM.  This is a critical bottleneck against fulfilling the promise of 
biomarker-guided precision medicine in time-sensitive critical care.  
 
Figure 3.1 Schematic concept of instantaneous single-molecule binary counting of pre-equilibrium protein 
binding events. The combination of pre-equilibrium reaction quenching with single molecular counting can 
theoretically achieve an assay with a near-zero incubation time without losing linearity. 
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Herein, we introduce the concept of instantaneous single-molecule binary counting of non-
equilibrium protein binding events to simultaneously realize speed and sensitivity – the two key 
combined features critically lacking in conventional technologies for acute illness. This concept 
provides the basis for the PEdELISA technique enabling a rapid, sensitive biomarker analysis with 
a significantly shorter (up to 10-fold) incubation time than the gold standard ELISA method. The 
technique captures the “snapshot” of a pre-equilibrated 2-step sandwich assay formation process 
quenched at its very early stage (within 15-300 sec) and applies single-molecule binary counting 
for biomarker quantification (Figure 3.1). In this study, we were surprised to find that this early 
quenching approach maintained a large assay linear dynamic range from fM to clinically relevant 
sub-nM, which is conventionally believed to be far outside the range permitted by single-molecule 
binary counting (56, 127). We developed a theoretical model to validate this concept and later 
demonstrated this concept with a digital assay that could uniquely performed in nearly real-time, 
longitudinal profiling of circulating protein biomarkers in septic mice for which the sample volume 
was highly limited, and in human patients treated with CAR-T therapy who were experiencing 
cytokine release syndrome (CRS). The captured temporal biomarker profiles manifested rapid 
feedback to the monoclonal antibody therapy, which may potentially guide individualized 
management of CRS under optimal intervention conditions.  
3.2 Materials and Methods 
3.2.1 Materials.  
The mouse CitH3 capture antibody was generated by ProMab Biotechnologies, Inc. 
(Richmond, CA, USA). CitH3 detection antibody and HRP-conjugated secondary antibody were 
purchased from Abcam and Jackson ImmunoResearch. Human IL-6 capture and biotinylated 
detection antibodies were purchased from BioLegend. Human TNF-α, IL-2, and MCP-1 assay 
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were developed based on uncoated ELISA kits (including capture antibody, biotinylated detection 
antibody, and avidin-HRP) from Invitrogen. Dynabeads, 2.7μm-diameter carboxylic acid, and 
epoxy-linked superparamagnetic beads, QuantaRedTM, an enhanced chemifluorescent HRP 
substrate, Alexa Fluor™ 488 Hydrazide, EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
hydrochloride), Sulfo-NHS (Sulfo-N-hydroxysulfosuccinimide), MES (2-(N-
morpholino)ethanesulfonic acid) buffered saline, TBS StartingBlock T20 blocking buffer, and 
PBS SuperBlock blocking buffer were obtained from Thermo Fisher Scientific.  
3.2.2 Finite Element Analysis of Transient Digital Assay.  
The commercial FEA software COMSOL 5.4 Multiphysics was used to model the 2-step 
PEdELISA process involving molecular transport and bead surface reaction. Several model 
assumptions were made based on experimental conditions. First, we assumed that the magnetic 
beads were evenly distributed in the buffer solution by the orbital shaker mixing during the 
incubation process. As a result, the model only considered the half of a single bead surface within 
the “reaction volume,” which is scaled by the sample volume divided by the number of the beads 
used. The cytokine diffusion profile was evaluated using the transient mass convection and 
diffusion equation as:  
 𝜕𝑐
𝜕𝑡
= 𝐷 ∙ ∇2𝑐 − ?⃗? ∙ ∇𝑐 + 𝑅 
(1) 
where c is the concentration, the convection term ?⃗? ∙ ∇𝑐 was omitted, and we adjusted the value of 
the diffusion coefficient D to reflect the mass transport under active mixing. The first step of the 
PEdELISA process was modeled by considering the simultaneous reactions between the capture 
antibody (Ab1), antigen ligand (L), and the detection antibody (Ab2). The derived kinetics equations 











where kon and koff are the association/dissociation constants, and [ ] represents the concentration or 
surface density of the three agents. For simplicity, we assumed that the affinity of Ab1 to L is the 
same as the affinity of Ab2 to L (kon1=kon2, koff1=koff2). For the second step labeling process, the 
avidin-HRP conjugate and the immune-complex Ab1LAb2, were modeled as the “free ligand” and 





Finally, to translate the molecular binding events into the digital assay readout, we used the 
Poisson distribution equation given as:  
 𝜆 = −ln (1 − 𝑃𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒) (6) 
where Ppositive is the fraction of fluorescence-activated “On” beads to the entire beads and λ is the 
mean expectation value, which represents the average number of immune-complexes per bead.  
3.2.3 Definition of the Pre-equilibrium State.  
Using the Langmuir adsorption model:  
 𝑑[𝐴𝑏𝐿]
𝑑𝑡
= 𝑘𝑜𝑛[𝐿]([𝐴𝑏]0 − [𝐴𝑏𝐿]) − 𝑘𝑜𝑓𝑓[𝐴𝑏𝐿] 
(7) 
where [𝐿] is volume ligand concentration, [𝐴𝑏]0 is initial surface antibody concentration, [𝐴𝑏𝐿] 
is the surface concentration of ligand-antibody complex, and 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 are respectively the on-
rate and off-rate constants.  
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For simplicity, we assume the surface ligand concentration (cytokine concentration) [𝐿] = 𝑐0 =
𝐶𝑜𝑛𝑠𝑡𝑎𝑛𝑡 (not changing with time, perfect mass transfer). Then the above differential equation 








[1 − 𝑒−(𝑘𝑜𝑛𝑐0+𝑘𝑜𝑓𝑓)𝑡] 
(8) 






In an increasing system, the time constant τ is the time for the system to reach (1 − 𝑒−1) ≈ 63.2% 












Figure 3.2 Theoretical binding kinetics of bead surface adsorption process. The pre-equilibrium state is 
determined by the time constant τ based on the Langmuir model.  
 
The PEdELISA is operating at pre-equilibrium state: t<τ. To estimate the τ value, typical 
dissociation constant Kd for antibody to antigen is 1nM, with kon≈106 M-1s-1 and koff<=10-3 s-1, and 
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clinical relevant cytokine detection concentration c0 is generally from 10fM to 0.1nM. The time 
constant τ is estimated to be around 1000sec (16.7min).  
In reality, the solution ligand concentration [L] is not a constant, but decreasing over time c(t) 
as the bio-reaction goes on and it also takes the time for the target molecules to diffuse to the sensor 
surface. Therefore, the real binding curve will look like the blue diffusion line as shown in Figure 
3.2 (solved by a numerical solver COMSOL) or somewhere in the middle of the convection and 
diffusion line. Nonetheless, a simple time constant defined based on the ideal Langmuir binding 
curves is good enough to define a pre-equilibrium zone. After considering the diffusion and koff 
less than 10-3 s-1 cases, this time constant will be longer than the estimated 16.7min. The incubation 
time of PEdELISA is in between 15-sec to 600-sec and it is operated at the early pre-equilibrium 
state. 
3.2.4 Device Fabrication and Assembly.  
The microwell structure and the microfluidic channel were fabricated in poly-dimethylsiloxane 
(PDMS, Dow Corning Sylgard 184) using the standard soft lithography technique.  Firstly, two 
silicon molds, one for the microwell structure with a thickness of 4 μm (SU-8 2005, Micro-Chem), 
the other for the microfluidic channel with a thickness around 100 mm (SU-8 2050, Micro-Chem), 
were fabricated by photolithography. Secondly, a precursor of PDMS prepared at a 10:1 base-to-
curing agent mass ratio was spin-coated onto the microwell silicon mold (300rpm, 1min) and 
poured over the microfluidic channel mold with a thickness around 4mm. Both of the molds were 
left on the flat surface overnight and then cured in an oven at 60 °C for 2h. The surface of the thin-
film PDMS microwell layer cured on the silicon mold wafer was treated by oxygen plasma. The 
film was aligned using a custom-machined aluminum jig and bonded onto a pre-cleaned 75×50mm 
glass slide, and finally removed from the silicon wafer. The PDMS microfluidic channel layer was 
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cut and peeled off of its silicon mold and punched manually to form its inlet and outlet. After 
second oxygen plasma treatment, the top surface of the thin-film PDMS microwell layer was 
aligned with and bonded to the PDMS microfluidic channel layer. Finally, the entire chip was 
briefly baked at 60 °C and stored at room temperature before use.  
3.2.5 Antibody Conjugation to Magnetic Beads.  
The non-color encoded magnetic beads were prepared by conjugating epoxy-linked Dynabeads 
with the capture antibody molecules at a mass ratio of 6 μg (antibody): 1 mg (bead). To prepare 
the fluorescence encoded magnetic beads for multiplex detection, carboxylic acid-linked 
Dynabeads were first labeled with AF 488 dye, and then conjugated with the capture antibody 
molecules as follows: 100 μL of a bead stock solution (30 mg beads/mL) was washed with 25mM 
MES buffer at pH=5 for two times, mixed with 100 μL of a 1mg/mL EDC solution and 100 μL of 
a 1.13mg/mL sulfo-NHS solution (25mM MES buffer), and then incubated at room temperature 
on an orbital shaker at 1000 rpm for 30min. Then, the beads were washed two times with the MES 
buffer and mixed with a 1 μg/mL AF488 hydrazide solution for 30min. Then, the beads were 
washed 5 times with 0.5 mL PBS-T (0.1% Tween20) solution, resuspended in 300 μL of a PBS-T 
(0.05% Tween20) solution, and transferred into a new polypropylene tube. The AF488-encoded 
beads were washed two times with the MES buffer, reactivated with 100 μL of a 50 mg/mL EDC 
solution and 100 μL of a 50 mg/mL sulfo-NHS solution for 30 min, and then rinsed two times with 
the MES buffer. A 100 μL capture antibody solution was prepared and mixed with the activated 
beads at a mass ratio of 12 μg (antibody): 1 mg (bead) for 2h at room temperature. Then the beads 
were separated and washed 4 times with 0.5 mL PBS-T (0.1% Tween20) solution and stored at 10 
mg beads/mL in PBS-T (0.05% T20 + 0.01% Sodium Azide) solution wrapped with aluminum 
foil at 4 °C. No significant degradation was observed within the 3-month usage. 
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3.2.6 Mouse CLP Preparation and Sample Collection.  
Sepsis was induced by cecum ligation puncture (CLP) in male mice with age between 8-12-
week-old. The peritoneal cavity was opened under inhaled isoflurane anesthesia. Cecum was 
eviscerated, ligated below the ileocecal valve using a 5-0 silk suture at three different points (50%, 
75%, and 100%), and punctured through (two holes) with a 21-ga needle. The punctured cecum 
was squeezed to expel a small amount of fecal material and returned to the peritoneal cavity. The 
abdominal incision was closed in two layers with 4-0 silk suture. The Sham mouse was handled in 
the same manner, except that the cecum was not ligated and punctured. Around 15 µL blood was 
drawn through the tail vein every 4-5 hours after CLP. The blood was allowed to clot by leaving 
it undisturbed at room temperature for 30 minutes. The clot was then removed by centrifuging at 
2000 × g for 15 minutes in a refrigerated centrifuge. The supernatant serum was used for the 
following PEdELISA assay. This protocol was approved by the University of Michigan 
(PRO00008861). All surgery was performed under anesthesia, and all efforts were made to 
minimize suffering. 
3.2.7 Patient Blood Sample Collection and Preparation.  
Subjects undergoing CAR-T therapy were recruited and samples collected with informed 
consent for each subject under the University of Michigan IRB protocol HUM00115179/UMCC 
2016.051. Control samples were obtained from healthy volunteers with informed consent under 
University of Michigan IRB protocol HUM00092161. All blood samples were collected on-site at 
the University of Michigan Medical School Hospital. Venous blood was collected for serum into 
a vacutainer containing no anticoagulant. Blood samples were then transported to the lab, allowed 
to clot for at least 30 minutes, and processed for serum isolation. Samples were centrifuged at 
1,200 × g for 15 minutes at room temperature. Serum was then removed by pipette and aliquoted 
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into 2 mL screw cap tubes. Serum aliquots were then transported fresh on wet ice for the 
PEdELISA assay or banked at -80 ºC.  
3.2.8 PEdELISA Assay.  
The capture antibody beads were first incubated with the TBS StartingBlock buffer (0.05% 
Tween20) for 30 min to block the beads surface and quench all the unreacted groups. Then the 
beads were washed once with a PBS-T buffer and divided into 96-well reaction tubes so that each 
tube has approximately 8×105 beads. The samples were diluted by the ELISA dilution buffer (1% 
BSA, 0.05% Tween20). The dilution ratio for CitH3 is 1:4. The dilution ratio for IL-2 and TNF-α 
is 1:2 due to their low abundance in serum and the dilution ratio for IL-6 and MCP-1 is 1:4 or 1:8 
based on the potentially high level under severe CRS condition. The recombinant standards were 
diluted by an ELISA dilution buffer spiked with 25% fetal bovine serum. The diluted samples 
were temporarily kept on wet ice until use. In the two-step assay protocol, a mixture of 10 μL of 
the sample or standard and 10 μL of a biotinylated detection antibody (0.25 μg/mL) solution was 
loaded to the tube and incubated with the magnetic beads for a period of 60 sec to 300 sec. After 
a quick buffer exchange (1× PBS-T, 0.1% Tween20), the beads were then incubated with 40 μL 
of the avidin-HRP solution for 30 sec. After washing in a 2× PBS-T (0.1% Tween20) buffer 
solution 6 times, they were resuspended in 11 μL of a 1× PBS-T (0.1% Tween20) buffer solution. 
10 μL of the bead solution was loaded into the premade microfluidic chip, which contains 16 
separate channels for different samples. Each channel was then loaded with 20 μL of the enhanced 
chemifluorescent HRP substrate QuantaRed solution and subsequently sealed with 20 μL of 
fluorinated oil (HFE-7500, 3M). The inlets and outlets of the channels were covered by glass 
coverslips to prevent evaporation during the imaging process. A programmable motorized 
fluorescence optical microscopy system was used to scan the image of the bead-filed microwell 
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arrays on the microfluidic chip, identify the bead type (non-color vs. AF488 dyed), and detect the 
enzyme-substrate reaction activity. This system is composed of Nikon Ti-S fluorescence 
microscope, a programmable motorized stage (ProScan III), a halogen lamp fluorescence 
illumination source, a SONY full-frame CMOS camera (α7iii), and a custom machined stage 
holder. The motorized stage was pre-programmed to follow the designated path to scan the entire 
chip. The image process took about 20 sec to scan each channel (1 sample/channel, total 16 
channels), following 3 sequential steps: 1. Scan the QuantaRed channel (532nm/585nm, 
excitation/emission) 2. Scan the AF488 channel (495nm/519nm, excitation/emission) 3. Scan the 
brightfield. 
3.2.9 Data Analysis and Image Processing.  
In the digital immunoassay, statistical analysis of the fraction of the fluorescence-activated 
“On” beads to the entire beads across 336,000 femtoliter-sized microwells per channel determined 
the analyte concentration value. A custom image processing MATLAB code was used to analyze 
scanned microwell-array images automatically with high speed and accuracy (Figure 3.3). Briefly, 
the code simultaneously captures the images from all of the AF488 (bead encoding dye), 
QuantaRed (labeling dye), and Brightfield channels and superimposes them. Then, it counts the 
numbers of the “On” and “Off” states for the two types of beads (AF488-encoded and non-color 
types) trapped in the microwells from the superimposed images. The code includes algorithms to 
avoid counting aggregated beads and to eliminate signals from false positives, imaging defects, 
and large fluorescence contaminations. The fraction of the “On” states were correlated with the 




Figure 3.3 Dual-plex PEdELISA assay encoded using (a) 2.8 µm-diameter superparamagnetic beads first 
dyed with Alexa Fluor (AF) 488 and then conjugated with capture antibodies against TNF-α or MCP-1 and 
(b) 2.8 µm-diameter non-color superparamagnetic beads conjugated with capture antibodies against IL-6 
or Il-2. Image of arrayed microwells in (c) bright field, (d) AF 488 channel, (e) QuantaRed (Qred) channel, 
and (f) three-channel (bright field + AF 488 + Qred) overlay modes . (g) MATLAB code-processed bright 
field image to determine the overall bead filling rate with filled (+) and empty (–) wells. (h) Sorted 
microwell intensity histogram. (i) Bead and microwell counting across 100 arrays of microwells. (j) 
MATLAB code-processed two-channel (AF 488 + Qred) overlay image for dual-color digital counting 
(dark green square: AF488-dyed bead, blue circle: non-color bead with Qred emission, light green diamond: 
AF488-dyed bead with Qred emission). Snapshot of Qred image showing enzyme active Qred "On" 
microwell spots with the presence of bead-bound analyte molecules (e.g., TNF-α and IL-2) at (k) 100 
pg/mL, (i) 20 pg/mL, and (m) 4 pg/mL.   
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The detailed 4-step algorithm is summarized below:  
Step 1: The code simultaneously reads all of the bright field (Figure 3.3c), Alexa Fluor (AF) 488 
(Figure 3.3d), and QuantaRed (Qred) (Figure 3.3e) images and first identifies the locations of 
AF488-dyed beads based on fluorescence intensity thresholding (the method of image 
segmentation by creating binary images). Sub-algorithms identifying the area and signal intensity 
of beads are used to remove counts of defects like clusters of aggregated beads. If a defect is 
identified by a pre-defined value of aggregation severity, it is removed from the counts for the 
Qred and bright field images (similar in step 2 and 3).  
Step 2: The Qred image is analyzed based on fluorescence intensity thresholding, size-based circle 
detection, and morphological dilation and erosion to identify the locations of all the enzyme active 
“On” (or Qred "On") microwells. Sub-algorithms identifying the total number, areas, signal 
intensities, inter-distances, and image boundaries of arrayed microwells are used to eliminate all 
false positives, image defects, and large fluorescence contaminations. Signal crosstalk is an issue 
uniquely found in the Qred image analysis. It is a type of false-positive counting that often happens 
when a microwell is so bright that a few of its nearest neighboring microwells in the hexagonal 
array arrangement are also brightened up to exceed the threshold intensity. In this case, these 
neighboring microwells are falsely counted as “On” signals even though they are not actually 
enzyme active. To mitigate this issue, we applied a distance pattern recognition algorithm, which 
first identified all the bright spots with their 6 nearest neighbors and then performed a second-
round intensity check (high threshold) to determine if their neighboring microwells are true or 
false positives.  
Step 3: The bright field image is analyzed to identify the areas of microwells using edge and pattern 
recognition algorithms based on the Sobel edge detection methods. Then, the microwell brightness 
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intensity is averaged over the identified area and its values are sorted for the entire arrayed 
microwells in the bright field image (Figure 3.3h). This microwell intensity sorting effectively 
helps divide the microwells into two distinct groups: those that contain (+) or do not contain (-) 
beads. The separation line was determined by the maximum intensity slope (first derivative) of the 
sorted intensity values. Sub-algorithms are subsequently used to eliminate local image areas with 
poor bead-to-well contrast, air bubbles, and large dust. Step 3 has intrinsic uncertainties due to 
image quality variances in focus adjustment during the image scanning process. To suppress error 
due to these uncertainties, the counting process is repeated and averaged over the repeats. For 
example, in Figure 3.3g, the original design of each array of microwells contains 2,100 microwell 
locations but our MATLAB program indicates that the number of recognized microwells is 2,071. 
Among them, 1,114 wells are identified to have beads inside. The numbers of counted beads and 
microwells are obtained and averaged across 100 arrays of microwells to determine the overall 
bead filling rate for our counting (Figure 3.3i).  
Step 4: Finally, the code overlays the local images of the recognized AF488 positive beads on top 
of the Qred image to determine the numbers of Qred "On" microwells with and without an AF488-
dyed bead inside (Figure 3.3j). Considering a potential misalignment in the image overlay process, 
each Qred "On" microwell is marked with a blue circle 1.4 times larger than its original size. 
Finally, dual-plex cytokine detection is achieved by determining the fractional population of the 
enzyme active Qred "On" microwells to the bead-filled (+) microwells for both the AF488 dyed 
and non-color bead types. Figure 3.3k-m show Qred image snapshots for a mixture sample of TNF-




3.2.10 Statistics.   
Experiments with synthetic recombinant proteins were performed 3 times (in independent 
tests) to obtain the error bar. Due to the extreme low sample volume (<7µL) obtained from the 
CLP mouse at each time point, the CitH3 PEdELISA assay was performed with no repeat. Either 
duplicate or triplicate PEdELISA measurement was performed for the CAR-T patient sample at a 
single time point of the near-real-time cytokine profile monitoring test. Conventional ELISA tests 
were conducted with no repeat for a few selected time points of the banked serum samples.  Here, 
Pearson’s R-value was used to quantify the PEdELISA to ELISA correlations. Group differences 
were tested using one-way ANOVA and comparing means with the Tukey test. A p-value of < 
0.05 was considered to be statistically significant.  
 
3.3 Results 
3.3.1 Design of PEdELISA platform. 
We designed the PEdELISA process to employ a 2-step semi-homogeneous format so that it 
only involves (1) mixing the capture antibody-coated magnetic beads with the analyte and 
detection antibody solution to form the capture antibody-antigen-detection antibody complex (Step 
1) and (2) labeling with enzyme HRP (Step 2) (Figure 3.4A). To ensure accurate single-molecule 
counting at a wide range (10 fM-1 nM), which is relevant to clinical diagnosis, the process was 
designed to keep the population of fully labeled immune-complex molecules less than one per 
bead despite the original abundance of analyte molecules in each sample partition. In PEdELISA, 
this single-molecule counting condition is achieved by intentionally stopping the immunologic 
reaction in its pre-equilibrium state (see Figure 3.2 for the definition of the pre-equilibrium state).  
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Figure 3.4 (A) Two-step ultrafast, dual-plex PEdELISA process for pre-equilibrated assay system, 
including short (15–300sec) two-color magnetic bead incubation for the formation of antibody-antigen-
antibody immune-complexes (Step 1), buffer exchange, quick (30sec) avidin-HRP labeling (Step 2), and 
6-repeated rinsing within 96-well low-retention tubes. (B) Digitization process that involves trapping of 
magnetic beads into on-chip microwell arrays, loading of HRP fluorescence substrate (QuantaRed), and 
sealing of beads with fluorocarbon oil. Digital signal readout by automated image scanning and counting 
of fluorescently activated “On”-state microwells. The two-layer (microwell layer, micro-chamber layer) 
PDMS-based microfluidic detection chip which contains a total of 5.376 million d=3.8 µm microwells can 
handle 16 samples per scanning. CapAb: capture antibody. DeAb: detection antibody. 
 
For practical operation in PEdELISA, we designed a fluid manipulation system with a 96-well 
low-retention tube plate, a multichannel pipette, a plate holder with permanent neodymium 
magnets, and an orbital shaker (Figure 3.4A). The system enabled us to achieve precise time 
control, reduce the total sample volume to 10 μL, efficiently pull the magnetic beads to the sidewall 
of the plate holder for buffer exchange, and actively mix reagents in each reactor tube. We used 
fluorescence-color encoded beads that were conjugated with different capture antibodies to 
achieve multiplex measurement at high throughput (see Figure 3.3).  
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The reaction process was followed by a digital signal detection process (Figure 3.4B), in which 
a custom-designed microfluidic detection chip was used to isolate individual beads into sub-arrays 
of 336,000 fL-sized partition wells.  HRP reaction with a fluorescent substrate was used to indicate 
which beads were bound to antigen complexes. Confining the HRP catalyzed fluorophores to the 
tiny fL-sized volumes significantly amplified the readout signal up to single-molecule sensitivity 
for the immune-complex formation detection. The wells with activated fluorescence were imaged 
by an inexpensive full-frame CMOS camera and analyzed by a customized MATLAB code (Figure 
3.3). We estimated that the average cost for reagents and device fabrication was $0.69 per test 
(Table 3.1). The 2-step assay format incorporated the conventional enzyme labeling strategy using 
biotin-avidin linkages, which makes PEdELISA compatible with any commercially available 
ELISA reagents. We anticipate that the PEdELISA assay expenses are significantly reduced by 
scale-up production of the system. This would manifest competitive cost advantages of PEdELISA 
over the current commercial ELISA ($2-5/test) or Luminex technologies ($30/test) in any clinical 
lab that is equipped with standard epifluorescence microscope.  
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Table 3.1 Cost estimation of the PEdELISA assay  








Dynabeads® Antibody Coupling Kit 
(ThermoFisher 14311D) 




Dynabeads® M-270 Carboxylic Acid 
(ThermoFisher 14305D) 




Purified anti-human IL-6 Antibody 
(BioLegend 501110) 
250 500 μg 36 ng 1.39×104 0.018 
IL-6 (Or MCP-1, IL-2, TNF-α) Human 







Detection Antibody Kit included 500 μL 
(250×) 
0.04 μL 1.25×104 - 
Avidin HRP Kit included 1.25 mL 
(100×) 
0.03 μL 3.75×104 - 
Recombinant protein standard Kit included 10 vials - - - 
Blocking buffer (1% BSA) Kit included 150 mL 
(5×) 
- - - 
96-Well Nonskirted PCR Plates 
(FisherScientific 14-230-232) 
39.55 25×96 test 3 800 0.05 
Plain Glass Microslides 
(FisherScientific 12-550C) 





Dow Corning Sylgard 184 Silicone 
Encapsulant Clear 0.5 kg Kit 
50.36 500 g 1g 500 0.1 
StartingBlock™ (TBS) Blocking 
Buffer (ThermoFisher 37579) 
188 1L 100 μL 104 0.019 
QuantaRed™ Enhanced 
Chemifluorescent HRP Substrate Kit 
(ThermoFisher 15159) 
350 110 mL 10 μL 104 0.035 
Others (pipette tips, microcentrifuge 
tubes, HFE Oil, washing buffers, 
Tween 20, cover slips, etc) 
- - - - 0.3 
    Total 0.69 
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3.3.2 Theoretical study of “quench-and-snapshot” measurement. 
To theoretically predict outcomes of PEdELSIA, we first carried out a finite element analysis 
(FEA) on biomolecular interactions in digital immunoassay and then performed a parametric 
analysis to optimize the assay conditions. Our analysis accounted for mass transport and surface 
reaction for a theoretical “reaction volume” with a bead placed in its center (Figure 3.5A). 
Assuming that the beads were evenly distributed in the buffer/sample solution, the quantity of the 
reaction volume was taken to be the total buffer/sample volume divided by the number of the beads 
used for the assay. We first modeled the simultaneous molecular interactions between the analyte 
molecules, the capture antibodies immobilized on the bead surface, and the detection antibodies 
freely floating in the reaction volume using the mass transport and Langmuir adsorption equations 
(Figure 3.5B and Method). For simplicity, we assumed the same affinity for the capture and 
detection antibody molecules. Then, the enzymatic labeling process was modeled for a biotin-
avidin linkage with an affinity (129) of kon= 5.5×10
8 M-1s-1 and koff= 3.1x10
-5 s-1 (Figure 3.5C).  
Using the key model parameters listed in Table 3.2, we predicted the kinetics of the antibody-
antigen-antibody immune-complex formation process in Step 1 of PEdELISA for the affinity value 
(Kd= 10
-10-10-9 M) of typical commercially available antibodies. We plotted the average number 
of immune-complexes formed on a single bead surface, λ, as a function of the incubation time for 
the immune-complex formation process (Step 1 incubation time) and the analyte concentration 
(Figure 3.5D, E). Here, our model shows that the kinetics of the immune-complex formation on 
the bead surface is non-linear with time due to the simultaneous interactions of the target analyte 
to both the capture and detection antibody molecules. Nonetheless, the model predicts a linear 
increase in the quantity of the formed immune-complexes with the analyte concentration 
independent of time, the analyte mass transfer type (forced advection or passive diffusion), and 
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the number of beads. This linear relationship allows the digital readout of PEdELISA to increase 
linearly with the analyte concentration even for a very short assay incubation time. This finding 
provides the theoretical foundation for securing both high sensitivity and a large linear dynamic 
range in our pre-equilibrium quenching approach. 
 
Figure 3.5 Finite element analysis of biomolecular interactions in the 2-step PEdELISA process. (A) 
Schematic of the theoretical sphere, namely the “reaction volume,” used for modeling work, whose quantity 
is equal to the total sample volume divided by the number of beads. Reagent mass transport and binding 
kinetics are considered at the surface of a single magnetic bead placed in its center for half of the geometry 
due to symmetry. (B) Step1: immune-complex formation process involving the conjugation between target 
antigen molecules, capture antibodies immobilized on the bead surface, and detection antibodies freely 
floating in the reaction volume. (C) Step 2: avidin-HRP labeling process involving the conjugation of 
avidin-HRP with the biotinylated detection antibodies. The average number of targets (i.e., capture 
antibody-antigen-detection antibody immune-complexes) formed per bead, λ, is calculated as a function of 
the Step 1 incubation time and the analyte concentration at (D) Kd = 10-10 M and (E) Kd = 10-9 M. The 
model predicts that the PEdELISA readout linearly increases with the analyte concentration when λ is small 
(< 0.1). By accounting for the experimentally obtained noise floor, the LOD value can be theoretically 
determined for a given value of the Step 1 incubation time. (F) Predicted kinetics of the second step of the 
PEdELISA process. The fraction of the formation of HRP enzyme-labeled antibody-antigen-antibody 
immune-complexes is presented for three representative HRP concentrations of 1 pM, 10 pM, and 100 pM. 
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To optimize the assay conditions, we also evaluated the influence of several other crucial 
factors, such as the total number of beads per assay, the detection antibody concentrations, and the 
effect of sample-reagent mixing to enhance reagent mass transport. For a system with a large 
antibody affinity value (Kd=10
-10 M, Figure 3.5D), the total number of beads and the mass transport 
both play crucial roles in determining the assay kinetics. In contrast, the Step 1 incubation time is 
the only dominant factor in determining the assay speed for a system with a weak affinity value 
(Kd=10
-9M, Figure 3.5E). The PEdELISA assay uniquely provides the means to shorten the assay 
time for a reaction-rate limited weak-affinity system, in which other existing ultrafast 
immunoassay methods primarily driven by mass transport enhancement through active mixing or 
surface-to-volume ratio enhancement fail to achieve this. Figure 3.5F shows the kinetics of the 
labeling process for three representative avidin-HRP concentrations and suggests that the 
concentration of 100 pM is sufficiently large to complete the process with the incubation time 
(Step 2 incubation time) of 30-sec.  





kon1&2 koff1&2 Diffusivity 
10 fM~10 pM 0.25-1 μg/mL 104~107 M-1s-1 10-3~10-5 s-1 10 μm2/s 
Time Step1 Bead number Sample volume Antibody / bead Bead radius 






0~600 s 1-100 pM 5.5×108 M-1s-1 3.1×10-5 s-1  
 
In addition, we further evaluated the influence of several other key assay parameters on the 
binding kinetics in Step1 reaction (Figure 3.6) to obtain optimal assay performance. Here, these 
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parameters include the detection antibody (DeAb) concentration, the number of magnetic beads 
used per sample, and the capture antibody binding site density (Bd). The parametric analysis was 
performed for different mass transport conditions with and without active mixing (diffusion only) 
with different on-rate association constant (kon) values ranging from 10
4 to 107 M-1s-1, which 
represent different affinities of the antibody-antigen pair. We limited the detection antibody 
concentration to be < 1μg/mL in the calculation. This condition allows the assay to avoid 
experiencing high background non-specific adsorption in practice. We kept the magnetic bead 
amount above 105 per reactor (i.e., PCR tube) to ensure statistically significant digital counting. 
The number of the capture antibody conjugated per magnetic bead was estimated based on the 
experimental data provided by Dynabeads® Antibody Coupling Kit Manual (Thermo Fisher 
Scientific, Catalog number: 14311D).  
For a case where the antibodies have a very weak affinity (kon=10
4, Figure 3.6A), the immune 
complex formation kinetics is limited by the rate of surface reaction between the antigen and 
capture antibody molecules. The calculation indicates that neither mixing-driven mass transport 
enhancement nor the number of beads (equivalent to sample volume) will improve the assay 
performance in this "reaction-limited" regime. Although increasing the binding-site density (Bd) 
or detection antibody concentration helps increase the assay signal, it is impractical or costly to 
largely increase these two parameters. The average number of capture antibody conjugated per 
bead is almost invariant on the bead surface area. Meanwhile, blindly increasing the detection 
antibody concentration will generate a high level of background false positives due to non-specific 
surface adsorption.  
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Figure 3.6 Impact of detection antibody (DeAb) concentration, number of magnetic beads per sample, 
capture antibody binding site density (Bd), and mass transport on immune complex formation kinetics of 
PEdELISA assay. Here the assay signal output is determined by the average number of targets (capture 
antibody-antigen-detection antibody immune-complexes) formed per bead as a function of the Step 1 
incubation time for different antibody-to-antigen on-rate association constant values: (b) kon = 104 M-1s-1, 
(c) kon = 105 M-1s-1, (d) kon = 106 M-1s-1, and (e) kon = 107 M-1s-1.  
 
For another extreme case where the antibodies have a very strong affinity to the analyte 
(kon=10
7, Figure 3.6D), the immune complex formation kinetics is limited by the mass diffusion 
of the originally unbound antigen and detection antibody molecules.  Compared to the incubation 
time, the mass transport condition, the number of beads, and the reaction volume size are more 
dominant factors affecting the assay readout in the “diffusion-limited” regime. For example, with 
a large number of beads (106) in a small sample volume (20μL), the reaction is shown to quickly 
reach the equilibrium state within 2 min due to the fast reaction rate and the small number of target 
molecules per bead. This is especially the case we wish to avoid in the digital immunoassay. In 
the “diffusion-limited” regime, a depletion region growing near the bead surface over time is the 
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primary factor limiting the transport of target molecules to the capture sites from the far-field. 
Enhancing mass transport of these molecules through active mixing helps reduce the depletion 
region growth.  
Commercially available antibodies for cytokine detection generally have affinity values falling 
between those in the above two extreme cases(130). Based on our study here, we concluded that a 
strategy of preparing beads densely coated with capture antibody molecules, using a small number 
of these beads in a relatively large sample volume, and enhancing mass transport by active mixing 
would help achieve ultrafast PEdELISA assay without sacrificing its sensitivity.    
3.3.3 Analytical validation of the assay. 
To experimentally characterize the PEdELISA assay performance, we selected four signaling 
cytokine biomarkers involved in the progression of cytokine release syndrome (CRS), a significant 
complication of CAR-T that impacts morbidity and mortality (131, 132): IL-6; TNF-α; IL-2; and 
MCP-1. we first spiked four different types of buffers with 100pg/mL each cytokine: the 1x ELISA 
diluent (1% BSA, 0.05% Tween20), 10%, 25% and 50% fetal bovine serum (FBS), examining the 
impact of the different levels of background protein on the digital immunoassay signal pertaining 
to these fluids (Figure 3.7A-D). We calculated the signal-to-noise ratio (SNR), which is defined 
as the measured signal divided by the average blank signal + 3σ. In general, a larger surface 
blocking effect, perhaps, owing to the presence of albumin, was observed for serum media, which 
resulted in a slightly lower spike-in signal and background noise compared to the ELISA buffer. 
However, there is no significant difference in the SNR value between the different media groups 
(P>0.1 n=5-8, one-way ANOVA, Figure 3.7E). Therefore, we selected 25% FBS as the assay 
buffer for recombinant protein dilutions to mimic the serum detection background.  
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Figure 3.7 PEdELISA assay medium tests for 1x ELISA buffer, 10%, 25%, and 50% fetal bovine serum 
(FBS) spiked with 100 pg/mL of (A) IL-6, (B) TNF-α, (C) MCP-1, and (D) IL-2. All the tests were 
performed with the total assay incubation time of 5min+30s. (E) Signal-to-noise ratio (SNR) of IL-6, TNF-
α, MCP-1, and IL-2 measurements in different media. The SNR value represents the ratio of the spike-in 
signal to the background (negative control) signal. The serum was diluted using the 1x ELISA buffer to 
prepare the 10%, 25%, and 50% serum media. In general, a larger surface blocking effect, perhaps, owing 
to the presence of albumin, was observed for serum media, which resulted in a slightly lower spike-in signal 
and background noise compared to the ELISA buffer. However, there is no significant difference in the 
SNR value between the different media groups (P>0.05 n=5-8, one-way ANOVA).  
 
Figure 3.8A-D show standard curves for the four cytokines ranging from 0.32 pg/mL to 5 
ng/mL in 25% FBS with the Step 1 incubation time varying from 60 to 300 sec while fixing the 
Step 2 incubation time at 30 sec. To push the limit of measurement speed, we even tested and 
succeeded the assay with 15-sec (Step 1) and 30-sec (Step 2) incubation times by simply mixing 
all three reagents (detection antibody, avidin-HRP, antigen) with magnetic beads (1-step assay 
format). As theoretically predicted, the digital readout (the fraction of fluorescence-activated “On” 
beads to the entire beads) is highly time-dependent and in general, linearly proportional to the 
analyte concentration. We observed a variation in the signal output depending on the cytokine 
species. This is likely due to the difference in the antibody pair affinity across the different 
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cytokines. Notably, the linearity of the assay was confirmed over a three-order-of-magnitude 
concentration range regardless of the analyte type and quite well maintained even for the 15-sec 
ultrafast PEdELISA assay of IL-6 (the primary mediator in CRS). Thus, quenching the extremely 
pre-equilibrated reaction does not compromise our measurement resolution, which makes 
PEdELISA suitable for practical clinical diagnosis. 
 
Figure 3.8 Characterization and optimization of PEdELISA assay. PEdELISA standard curves for the four 
cytokines: (A) IL-6, (B) MCP-1, (C) TNF-α and (D) IL-2, with the Step 1 incubation time varying from 60 
sec to 300 sec and the Step 2 incubation time fixed at 30 sec. Due to the extreme under-labeled nature of 
the assay, the 15-sec and 30-sec assays were performed by merging the Step 1 and Step 2 process into a 
single step by mixing all required reagents. The LOD was determined by concentration from the reagent 
blank’s signal + 3σ (dotted line). 
 
We further validated the assay by comparing measurement results for spiked-in FBS samples 
between the conventional 3-step sandwich ELISA and PEdELISA with the Step 1 incubation time 
of 15-sec (Figure 3.9A) and 300 sec (Figure 3.9B). The ground truth (spike-in) value of the analyte 
concentration was set between 40pg/mL (2pg/mL) to 1000 pg/mL for the 15-sec (300-sec) assay. 
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We found good agreement between the two methods for both the 15-sec (R2=0.92) and 300-sec 
(R2=0.96) assays.  
 
Figure 3.9 Correlation between PEdELISA and conventional sandwich ELISA tests for the four cytokines 
using spike-in recombinant proteins in 25% fetal bovine serum: (A) 15-sec PEdELISA incubation time 
(R2=0.92), (B) 300-sec PEdELISA incubation time (R2=0.97). The ground truth is plotted in dotted line 
with scattered pre-determined spike-in concentrations. 
 
Table 3.3 Limit of detection (LOD) and standard root mean square coefficient of variance (RMS CV) of 
15-sec and 5-min PEdELISA. The LOD was determined by reagent blank’s signal + 3σ. 
 
Considering the noise floor of our experimental setup, we theoretically predicted the minimum 
incubation time for a given target value of LOD using our model and compared it with our 
experimental data (Figure 3.10). An excellent match was found between the experimental data and 
the theoretical curves with the assumption of typical antibody affinities ranging from 10-9-10-10 M. 
We observed and established a trade-off relationship between the LOD and incubation time of the 
digital assay. With an incubation time < 60 sec, it becomes difficult to precisely control the assay 
Cytokine 
Type 








Patient Assay standard 
RMS CV (%) 
IL-6 5 0.03034 25.9 0.58 17.3 
MCP-1 5 0.06402 333.2 8.29 27.5 
TNF-α 10 0.09152 96.7 2.20 24.4 
IL-2 10 0.03671 43.9 1.22 17.8 
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timing, which tends to cause more error to our measurement. Therefore, we selected a 300-sec 
incubation time for the later CAR-T patient study to maintain a high sensitivity and reliability.  
 
Figure 3.10 Theoretical (line) and experimental (scatter) LOD of PEdELISA as a function of the Step 1 
incubation time for four cytokines. 
 
 
Figure 3.11 Dual-plex PEdELISA specificity determined for combinations of (a) IL-6 and MCP-1 
(b) TNF and IL-2 with a 5-min incubation process. Only one type of cytokine was spiked-in into 
each medium and signals were measured for both probes in the dual-plex PEdELISA assay. 
Considering the relatively weak antibody-antigen affinity of MCP-1, the spike-in concentration of 
MCP-1 was set to be 5 times higher than those of the other three cytokines.   
 
Additionally, we verified the dual-plex assay’s specificity by quantifying the different antibody 
pair’s cross-reactivity (Figure 3.11). The assay LODs and the root mean square coefficient of 
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variance (RMS CV%) accumulated over the titration experiments for the four cytokines are 
summarized in Table 3.3. 
3.3.4 Longitudinal biomarker profile measurement for septic mice. 
To demonstrate our sample-sparing capability (5 µL), we applied the PEdELISA assay to 
measure serum biomarkers in a mouse model of sepsis. Frequent, longitudinal monitoring of serum 
biomarkers in a living mouse is impossible with current gold-standard ELISA technology, as it 
requires ~0.5 mL of whole blood (for duplicate assay) for each time point, which exceeds the 
amount feasible to sample consistently and longitudinally from a single mouse. As a result, the 
conventional approach for such longitudinal studies is to sacrifice mice at each time point to collect 
sufficient blood, comparing across mice for different time points. For this test, we studied a mouse 
model of CLP-induced septic shock, which provides a clinically realistic model of sepsis involving 
polymicrobial infection. In this model, the cecum is ligated at 50, 75, and 100% of the total length 
(Figure 3.12A) (133) (see 3.2.6 Materials and Methods). We developed and validated a PEdELISA 
assay (Figure 3.12B) for quantifying the sepsis biomarker, citrullinated histone H3 (CitH3). 
Catalyzed by peptidylarginine deiminase (PAD), CitH3 has recently been identified as an early 
step in neutrophil extracellular traps (NETs)-induced immune cell death (NETosis) in response to 
infection (134). We monitored the dynamic variations of serum CitH3 in four mice with different 
CLP-induced septic shock severity over their lifetimes (Figure 3.12C). Blood samples were 
collected through the tail vein every 4-5 hours from 0, 1, 5, 10 hr until death. To minimize and 
control for any effects of repetitive tail vein blood sampling on disease progression, only 15 µL of 
whole blood was collected through a capillary tube at each time point, and samples from a sham 
mouse without CLP were analyzed following the same surgical procedure. Blood samples were 
processed to obtain 5-7 µL serum and were then subsequently quantified by the PEdELISA.  
 57 
 
Figure 3.12 Fine-time monitoring of CitH3 on living mice (M1-4) with cecal ligation puncture (CLP). (A) 
CLP and mouse blood collection procedures. To induce different septic shock severity, the cecum was 
punctured and ligated at 100%, 75% and 50% of its total length. Around 15 µL of tail blood was collected 
at 0, 1, 5, 10, 15, 20 hr time points until the mouse’s death. (B) Correlation between PEdELISA and 
conventional sandwich ELISA for the CitH3 assay using a 10% sham mouse serum spiked with 
recombinant peptide (C) longitudinal CitH3 profiles of the four mice: 100%, 75%, 50% ligation, and sham 
over their lifetimes. 
 
For the 100% CLP mouse, a significant increase of CitH3 was observed at 5 hr time point 
(106.6 pg/mL) and the mouse was found dead within 12 hr. For the 75% CLP mouse, the increase 
of CitH3 was relatively delayed comparing to the 100% CLP mouse. But CitH3 continued to 
increase and reached a peak value of 1149.2pg/mL at around 32 hr when the 75% CLP mouse 
died.  For the 50% CLP mouse, no significant increase of CitH3 was observed in the first 10 hr, 
but then it started to increase between 10 and 20 hr and reached its plateau (~300pg/mL) at 20-30 
hr. We observed that the physical condition of the 50% CLP mouse recovered at 24 - 48 hr, and 
the CitH3 level went down during that period. However, its condition quickly became worse after 
70 hr and was found dead at 76h. For the sham case, the CitH3 level stayed low < 21.5pg/mL and 
the mouse stayed alive during the entire experiment. 
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3.3.5 Near-real-time multiplexed cytokine monitoring of post-CAR-T cell infusion CRS. 
Finally, we applied PEdELISA to real-time monitor the IL-6, TNF-α, IL-2, and MCP-1 profiles of 
hematological cancer patients showing severe (Patient A), moderate (Patient B), and mild (Patient 
C) CRS symptoms after CAR-T cell therapy following a pre-approved sample collection protocol 
(see Methods). CRS is a form of systemic inflammatory response accompanied by a high level of 
inflammatory cytokines released into the bloodstream by activated white blood cells. It can rapidly 
evolve (i.e., within 24-48 hours) from manageable constitutional symptoms (grade 1) to more 
severe forms (grade 2-4) (135), for which rapid and sensitive serum cytokine measurements could 
direct urgent interventions (136). Here, we performed real-time cytokine profile measurements 
within 2 hours after blood samples were freshly drawn in ICU with a serum sample to answer time 
in around 30 minutes (Figure 3.13A). To ensure the highest accuracy and sensitivity for these 
clinical measurements, we chose the total incubation time to be 300-sec (Step 1) + 30-sec (Step 2) 
in the 2-step assay format. We first assayed banked CAR-T patient serum samples (n = 23) with 
unknown analyte concentrations and validated them by ELISA (Figure 3.13B). The data between 
these two methods show an excellent linear correlation (R2=0.96), which confirmed the accuracy 
of the 2-step PEdELISA assay for human biomarker detection. Then, we performed real-time 
measurements which captured the patients’ complex immune responses to the immunomodulatory 
interventions manifested by the time-course variations of the cytokine profiles (see Figure 3.13C-
E). The dynamic behavior of these responses vary from patient to patient and decisions for 
treatment of CRS in these patients were made solely based on clinical criteria (e.g., CRS grades) 
summarized in Appendix A, which did not involve any serum cytokine data. 
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Figure 3.13 Near-real-time molecular monitoring of multi-cytokines of hematological cancer patients 
under CAR-T cell therapy. (A) Timeline of the hematological cancer patients received CAR-T cell therapy. 
Daily blood draw in general started five days before the infusion for baseline collection until the patient 
was discharged. For the real-time monitoring, the sample was first processed within 45 min of blood draw 
to extract serum and then tested by the PEdELISA within an hour. The data typically became available for 
clinicians within 2-3 hours from the initial point of patient blood collection. The initial onset of CRS and 
the development of neurotoxicity of three patients were labeled along the timeline. (B) Good agreement 
(R2=0.96) between 300-sec PEdELISA and ELISA was found for measurements of selected unknown 
CAR-T patient samples at different time points for four cytokines. Time-series profiles of CRS and CRES 
grade, IL-6, MCP-1, TNF-α, and IL-2 for (C) Patient A (grade 4 severe CRS), (D) Patient B (grade 2 mild 
CRS) and (E) Patient C (grade 0-1 very mild-CRS). Day 0 represents the day of CAR-T cell infusion. Data 
before Day 0 represents the baseline. The dotted line represents the time point when anti-cytokine drug 
tocilizumab (Anti-IL-6R), infliximab (Anti-TNF-α) were administered. The shaded region marks the period 
that the patient was received dexamethasone (corticosteroid).  These data do not account for a time lag of 
a few hours (or occasionally 8-12 hours) between the points of CRS grade recording and blood draw. 
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For Patient A, who had a high tumor burden, the time to initial onset of CRS was as short as 
13.5 hours. We found that the MCP-1 and IL-2 levels rose rapidly and reached the peak values 
(MCP-1 2947pg/mL; IL-2 39.72pg/mL) within 24 hours after CAR-T infusion, which is correlated 
with the patient’s grade 2 CRS accompanying the fever (39.3 ℃) on Day 1 (Figure 3.13C). We 
also observed the continuous rise of IL-6 transiently after the first tocilizumab administration (Day 
1) from 89.9pg/mL (Day 1) to its peak level of 1676 pg/mL through Day 2. A similar trend was 
also noted for Patient B (Figure 3.13D), who received the first dose on Day 2 with grade 1 CRS, 
and the peak (1546 pg/mL) was detected on Day 3. Patient A later developed grade 3-4 life-
threatening CRS on Day 6-9 and was readmitted into the ICU. During this period, the IL-6 level 
was found to approach an extremely high level of 4383pg/mL (Day 7) and 4189pg/mL (Day 8), 
and MCP-1 also reached its second peak 2103pg/mL, despite the fact that Patient A was 
administered with multiple immunosuppressing agents (see Appendix A). Interestingly, we did not 
see a significant rise of TNF-α and IL-2 during the second CRS peak. Later, the patient was 
diagnosed with grade 3 CRES (CAR-T cell-related encephalopathy syndrome) on Day 11. For 
Patient B (Figure 3.13D), one peak for all four cytokines was observed during the first eight days 
after CAR-T cell infusion, which is correlated with the patient’s clinical symptoms during this 
period (Grade 1-2 CRS). Patient C did not develop CRS until 6 days after the CAR-T cell infusion, 
although a slight elevation for all four cytokines was observed on Day 1 (Figure 3.13E). However, 
Patient C developed prolonged neurotoxicity starting from Day 8 and was therefore on steroids 
from Day 9 to Day 33. During this period, all four cytokines stayed at low levels. After steroids 
were stopped, Patient C’s IL-6 and MCP-1 levels rose back from Day 35 to Day 50 and grade 1 
neurotoxicity relapsed. We sorted the time-series cytokine data in Figure 3.13 all combined for the 
three CAR-T patients into non-CRS and CRS (grade 1 or higher) groups (Figure 3.14). We found 
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a clear group difference among IL-6, MCP-1 (P<0.001) and IL-2 (P=0.0059) concentration levels, 
even including the time points when CRS-suffering patients were put on steroids or 
immunosuppressive agents. However, for TNF-α, we did not observe a significant statistical 
difference (P = 0.142) and the data show a consistently low level of TNF-α for both groups across 
all the three patients. 
 
Figure 3.14 Group comparison (non-CRS vs CRS) of the three CAR-T cell therapy patients for (A) IL-6, 
(B) MCP-1, (C) TNF-α, and (D) IL-2. The statistical analysis between the two data groups was performed 
by one-way ANOVA comparing means with the Tukey test. IL-6 (P<0.001), MCP-1 (P<0.001) and IL-2 
(P=0.0059) levels were significantly higher in CRS condition than in non-CRS condition. TNF- α level was 
not significant (P=0.142). Note that the data include those obtained at the time points when CRS-suffering 
patients were put on steroids or immunosuppressive agents (tocilizumab, infliximab). 
 
3.4 Discussion 
While precision medicine approaches for cancer and genetic diseases have been remarkably 
successful (116, 117, 137), the area of clinical care of acute, severe systemic immune disorders 
has seen highly limited benefits, owing in part to the lack of sufficiently accurate, sensitive and 
clinically practical biomarker measurement technology (118). Real-time monitoring of acute 
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immune responses in patients over time poses significant technical challenges. In addition to a 
need for high speed and sensitivity, it requires the ability to capture temporal cytokine profiles 
varying over a wide concentration range between 10 fM and 1 nM for various cytokines. Meeting 
such stringent requirements, PEdELISA shows promise to enable early detection and intervention 
of the inflammatory response accompanying sepsis and CRS. Unlike conventional ultrafast 
immunoassay approaches, PEdELISA achieves high speed by applying single-molecule counting 
for an antibody-antigen-antibody immune-complex formation quenched at an early pre-
equilibrium state. As a result, total assay incubation time has been shortened from a few hours to 
a few minutes while achieving high sensitivity and linearity at a clinically relevant dynamic range. 
Our multi-physics FEA modeling analysis validated that the 2-step transient assay format of 
PEdELISA can maintain a linear relationship between the analyte concentration and the assay 
readout regardless of the snapshot acquisition timing.  Additionally, the modeling predicted very 
well the minimum required incubation time for the desired detection limit, which guided the digital 
assay design. For IL-6, the primary mediator of CRS, we experimentally showed that the entire 
assay incubation time can be as short as 15 sec with a LOD of 25.9 pg/mL while maintaining a 4-
order dynamic range up to 10 ng/mL. To our knowledge, the immunoassay demonstrated here is 
faster than any current ELISA-based assays with comparable sensitivity.  
Using the PEdELISA platform, we successfully demonstrated two applications: (i) 
longitudinal measurement of the protein biomarker CitH3 in the same, live animal (i.e., without 
need for mouse sacrifice) in a mouse model of sepsis with a serum volume as small as 5 µL, and 
(ii) rapid, high-sensitivity, near-real-time multiplex monitoring of CRS relevant circulating 
cytokines (IL-6, TNF-α, IL-2, and MCP-1) for three hematological cancer patients showing severe 
and moderate CRS symptoms after CAR-T cell therapy. With conventional ELISA or Luminex 
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methods, time-course biomarker measurement is only achieved by retrospective tests using banked 
samples.  In contrast, PEdELISA continuously provided real-time data for blood samples freshly 
collected from mice and human patients with a high time-resolution limited only by blood 
sampling frequency (1-5 hr for mice and 24 hr for humans, over most of the course of our studies).  
Our study using the CLP septic mice demonstrated the utility of the PEdELISA in a setting 
where blood sample volume is extremely limited. The demonstrated sample-sparing capability 
enabled us to longitudinally monitor the distinct characteristics of the CitH3 biomarker profiles in 
mice experiencing different illness severities (Figure 3.12C). CitH3 is shown to be a common 
mediator in various inflammation signaling pathways that trigger the neutrophil response to 
microbial infection (138, 139). Thus, temporal CitH3 profiles have the potential to indicate the 
progression and severity of infection-induced septic shock.  Interestingly, we observed a decrease 
in the CitH3 level in the late phase of the measurement for the mouse with 50% ligated-cecum, 
which represents a condition for inducing a low-severity state of sepsis.  The reason remains 
unknown but may potentially be revealed by a finer blood draw in the later phase of sepsis 
progression.  In addition to sepsis, the technology enables longitudinal serum biomarker research 
on a broad range of mouse models of disease, and is also relevant to critical care of infants or 
pediatric patients, from whom only limited blood volumes can be drawn. 
The PEdELISA test for human patients (Figure 3.13C-E) captured two CRS peaks after the 
CAR-T infusion for Patient A with severe CRS who had high tumor burden. The significantly 
elevated IL-6 and MCP-1 levels appearing at the second peak were associated with the severe, 
Grade 4 CRS experienced by the patient. Specifically, upon the first administration of tocilizumab 
(anti-IL-6R), we observed a temporary increase and then an eventual decline in serum IL-6 level 
for Patient A and B. In the future, such data if obtained from studies of larger numbers of patients, 
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could reflect pharmacodynamic information regarding the drug’s activity in inhibiting IL-6 
receptors (40), and potentially be used to predict treatment outcome. Interestingly, no elevation 
was observed for both TNF-α and IL-2 in Patient A during the second CRS grade peak. The reason 
remains unknown, although it could be partially attributed to the heavy dose of the general 
immune-suppressive corticosteroids the patient had received during this period. The mismatch 
between the detected low level of TNF-α and the clinical timing of infliximab treatment (anti-
TNF-α) opens up the possibility of biomarker-guided therapy to administer the correct targeted 
therapy at the optimal timing. We envision real-time cytokine profile data enabled by the 
PEdELISA method may in the future facilitate the early identification of patients with evolving 
CRS, to allow for more targeted and timely anti-cytokine treatment, as well as providing real-time 
feedback regarding cytokine levels after initiating treatment.  
Moving forward, further development of several aspects of our pre-equilibrium digital assay 
technology will be important for enabling direct implementation in the clinical setting. First, the 
manual sample preparation, handling, and washing procedures of the assay could be automated 
and integrated. All the processes of our test from the initial blood draw to the end result delivery 
currently takes up to 2 hours, including sample preparation and transportation. Our future work 
will integrate a finger-pricked inlet, an on-chip plasma separation unit, and a precisely controlled 
sample/reagent handling automation system into the PEdELISA platform for near-bedside 
operation. This would allow the whole test to be completed with a blood draw-to-answer time < 
30 min and truly enable “real-time” biomarker detection. Second, the current multiplex capacity 
could be extended by microfluidics-based assay miniaturization and operation. Multiplex 
measurement to screen multiple cytokines and other biomarkers at different time points would 






Machine Learning-Based Cytokine Microarray Digital Immunoassay Analysis 
 
4.1 Introduction to the Study 
Over the past few years, the approach of providing personalized treatment for severely ill 
patients based on their individualized molecular profiles has received considerable attention as a 
next step to advance critical care medicine (118, 140, 141). Progress has been made in identifying 
predictive and prognostic protein biomarkers in critical care which holds great promise in patient 
stratification (120, 142), disease monitoring (143, 144), and therapy development (141, 145).  For 
example, Huang et al (16) tested patients infected with the 2019 novel coronavirus (COVID-19) 
and reported that a panel of eight plasma cytokines showing significantly hightened levels allowed 
them to distinguish a group of severely ill patients from a group of mildly ill patients. However, 
even with the discoveries of these biomarkers, the medical community still falls behind with 
adopting the precision medicine approach to treat life-threatening acute illnesses, such as cytokine 
release syndrome (CRS), acute respiratory distress syndrome (ARDS), which are frequently 
associated with the 2019 novel coronavirus (COVID-19) (16, 146), due to the lack of a sensitive 
molecular profiling tool to quickly guide clinical decisions or interventions with a near-real-time 
assay turnaround (140). Additionally, to monitor the highly heterogeneous and time-pressing 
illness conditions, high multiplex capacity is equally important as sensitivity and speed for 
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improving diagnosis and prognosis accuracy with rich, comprehensive information on multiple 
biomarker profiles (16, 131, 132, 140). Currently, the commonly used clinical tools for multiplex 
serum/plasma protein analysis (147), including the bead-based assay coupled flow cytometry and 
the western blot, fall short of achieving the performance needed for critical care as they require a 
long assay time (>4 hrs), and laborious steps with limited sensitivity. 
Researchers have developed rapid (37, 39, 105, 148), point-of-care (32, 36, 149), multiplex 
(31, 63) immunoassays powered by microfluidics. Nonetheless, it is still challenging for these 
assays to simultaneously achieve a combination of high multiplexity and sensitivity with a rapid 
assay turnaround time in a clinical setting. By counting single-molecule reactions in fL-nL-volume 
microwells or droplets (52, 122, 124), digital immunoassays can provide unprecedented sensitivity 
(sub-fM detection) for biomarker analysis. Contrary to the conventional belief based on Possion 
distribution theory (56), our recent study (67) demonstrated that it is feasible to extend the single-
molecule counting approach to achieve near-real-time protein biomarker profiling at a clinically 
relevant pM-nM range by quenching reagent reaction at an early pre-equilibrium stage with an 
incubation process as short as 15-300 sec. However, existing digital immunoassay platforms (150) 
have limited multiplex capacity (up to 6-plex). The current method (122, 151) utilizes fluorescence 
dye-encoded beads to identify different analytes. Unfortunately, the nature of binary-based 
statistical counting brings a few critical challenges to multiplexing digital immunoassays with this 
method. First, the assay typically requires a large number of beads (e.g. Simoa uses 100,000 beads 
per plex (150)) for reliable analyte quantification. Mixing and counting such a large number of 
multi-color-encoded beads tends to cause false signal recognition due to optical crosstalk or non-
uniform color coating. Second, increasing multiplexity while keeping the assay’s sensitivity and 
accuracy additionally requires a large number of microwell arrays to accommodate the large 
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number of beads. This becomes impractical with the current platform as it demands a significantly 
increased assay device footprint and an image area size.  Third, the assay also encounters a 
significant bead loss during the digitization process partitioning the beads into sub-volumes after 
the initial reaction process performed for bulk reagent volume in a cuvette (100 L). All of these 
issues prohibit the translation of a cheap, robust, point-of-care multiplexed digital assay platform 
into near-patient applications, thus necessitating a new strategy. 
Here, we have developed a highly multiplexed digital immunoassay platform, termed the “pre-
equilibrium digital enzyme-linked immunosorbent assay (PEdELISA) microarray.” The 
PEdELISA microarray analysis integrates on-chip biosensors with a small footprint to minimize 
the number of images that are needed to read and fully automates the signal counting process, both 
of which are critically necessary for overcoming the bottlenecks against multiplexing digital 
assays. The analysis incorporates a powerful microfluidic spatial-spectral encoding method and a 
machine learning-based image processing algorithm into multi-biomarker detection. The spatial-
spectral encoding method confines color-encoded magnetic beads into the arrayed patterns of 
microwells on a microfluidic chip. The locations of the microwell patterns on the chip indicate 
which target analytes are detected by trapped color-coded beads. In contrast to the existing digital 
immunoassay protocol, the fully integrated microfluidic architecture allows the assay reaction to 
be performed entirely on-chip (no bead loss) at an early pre-equilibrium state, which only requires 
a sample volume < 10 L, a 5-min assay incubation and a 75 mm × 50 mm chip size. Based on a 
convolutional neural network (CNN), the machine learning algorithm permits unsupervised image 
data analysis while resolving false signal recognition accompanying the multiplexing of digital 
immunoassays. Employing these biosensing schemes, the PEdELISA microarray platform allows 
us to simultaneously quantify a large panel of biomarkers in half an hour without sacrificing the 
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accuracy. We used the platform to obtain longitudinal data for blood samples from human patients 
experiencing cytokine release syndrome (CRS) after chimeric antigen receptor T cell (CAR-T) 
therapy. The data signify the time-course evolution of the profiles of 14 circulating cytokines over 
illness development. With its near-real-time assay turnaround and analytical power, the platform 
manifests great potential to enable acute immune disorder monitoring that guides timely 
therapeutic interventions. 
4.2 Materials and Methods 
4.2.1 Materials.  
We purchased human IL-6, TNF-α, IL-2, IL-8, IL-13 capture, and biotinylated detection 
antibody pairs from Invitrogen™, and IL-1α, IL-1β, IL-10, IL-12, IL-15, IL-17A, IFN-γ, GM-CSF 
and MCP-1 from BioLegend. We obtained Dynabeads, 2.7μm-diameter carboxylic acid, and 
epoxy-linked superparamagnetic beads, avidin-HRP, QuantaRed™ enhanced chemifluorescent 
HRP substrate, Alexa Fluor™ 488 Hydrazide, EDC (1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride), Sulfo-NHS (Sulfo-N-hydroxysulfosuccinimide), MES (2-(N-
morpholino)ethanesulfonic acid) buffered saline, bovine serum albumin (BSA), TBS 
StartingBlock T20 blocking buffer, and PBS SuperBlock blocking buffer from Thermo Fisher 
Scientific. We obtained Phosphate buffered saline (PBS) from Gibco™, Sylgard™ 184 clear 
polydimethylsiloxane (PDMS) from Dow Corning, and Fluorocarbon oil (Novec™ 7500) from 
3M™. 
4.2.2 Antibody Conjugation to Magnetic Beads. 
We prepared the non-color encoded magnetic beads by conjugating epoxy-linked Dynabeads 
with the capture antibody molecules at a mass ratio of 6 μg (antibody): 1 mg (bead). The Alexa 
Fluor™ 488 (AF488) encoded magnetic beads were prepared by first labeling carboxylic acid-
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linked Dynabeads with AF 488 Hydrazide dye and then by conjugating the beads with capture 
antibody at a mass ratio of 12 μg (antibody): 1 mg (bead) using standard EDC/sulfo-NHS 
chemistry. Detailed protocol has been described in the previous chapter (67). We stored the 
antibody-conjugated magnetic beads at 10 mg beads/mL in PBS (0.05% T20 + 0.1% BSA + 0.01% 
Sodium Azide) buffer wrapped with an aluminum foil sheet at 4 °C. No significant degradation of 
these beads was observed within the 3-month usage.  
4.2.3 Microfluidic Chip Fabrication and Spatial-Spectral Encoding.  
The first step of the PEdELISA microarray chip fabrication involved the construction of three 
different PDMS layers (Figure 4.1). The first PDMS layer has arrays of hexagonal biosensing 
patterns with microwell (d=3.4 μm) structures (multi-array biosensor layer). The second one has 
bead settling flow channels of 2500 µm in width, 70 µm in height, and 65 mm in length (bead 
setting layer). The third one has channels of 4500 um in width, 90 µm in height, and 30 mm in 
length for the detection of analytes in loaded samples (sample detection layer). First, we 
constructed SU-8 molds for these three PDMS layers on separate oxygen plasma treated silicon 
wafers by standard photolithography. This process involved depositing negative photoresist (SU-
8 2005, SU-8 2050, MicroChem) layers at different spin coating speeds to form the designed 
thicknesses for the PDMS microstructure patterns. Subsequently, a precursor of PDMS was 
prepared at a 10:1 base-to-curing-agent ratio. To construct the multi-array biosensor layer, we 
deposited a thin PDMS precursor film (~300 μm) onto the microwell-patterned SU-8 mold by spin 
coating, baked it overnight (60 °C), and then attached it to a pre-cleaned 75×50mm glass substrate 
through oxygen plasma treatment. We made both of the bead settling layer and the sample 
detection layer by pouring the PDMS precursor over the other SU-8 molds in a petri dish and then 
baked overnight (60 °C).  
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The second step involved the settlement of beads in the microwells of each hexagonal patter 
on the multi-array biosensor layer.  We first aligned and attached the bead setting layer to the 
multi-array biosensor layer on the glass substrate. Then, we prepared 7 sets of a 25 uL mixture of 
AF488 encoded beads (anti-cytokine 1) and non-color encoded beads (anti-cytokine 2) at the 
concentration of 1mg/m in vials for the 14-plex detection. This was followed by loading each of 
the 7 mixtures into one of the microfluidic channels in the bead settling layer (Figure 4.1A). After 
waiting for the beads to settle in the microwells for 5 min, we washed the bead settling channels 
with 200 uL PBS-T (0.1% Tween20) to remove the unstrapped beads thoroughly. At this step, we 
ensured that the microwells were filled with the beads at a sufficient rate (typically above 50%) 
using an optical microscope. (If not, the bead mixture solution was reloaded and washed again.)  
 
Figure 4.1 Multiplexing the digital immunoassay by constructing a PEdELISA microarray chip based on 
the concept of microfluidic spatial-spectral encoding: (A) Trapping beads into microwells of the arrayed 
biosensing patterns on the multi-array biosensor layer. Mixtures of fluorescently encoded beads of Ncolor 
colors are loaded to the microfluidic channels on the bead settling layer. (B) Peeling off the bead settling 
layer from the multi-array biosensor layer, and attaching the sample loading layer on the multi-array 
biosensor layer. The 90º orientation of the sample loading channels permits each channel to contain an array 
of biosensing patters of Narray types. Loading serum samples to the channels of the sample detection layer 
with pipettes. The chip arrangement yields a total of Ncolor×Narray plex for the analysis of each sample. 
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The third step involved the assembly of the chip with the multi-array biosensor and sample 
detection layers. After the bead setting channels were dried by sucking out the washing buffer 
using a pipette, we peeled off the bead settling layer from the multi-array biosensor layer and 
replaced it with the sample detection layer. Here, the sample detection layer was aligned and 
attached to the multi-array biosensor layer so that its channels were oriented perpendicular to the 
direction of the channels of the bead settling layer. We then slowly loaded the sample detection 
channels with Superblock buffer to passivate the PDMS surface and incubate the whole chip for 
at least 1 hour before the assay to avoid non-specific protein adsorption. The sample detection 
layer was punched to form  inlets and outlets for its channels. The chip was tape cleaned and 
covered before the assay usage. Finally, serum samples were loaded to the sample detection 
channels from their inlets (Figure 4.1B).   
4.2.4 Patient Blood Sample Collection and Preparation.  
Blood samples were collected from patients receiving CAR-T cell therapy and was performed 
with informed consent under the University of Michigan Institutional Review Boards (IRB) 
protocol HUM00115179/UMCC 2016.051. Venous blood was collected into a vacutainer 
containing no anticoagulant on-site at the University of Michigan Medical School Hospital and 
transported it to a biological lab. After allowing the sample to clot for a minimum of 30 minutes 
at room temperature, we isolated serum by centrifuging the vacutainer at 1200 × g, for 15 minutes 
at room temperature. The serum was removed by a pipette, aliquoted into screw cap tubes, and 
then stored at -80 ºC prior to the assay.  
4.2.5 14-plex PEdELISA assay.   
All assay reagents were prepared in 96-well plate low retention tubes and kept on ice until use. 
The reagent preparation involved preparing a mixture of the biotinylated detection antibody (up to 
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14 cytokines for CAR-T study) in a carrier protein buffer (0.1% BSA, 0.02% Sodium Azide) and 
storing it at 4C, and preparing an Avidin-HRP solution in a superblock buffer at 100 pM. For the 
PEdELISA chip calibration, we prepared a mixture of recombinant proteins in 25% fetal bovine 
serum (standard solution), which was 5x serially diluted from 2.5 ng/mL to 0.16 pg/mL. Prior to 
the assay, we diluted patient serum samples (5uL) two times with PBS (5uL) to prepare a sample 
solution.  As the first step of the assay, we mixed the sample solution (10 μL) and the biotinylated 
detection antibody solution (10 μL) (sample mixture) and mixed the 5 titrated standard solutions 
(10 μL) and the biotinylated detection antibody solution (10 μL) (standard mixtures). Then, we 
loaded these sample and standard mixtures into the detection channels in parallel and incubated 
the chip for 300 sec. The signals obtained from the standard mixtures were used for calibrating the 
biosensors of the chip. The microfluidic channels were then washed with a PBS-T (0.1% Tween20) 
solution at 50 uL/min by a syringe pump for 2 min. 40 μL of the avidin-HRP solution was then 
loaded into the channel and incubate for 1 min. The chip was washed again with the PBS-T (0.1% 
Tween20) solution at 50 uL/min for 5 min. To reduce the interference between Tween20 and the 
enhanced chemifluorescent HRP substrate (QuantaRed substrate), we exchanged the PBS-T 
solution remaining in the channes with a 1x PBS solution. After loading 30 μL of the QuantaRed 
substrate solution, the channels were sealed with 35 μL of fluorinated oil (HFE-7500, 3M). The 
inlets and outlets of the channels were covered by glass coverslips to prevent evaporation during 
the imaging process. A programmable motorized fluorescence optical microscopy system was 
used to scan the image of the bead-filed microwell arrays on the microfluidic chip, identify the 
bead type (non-color vs. AF488 dyed), and detect the enzyme-substrate reaction activity. This 
system is composed of a Nikon Ti-S fluorescence microscope (10x objective), a programmable 
motorized stage (ProScan III), a mercury lamp fluorescence illumination source, a SONY full-
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frame CMOS camera (α7iii), and a custom machined stage holder. The motorized stage was pre-
programmed to follow the designated path to scan the entire chip (160 images) in 3 sequential 
steps: 1. Scan the QuantaRed channel (532nm/585nm, excitation/emission) 2. Scan the AF488 
channel (495nm/519nm, excitation/emission) 3. Scan the brightfield. It typically took around 5-7 
min to scan the entire chip for 10 samples in 16-plex detection. 
4.2.6 Training of the Dual-pathway Convolutional Neural Network. 
Figure 4.2 shows the training process of our dual-pathway CNN algorithm, which involves 
data set preparation and 2-step neural network training. We first developed pre-stage neural 
networks trained with a data set of 3,000 representative locally-cropped (32×32 pixel) images.  For 
each of these images, two types of images (6,000 in total) only showing the labeling information, 
which are called “masks” were generated by thresholding and manual labeling (Figure 4.2A 
Labeled). In the pre-stage mask for Pathway 1, all the target pixels representing “On” (Qred+) 
microwell sites and other sites (defects or background) were labeled as ‘1’ and ‘0’, respectively. 
In the pre-stage mask for Pathway 2, the defects and other sites were labeled as ‘1’ and  ‘0’, 
respectively. The pre-trained networks were able to identify and segment the labeled objects to 
some degree of accuracy (i.e., 60-80% “On” wells). But they still lacked the accuracy to extract 
more in-depth features of the object, such as its shape and fluorescence intensity variations of the 
objects, and other defects that were hard to identify with the small-scale images. 
To further improve the accuracy, we built three second-stage parallel CNN networks to identify 
AF 488+ pixels, Qred+ pixels, and defects that were trained with 256×256-sized images (around 
200 images per network). The labeling masks to be used to train the second-stage networks were 
generated by the pre-stage neural networks with human correction (see Figure 4.2Bii). By taking 
into account that the sizes of lithographically patterned microwells and beads were predetermined, 
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we trained the second-stage networks to accurately recognize these objects independent of their 
image intensity variations. Additionally, we selected 30 images for each error source caused by 
optical crosstalk, carefully determined the intensity threshold to set a clear boundary between 
adjacent microwells for each of these images, and generated second-stage labeling masks.  
 
Figure 4.2 Training process of the dual-pathway convolutional neural network (CNN) with semantic 
segmentation. (A) The data library was carefully pre-selected based on 3000 representative images (32×32 
pixels) to pre-train the CNN. The images were first labeled based on global thresholding and segmentation 
(GTS) and then manually modified based on human supervision. (B) The pre-trained CNN was then used 
to label a new data library which contains around 200 larger images (256×256 pixels) to further improve 
the feature extraction and classification accuracy.  
 
As for training the defect recognition-network, we first enhanced the image brightness and 
contrast to recognize even low-intensity regions. We then applied image dilation for the defect 
location to ensure the generated mask area is large enough to cover the entire defect area as shown 
in Figure 4.2iii. Here, only defect locations were labeled as ‘1’ and all others were labeled as ‘0’. 
The region labeled as ‘1’ was eventually removed from the total analyzed area to eliminate it from 
the fluorescence signal counting.   
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Our neural network contains 5 classes: Qred+ class, AF488+ class, Qred defect class, Qred 
background class, and AF488 background class. Before training the neural network with the 
labeling masks above, we also added weight information to each class to further enhance the pixel 
identification accuracy. We used the inverse frequency weighting method which gives more 





where Nimage total pixels is the number of total image pixels of 256×256 = 65,536, and the Nclass pixels is 
the number of pixels for each class. This class weighting strategy was added into the neural 
network training process because the number of Qred+ or AF488+ class pixels were significantly 
smaller than the number of their total background pixels.   
4.2.7 Statistics.   
Experiments with both synthetic recombinant proteins (for assay standard curves) and CAR-T 
patient samples at each time point were performed 3 times (in independent tests) with two on-chip 
repeats. The standard deviation was calculated to obtain the error bar. Group differences were 
tested using a two-tailed unequal variance t-test. A p-value of < 0.05 was considered to be 
statistically significant. 
 
4.3 Results and Discussion 
4.3.1 Multiplexed Digital Immunoassay with CNN Image Processing. 
The PEdELISA microarray analysis used a microfluidic chip fabricated using 
polydimethylsiloxane (PDMS)-based soft lithography. The chip contains parallel sample detection 
channels (10-16) on a glass substrate, each with an array of hexagonal biosensing patterns. The 
hexagonal shape allows each biosensing pattern to densely pack 43,561 femtoliter-sized 
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microwells, which fits into the entire field of view of a full-frame CMOS sensor through a 10x 
objective lens (Figure 4.3). Prior to the assay, we deposited magnetic beads (d = 2.8 μm) encoded 
with non-fluorescent color (no color) and those with Alexa Fluor® 488 (AF 488) into physically 
separated microwell arrays. These beads were conjugated with different capture antibodies 
according to their colors and locations on the chip. In the current design, the arrangement of 2 
colors and 8 arrayed biosensing patterns in each detection channel allows the PEdELISA 
microarray chip to detect 2 × 8 = 16 protein species (16-plex) at its maximum capacity for each 
sample loaded to the detection channel. Compared with a single color-encoded method, this 
combination greatly reduces potential optical crosstalk and fluorescence overlap during a signal 
readout process. The pre-deposition ensures a fixed number of beads to target each biomarker, 
which allows more accurate digital counting for each biomarker. It also eliminates bead loss during 
the conventional partition process and achieves nearly a 100% yield in the signal readout for 
enzyme active QuantaRedTM (Qred)-emitting beads (“On” beads or “Qred+” beads). The 
microwell structure (diameter: 3.4 µm and depth: 3.6 µm) was designed to generate sufficient 
surface tension to hold beads in the microwells. This kept false signals resulting from physical 
crosstalk between the trapped beads at a negligible level. 
There is another challenge unique to applying the digital assay approach for near-real-time 
cytokine profiling with high multiplex capacity. The assay needs to provide a truly rapid and 
trustful data analysis (without human supervision) originating from ~7 million microwells per chip. 
Additionally, the signal counting process needs to distinguish precisely between images of multi-
color bead-filled and empty microwells and to identify signals accurately while subjected to a large 
fluorescence intensity variance, occasional image defects due to reagent mishandling, and image 
focus shifts. These challenges make the conventional image processing method with the 
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thresholding and segmentation (GTS) scheme inaccurate and require human supervision for error 
correction in handling digital assay images. Mu et al. (152, 153) showed that the use of machine 
learning algorithms would provide promising solutions to significantly improve the accuracy of 
digital assay image processing. However, this approach is only applied for single-color images 
with a small number of microreactors (a few thousand) with 1080×1120 pixels, which is 
impractical for high-throughput analysis. To address these challenges, we developed a novel dual-
pathway parallel-computing algorithm based on convolutional neural network (CNN) 
visualization for image processing.  
 
Figure 4.3 Concept of CNN processed PEdELISA microarray analysis. Microfluidic spatial-spectral 
encoding method used for multiplexing digital immunoassay. Fluorescence color-encoded magnetic beads 
coated with different capture antibodies are pre-deposited into the array of hexagonal-shaped biosensing 
patterns in the microfluidic detection channel. The locations of the biosensing patterns are physically 
separated from each other. This arrangement yields Ncolor×Narray measurement combinations determining 
the assay plexity, Nplex, where Ncolor is the total number of colors used for encoding beads deposited in each 
biosensing pattern, and Narray is the total number of the arrayed biosensing patterns in each detection 
channel. In this study, Ncolor=2 (non-fluorescent and Alexa Fluor® 488: AF488) and Narray=8. 
 
The CNN-based analysis procedure (Figure 4.4) includes multi-color fluorescence image data 
read-in/pre-processing (image crop, noise filtering, and contrast enhancement), microwell/bead 
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image segmentation by pre-trained dual-pathway CNN, post-processing, and result output. The 
key component, dual-pathway CNN, was pre-trained to classify and segment image pixels by 
labels of (I) fluorescence “On” (Qred channel) microwells, (II) Alexa Fluor® 488 color-encoded 
beads (AF488 channel), (III) image defects, and (IV) background. The architecture of the network 
is separated into a downsampling process for category classification and an upsampling process 
for pixel segmentation. The downsampling process consists of 3 layers, including 2 convolution 
layers (4-6 filters, kernel of 3×3) with a rectified linear unit (ReLU), and a max-pooling layer 
(stride of 2) in between. The upsampling process consists of a transposed convolution layer with 
ReLU, a softmax layer and a pixel classification layer. To speed up the training process, we started 
with dividing an image with 32 × 32 pixels and classifying them with the labels and then eventually 
expanding the image pixel size to 256 × 256 using a pre-trained network (Figure 4.2). We found a 
large intensity variance across the optical signals from beads in different microwell reactors. As a 
result, the intensity-based labeling of microwells leads to recognition errors. Microwells with 
bright beads can be misrecognized to have larger areas with more pixels than those with dim beads. 
Instead, given that all microwells are lithographically patterned to have an identical size, we 
labeled them using the same pre-fixed area scale (octagon, r=3 pixel for microwell, disk, r=2 pixel 
for bead) regardless of their image brightness to make the machine to recognize them correctly. 
The majority of pixel labels are for the background (Label IV) with no assay information in typical 
digital assay images. We used the inverse frequency weighting method to further enhance the 
classification accuracy, which gives more weights to less frequently appearing classes that are 
identified by Labels (I), (II), and (III) (See 4.2.6 for training details).  
In contrast to a previously reported study (152), we greatly reduced the number of convolution 
layers and filters (depth of network) for high speed processing. Our algorithm employs much fewer 
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labels and features required for imaging processing than those for other typical CNN applications, 
such as autonomous driving. The unique feature of our algorithm is the ability to run two neural 
networks in parallel for two detection pathways: one for assay targets (e.g. microwells, beads, and 
fluorescence signals) and the other for defects. This allows the imaging processing to achieve high 
speed while maintaining good precision. As a result, it only took ~5 seconds (CPU: Intel Core i7-
8700, GPU: NVIDIA Quadro P1000) to process two-color channel data for two 6000×4000 pixel 
images which contain 43561 micro-reactors. 
 
Figure 4.4 A convolutional neural network-guided image processing algorithm for high throughput and 
accurate single molecule counting. Two neural networks were run in parallel, reading multi-color 
fluorescence image data, recognizing target features versus defects, and generating an output mask for post 
data processing. The brightfield image was analyzed using a Sobel edge detection algorithm. The images 
were finally overlaid to determine the fraction of enzyme active beads emitting QuantaRedTM signal (Qred+ 
beads) to total beads for each color label. The unlabeled scale bars are 25 μm. 
 
4.3.2 PEdELISA Microarray Platform Performance. 
To evaluate the platform performance, we first considered false signals resulting from 
misplacing beads during the preparation of the PEdELISA chip. If some of the beads targeting 
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analyte A were accidentally trapped into the microwell arrays of a biosensing pattern to detect 
analyte B, these misplaced beads would yield either false positive or false negative signals of 
analyte B, thus confounding the assay (“physical crosstalk” between beads). Previous studies (154, 
155) revealed that choosing an appropriate design for the PDMS microwell allowed surface tension 
to hold firmly a bead trapped in it even when the entire chip was flipped upside down under 
prolonged sonication. Guided by these studies, we designed the microwell structure to be 3.4 µm 
in diameter and 3.6 µm in depth to generate sufficient surface tension to hold beads in microwells 
(using a permanent magnet could further facilitate the seeding and retention of beads (155, 156). 
 
Figure 4.5  Fraction of AF-488 encoded beads invading the channel to be loaded with non-color coded 
beads before and after the bead flushing test assay (P=0.550). On average, only 0.087% of the trapped beads 
were misplaced in the channel for the both cases. The result was obtained from the fluorescence images of 
160 independent microwell sites. The harsh assay conditions with a washing buffer flow rate of 40uL/min 
and a duration of 15 min caused negligible physical crosstalk between the beads.   
 
To assess the impact of physical crosstalk on our assay, we ran a control test. The test started 
with settling AF-488 encoded magnetic beads into one of the sample loading channels of the chip 
(AF-488 bead channel), and then subsequently settling non-color encoded beads into another 
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channel next to it (non-color bead channel). Then, we washed away the untrapped beads from these 
channels, peeled off the bead settling layer from the multi-array biosensor layer, replaced it with 
sample loading layer, and applied harsh flushing first for the AF-488 bead channel and next for 
the non-color channel at a washing buffer flow rate of 40uL/min for 15 min. Finally, after sealing 
the microwells in the channels with oil, we took a fluorescence microscopy image of the chip and 
evaluated the number of AF-488 encoded beads invading the non-color bead channel before and 
after the flushing process. Across 160 independent microwell sites, we observed physical crosstalk 
occurring at an average bead misplacement percentage of 0.087% out of the total beads originally 
settled in the non-color bead channel with a 0.0012% standard deviation (Figure 4.5). Given that 
digital ELISA typically forms less than 0.1 antibody-antigen-antibody immune-complexes per 
bead on average, the false positive signal generated by physical crosstalk is nearly an order less 
than the typical negative control signal (0.0005-0.001 average molecule per bead) due to non-
specific adsorption of proteins. 
To validate the effectiveness of the dual-pathway CNN method developed in this work, we 
compared its performance with that of the standard method based on global thresholding and 
segmentation (GTS). Figure 4.6 shows the side-by-side comparison between the GTS method and 
the CNN method in PEdELISA image processing. Both of the methods start from a pre-processing 
process, which typically includes image cropping, contrast enhancement and noise filtering. The 
GTS method involves finding and adjusting a global threshold value based on the gray histogram 
of the image (Figure 4.6A, black dash line). This method labels a microwell site showing a 
fluorescence intensity level above the threshold value as a positive (“On”) pixel. Then, it applies 
a 2×2 pixel image erosion mask along the edge to remove the randomly appearing shot noise pixels 
with intensities above the threshold. The post-processing process of the GTS method includes 
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image dilation and segmentation, “On” microwell/bead counting, error correction and image 
overlay. Whereas, the CNN method runs two signal recognition pathways in parallel, which are 
pre-trained to recognize enzyme active “On” microwells (Red channel, Qred) or beads (Green 
channel, AF488) versus defects and contaminations using 5,750 labeled images. As a result, this 
method does not need to predetermine the intensity threshold value required for the GTS method.  
 
Figure 4.6 Algorithm comparison between the global thresholding segmentation (GTS) and the 
convolutional neural network (CNN). In GTS, an optimized global threshold value is predetermined based 
on the intensity histogram of the image to be processed (shown by the black dash line). The CNN method 
does not require the predetermination of the threshold value.  
 
Figure 4.7A shows representative two-color-channel images causing errors to the image 
labeling and signal counting of the GTS method. These errors are corrected by the CNN method. 
For example, false signal counting derives from chip defects or poor labeling reagent confinements 
within individual microwell reactors due to the local failure of oil sealing. Defocusing can cause 
two neighboring microwells to be dilated with each other.  Highly bright Qred fluorescence from 
an “On” microwell can cause secondary illumination to light up neighboring microwells. This 
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results in “optical crosstalk” between neighboring microwells (151), which causes the false 
counting of secondarily illuminated microwells as “On” sites. The uneven illumination of 
excitation light causes the failure of recognizing dim AF-488 encoded beads (recognized as non-
color beads).  
 
Figure 4.7 Image processing by convolutional neural network (CNN) and global thresholding and 
segmentation (GTS) methods (A) representative images causing false signal counting (red dot: Qred+ 
microwell, green dot: AF-488-colored bead, yellow dot: recognized spot to be counted). (i) The circle 
represents an area covered by an aqueous reagent solution that is spread over multiple microwell sites due 
to poor confinement during the oil sealing process. GTS counts potentially false and unreliable signal spots 
from the area. CNN removes the area from counting. (ii) Image defocusing causes GTS to merge two signal 
spots from a pair of the neighboring Qred+ microwells in the circle and to count it as a single signal spot. 
(iii) Secondary illumination of microwell sites due to optical crosstalk in the circle results in their false 
counting by GTS. (iv) GTS fails to label and count microwell sites holding dim AF-488-colored beads.  
Error analysis of CNN and GTS methods on (B) Qred-channel (C) AF488-channel and (D) brightfield 
images. (E) Tests assessing the impact of optical crosstalk on the accuracy of CNN and GTS using dual-
color IL-1α and IL-1β detection by spiking (i) IL-1α:1ng/mL IL-1β:1ng/mL (ii) IL-1α:1ng/mL IL-
1β:1pg/mL (iii) IL-1α:1pg/mL IL-1β:1ng/mL (iv) IL-1α:1pg/mL IL-1β:1pg/mL (v) IL-1α:1pg/mL IL-
1β:1pg/mL assay in single plex for validation. All assays were performed in fetal bovine serum buffer. 
 
     In the CNN training process, we collected a large number of images for each error source and 
used them to train the neural network to achieve results similar to those from manual counting 
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with the human eyes. We applied the following equation to evaluate the error in terms of deviation 
to the ground truth (%):  
    
 
where NCNN or GTS is the number of microwell or bead counted either by CNN or GTS method 
respectively, NTP is the number of true positives determined by human labeling. The human 
labeling process includes the pre-processing with the GTS method together with human correction 
to obtain the ground truth, which has been validated by the conventional sandwich ELISA method 
in our previous study (67). 
In counting enzyme active microwells with the Qred channel, we observed that the deviation 
percentage from ground truth varied with the number of the counted “On” (Qred+) microwells, 
which is proportional to the analyte concentration.  Each data point in Figure 4.7B-D was taken 
for a hexagonal-shaped biosensing pattern (Figure 4.4) that contains 43561 microwell arrays with 
an average bead filling rate of 55.1%. In these data, the number of Qred+ microwells ranged from 
1 to 10000 (Figure 4.7B). At higher analyte concentrations (NQred>100), both of the methods 
achieved reasonably high accuracy with a deviation to the ground truth of 3.92% (CNN) and 9.96% 
(GTS). However, at the lower concentrations (NQred<100), this deviation became significant 
(CNN: 5.14% GTS: 71.6%). The larger error of the GTS scheme is attributed to the false counting 
of regions contaminated with fluorescent reagents and the miscounting of Qred+ microwells of 
low fluorescence intensity. Thus, the dual-pathway CNN greatly improved the accuracy of the 
image processing and eliminated the need for human supervision to correct the significant errors 
in the low concentration region.   
In counting color-encoded magnetic beads with the AF-488 channel, we found that the 
deviation was very small (CNN: 0.021%, GTS: 0.161%). The deviation was suppressed by the 
𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛(%) =




little spectral overlap between AF488 and Qred channels and the high image contrast that we 
intentionally created between AF-488 and non-color encoded beads (Figure 4.7C). Some 
miscounting under the uneven spatial distribution of illumination light intensity and the spherical 
aberration of objective lens over the entire field of view still contributed to the deviation. The CNN 
method achieved a nearly 8-fold improvement of accuracy. Counting the total number of beads 
(both no color and fluorescence color-encoded ones) with brightfield images using a customized 
Sobel edge detection algorithm yielded an average deviation to the ground truth of 0.256% as 
shown in Figure 4.7D. 
To verify our ability to suppress optical crosstalk in the multiplexed assay incorporating the 
CNN method, we prepared a fetal bovine serum (FBS) sample spiked with two different cytokine 
species of 1000-fold concentration difference: IL-1α (AF488 encoded) and IL-1β (non-color 
encoded). Optical crosstalk becomes problematic especially in multiplexed analysis, where the 
quantity of one biomarker can be serval orders of magnitude higher than those of other biomarkers 
in the same sample. A slightly false recognition can even give a significantly higher value of 
biomarker concentration than its true value. Figure 4.7E shows the comparison between the 
conventional GTS method and the CNN method. False recognition was greatly reduced by the 
CNN method and we verified that 1pg/mL of IL-1α or β will not interfere even when the other 
protein reaches 1ng/mL. Furthermore, we performed single-plexed measurements of 1pg/mL of 
IL-1α and IL-1β, which give “true” concentration values while eliminating optical crosstalk.  The 
single- and dual-plexed measurements both yielded statistically similar results with the CNN 
method (two-tailed unequal variance t-test, IL-1α P=0.253; IL-1β=0.368 ), which proves the 
accuracy of this method even at the presence of strong optical crosstalk.  
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4.3.3 Multiplex Pre-equilibrium Cytokine Detection. 
 
Figure 4.8 Arrangement of a panel of 14 cytokine detection for CAR-T cytokine release syndrome 
detection test. The two cytokines labeled with the black and green fonts on each row were detected 
in the sample detection channels (1, 2, 3, and 4) vertical to the row using non-color (black) and 
AF-488 (green) encoded beads, respectively. 
 
Using 2-color encoded (AF488, non-color) magnetic beads with 8 physically separated 
microarrays, we designed a microfluidic chip to detect 14 cytokines (up to 16-plex) simultaneously 
(see chip design in Figure 4.8). Figure 4.9A shows standard curves obtained from PEdELISA 
microarray analysis with CNN image processing for cytokines ranging from 0.16 pg/mL to 2.5 
ng/mL. To mimic the serum detection background, we choose to use 25% FBS as the detection 
buffer, which has been previously verified to match with human serum background (typical 2-4 
fold dilution). Here, the measurement output is the fraction of the number of enzyme active 
(Qred+) beads to the total number of beads used for assaying the particular analyte. This fraction 
is directly correlated to the analyte concentration. The assay was performed for a system at the 
early state of a transient sandwich immune-complex formation reaction process with a 5-min 
incubation period, followed by a 1-min enzymatic labeling process. The reaction conditions have 
been optimized to match all cytokine biomarkers within the clinically relevant range, and a linear 
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dynamic range of three orders of magnitude was achieved in general. Table 4.1 summarizes the 
values of the limit of detection (LOD) and limit of quantification (LOQ) of the assay for each 
cytokine. The antibody-antigen affinity affects the LOD of the assay, and it varies across the 
detected cytokine species. As a result, we obtained different LOD values for these cytokines even 
if the capture antibody-conjugated beads were prepared by the same protocol regardless of the 
analyte types. The LOD value tends to decrease with an increasing incubation period.  Although 
the assay was performed with a short incubation period of 5 min, the LOD was found to be still 
below 5pg/mL (with IL-1β reaching the lowest 0.188pg/mL) after optimizing the detection 
antibody mixing ratio and the enzyme labeling concentration.  
 
Figure 4.9 PEdELISA microarray analysis. (A) Assay standard curves for 14 cytokines from 0.16pg/mL 
to 2500pg/mL in fetal bovine serum (FBS). Three independent tests with two on-chip repeats were 
performed using recombiant proteins (error bar = standard deviation: σ). (B) Assay specificity test with 
FBS “all-spike-in,” “single-spike-in,” and “no-spike-in” (negative) samples. The analyte concentration of 
500pg/mL used for spiking FBS is the optimal value to assess both false positive and negative signals. The 
limit of detection (LOD), limit of quantification (LOQ), and standard root mean square coefficient of 
variance (RMS CV) of each cytokine were cacluated from these data and summarized in Table 4.1.  
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Table 4.1 Limit of detection (LOD), Limit of Quantification (LOQ) and standard root mean square 
coefficient of variance (RMS CV) summary of 5-min 14-plex PEdELISA. Here, the LOD was determined 
by concentration from the reagent blank signal + 3σ and the LOQ was reagent blank’s signal + 10σ. The 
RMS CV was determined by the root mean square average signals from 20, 100, and 500 pg/mL assay 
standard with typical three day-by-day repeats and 2 on-chip repeats. 
 








0.1355 0.1168 0.1820 0.0404 0.0601 0.0584 0.1109 
LOD 5-min 
(pg/mL) 
2.195 2.667 2.033 0.188 0.535 0.210 0.613 
LOQ 5-min 
(pg/mL) 
12.80 12.21 11.54 0.696 11.24 5.661 4.996 
Assay standard 
RMS CV (%) 
16.0 6.30 14.6 5.19 15.3 9.96 14.1 
 








0.1240 0.3769 0.1758 0.1299 0.6641 0.3566 0.2896 
LOD 5-min 
(pg/mL) 
0.349 3.406 1.733 3.206 4.120  3.448 7.797 
LOQ 5-min 
(pg/mL) 
2.674 47.83 18.296 57.944 43.423 62.66 35.33 
Assay standard 
RMS CV (%) 
13.1 18.8 10.1 20.6 11.1 12.6 10.7 
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We further assessed the level of antibody cross-reactivity among 14 cytokines in FBS. Figure 
4.9B shows the assay results for sera spiked by all, one, or none of the recombinant cytokines of 
14 species, namely “all-spike-in,” “single-spike-in,” and “no-spike-in” samples. We observed 
more than 100 times lower background signals from the no-spike-in (negative) sample than those 
from the all-spike-in sample across the 14 cytokines (except IL-17A for which there is a slightly 
higher background due to the more active binding between its capture and detection antibodies). 
The signal-level variation across the 14 cytokines at the same concentration from the all-spike-in 
and single-spike-in samples could derive from the different levels of analyte-antibody affinity for 
these cytokines. We also observed a similar trend in the variation of the LOD values for the 
cytokines from the curves in Figure 4.9A. The signal from each of the 14 single-spike-in samples 
manifests a high level of specificity to the target analyte. This verifies that the multiplexed assay 
measurements cause negligible cross-reactivity between each cytokine analyte and other capture 
and detection antibodies that should not couple with it.  
Finally, we applied the 14-plex PEdELISA microarray analysis for the longitudinal serum 
cytokine measurement from patients receiving CAR-T cell therapy. CAR-T therapies have 
demonstrated remarkable anti-tumor effects for treatment-refractory hematologic malignancies 
(157, 158). Unfortunately, up to 70% of leukemia and lymphoma patients who receive CAR-T 
therapy experience cytokine release syndrome (CRS). CRS is a potentially life-threatening 
condition of immune activation caused by the release of inflammatory cytokines (e.g., IL-6, TNF-
α, and others) (121, 135). CRS initially causes fevers and other constitutional symptoms that can 
rapidly (i.e., within 24 hours) progress to hypotension and organ damage requiring intensive care. 
Previous studies (131, 132) have shown the measurement of a panel of cytokines can indicate the 
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early onsite of severe CRS. Thus, the way of intervening CRS could be significantly improved by 
the multiplex PEdELISA microarray analysis. 
 
Figure 4.10 14-plex cytokine measurements in longitudinal serum samples from CAR-T patients who were 
diagnosed (A) grade 1-2 CRS (B) no CRS. Day 0 represents the day of CAR-T cell infusion. Data before 
Day 0 represents the baseline. The shaded region marks the period that the patient was diagnosed with grade 
1-2 CRS. For better visualization, the data was organized and separately plotted based on the cytokine level 
from high to low.  
     
To demonstrate the clinical utility of the assay technology, we ran our assay for two CAR-T 
patients, one who experienced up to grade 2 CRS and one who did not experience CRS in the first 
few days after the CAR-T infusion. The total sample-to-answer time achieved was 30 min for the 
entire 14-plexed measurement including the sample incubation (5 min), labeling (1 min), 
washing/reagent confining (10 min), and image scanning/analysis (14 min). Figure 4.10A shows 
that Patient 1 developed CRS on day 4 that persisted until day 9. We found significant elevations 
for all assayed cytokines on Day 0 in comparison to their baseline levels on Day -2 and Day -9. 
 91 
Interestingly, the spike on Day 0 is not due to the CAR-T cells, as the blood sample was taken 
prior to CAR-T infusion. Typically, CRS patients exhibit a high IL-6 concentration within their 
blood (159). However, Patient 1 manifested a significantly higher level of TNF-α. This suggests 
biological heterogeneity in the pathogenic cytokine profiles of patients who develop CRS. We also 
conducted a similar analysis for a patient who did not develop CRS (Figure 4.10B). We recorded 
an increase in IL-2 and a relatively high level of IL-17A for this patient, while other cytokines 
showed no significant changes throughout the analysis. Presumably, normal CAR-T cell expansion 







A Digital Protein Microarray for COVID-19 Cytokine Storm Monitoring 
 
5.1 Introduction to the Study 
With the global outbreak of the novel coronavirus pneumonia (COVID-19), 
accumulating evidence (16, 160, 161) indicates that cytokine release syndrome (CRS) is 
associated with severe illness. CRS is observed in several disease states associated with 
dysregulated immunity, including as a consequence of CAR-T cell immunotherapy(121), a 
manifestation of hemophagocytic lymphohistioctytosis (HLH) in malignancy, macrophage 
activation syndrome in autoimmune disease (162), or severe sepsis (163).  Selective 
cytokine blockade is a mainstay of care for CRS related cancer immunotherapy (121, 136, 
159), and macrophage activation syndrome (164).  In COVID-19, early translational studies 
suggest that high serum cytokines are a result of complex interplay between lymphocytes 
and myeloid cells (165). Modulation of cytokine signaling pathways is currently the subject 
of over 50 clinical trials worldwide (166). However, most studies enroll based on clinical 
criteria without rapid assessment of specific cytokine levels, despite delivering therapies 
that are targeted to specific cytokines, such as interleukin (IL)-6.  In our center, the current 
clinical practice is to use a variety of less specific surrogate markers, such as ferritin and 
CRP, to gauge a patient’s overall level of inflammation. While cytokine levels are being 
 93 
checked in patients with severe COVID-19, the results of these tests return in days, not 
hours. Ideally, treating physicians would understand the “real-time” level of a variety of 
cytokines in a particular patient before administering specific medications to blunt cytokine 
storm in critical illness, which urgently requires a low-cost near-bedside multiplex cytokine 
profiling assay with near-realtime assay turnaround.   
Digital immunoassay (52, 56) has been considered as the next generation protein 
detection method which provides single-molecular sensitivity (aM-fM) detection by 
digitizing and amplifying enzymatic reaction in extremely confined volumes (fL-nL). 
Several groups invented microfluidic platforms for lab-on-a-chip operation of digital assays 
(78, 124, 156, 167) and notably, Yelleswarapu et al (122) demonstrated a mobile-phone-
based, droplet microfluidic digital immunoassay for point-of-care (POC) settings. However, 
few studies have implemented a digital assay platform applicable to the clinical treatment 
of a COVID-19-induced cytokine storm. If continuous monitoring of the cytokine profiles 
of a COVID-19 patient is needed, the assay requires more than speed, sensitivity, and 
multiplex capacity. Other important but often overlooked requirements include (1) 
flexibility of running a small number of samples based on the demand of the physician with 
minimum preparation; (2) great inter-assay precision between multi-time point 
measurements, which is not an issue in conventional large batch-based retrospective tests; 
(3) a low-cost, compact, automated fluidic handling and readout instrumentation that can 
be operated inside the bio-safety cabinet with minimum user exposures to virus-
contaminated blood samples. 
Here, we report the development and application of an automated digital assay platform 
using a method termed the “pre-equilibrium digital enzyme-linked immunosorbent assay 
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(PEdELISA) microarray” for rapid multiplex monitoring of cytokine: IL-6, TNF-α, IL-1β 
and IL-10 from COVID-19 patients admitted to the ICU in the University of Michigan 
hospital. The PEdELISA microarray analysis employs magnetic beads trapped into 
spatially registered microwell patterns on a microfluidic chip. The locations of the 
microwell patterns on the chip indicate which target analytes are detected. Unlike the 
existing digital assays, our method employs an approach of quenching the assay reaction 
entirely on-chip at an early pre-equilibrium state. This approach achieves near-realtime 
assay speed (<10 min incubation) with a clinically relevant fM-nM dynamic range without 
losing assay linearity. Furthermore, using a simple microfluidic spatial encoding technique 
and machine learning-based image processing algorithm, we achieved multiplex detection 
with high-accuracy counting and eliminated significant bead loss faced by the commercial 
state of the art platform (150). The advancements of our digital assay demonstrated here 
enable it as a great candidate for near-bedside cytokine profiling with the combination of 
speed and sensitivity, both greater than those of current analog (36-38, 63) and label-free 
POC diagnostic systems (32, 39, 105, 168).   
5.2 Materials and Methods 
5.2.1 Materials.  
We purchased human IL-6, TNF-α capture, and biotinylated detection antibody pairs from 
Invitrogen™, and IL-1β, IL-10 from BioLegend. We purchased the corresponding ELISA kits 
from R&D Systems (DuoSet®). We obtained Dynabeads, 2.7μm-diameter epoxy-linked 
superparamagnetic beads, avidin-HRP, QuantaRed™ enhanced chemifluorescent HRP substrate, 
bovine serum albumin (BSA), TBS StartingBlock T20 blocking buffer, and PBS SuperBlock 
blocking buffer from Thermo Fisher Scientific. We obtained Phosphate buffered saline (PBS) from 
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Gibco™, Sylgard™ 184 clear polydimethylsiloxane (PDMS) from Dow Corning, and 
Fluorocarbon oil (Novec™ 7500) from 3M™. The automated PEdELISA system was mainly 
constructed by a micro-controller (Arduino Uno and MEGA 2560), stepper motors and shields 
(NEMA 17, 0.9 degree, 46 N·cm, TB6600 and DM542T motor shields), linear rail guide with 
ballscrews (5 mm/revolution), standard anodized aluminum profiles, clear acrylic boards and other 
supporting wheels, connectors and parts purchased from Amazon through various vendors. The 
optical scanning system mainly consists of a consumer-grade CMOS camera (SONY α6100), 10x 
Objective lens (Nikon, CFI Plan Achro), tube lens (200 mm), optical filter sets (Chroma), halogen 
light source, LED light source (560 nm), optical mountings and tubings (mainly from Thorlabs 
and Edmund Optics). 
5.2.2 Antibody Conjugation to Magnetic Beads.  
We conjugated human IL-6, TNF-α, IL-1β, IL-10 capture antibodies using the epoxy-linked 
Dynabeads (2.7 μm) with the capture antibody molecules at a mass ratio of 6 μg (antibody): 1 mg 
(bead) following the protocols provided by Invitrogen™ (Catalog number:  14311D). The beads 
were then quenched (for unreacted epoxy groups) and blocked with TBS StartingBlock T20 
blocking buffer. We stored the antibody-conjugated magnetic beads at 10 mg beads/mL in PBS 
(0.05% T20 + 0.1% BSA + 0.01% Sodium Azide) buffer sealed with Parafilm at 4 °C. No 
significant degradation of the beads was observed within the 3-month usage. 
5.2.3 PEdELISA Cartridge Fabrication and Patterning. 
The disposable microfluidic cartridge used for PEdELISA assay is plastic-based and fabricated 
by laser cutting and PDMS molding. It has a transparent sandwich structure for optical imaging as 
shown in Figure 5.1. The top and bottom layers are laser-cutted using 3.175 mm (1/8 inch) and 1 
mm thin clear polymethyl methacrylate (PMMA) boards which contains through-holes for venting 
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and screw assembly purposes. The microfluidic channels (designed with AutoCAD software) are 
laser-cutted through a 120 µm high definition transparency polyethylene terephthalate (PET) thin 
film (adopted from standard screen protector) which has a silicone gel layer to create a vacuum for 
securely sealing to the top acrylic layer without adhesives. The power and speed of the laser cutter 
are optimized to ensure a high-resolution smooth cut so that resistance difference or bubbles 
generation can be minimized during the fluidic handling process. The femtoliter-sized microwell 
(d=3.4 μm) array layer (~300 μm) was made by polydimethylsiloxane (PDMS) through a standard 
SU-8 molding. First, we constructed SU-8 molds on oxygen plasma treated silicon wafers by 
standard photolithography which involved depositing negative photoresist (SU-8 2005 
MicroChem) layers at 5000 rpm to form the desired thicknesses 3.8±0.1 µm. Subsequently, a 
precursor of PDMS was prepared at a 10:1 base-to-curing-agent ratio and deposited onto the SU-
8 mold by spin coating (300 rpm) and baking overnight at 60 °C. We then transferred the fully-
cured PDMS thin film onto the bottom acrylic layer using a modified surface silanization bonding 
method based on a previous publication (169). We also drilled 2 mm countersink holes (60°) using 
a benchtop mini drill press (MicroLux®) on the top venting layer for guiding the multi-pin fluidic 
dispensing connector. Each layer was cleaned by water bath sonication and the PET microchannel 
layer was carefully attached to the top venting layer for the later bead patterning process. 
 
Figure 5.1 Fabrication of the disposable PEdELISA microfluidic cartridge. The cartridge contains two 
PMMA layers top (venting) and bottom layer (substrate), a thin PDMS layer (200 µm) which contains fL-
sized microwell arrays for digital assay, and a PET thin film (120 µm) with microfluidic channels.  
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The PEdELISA bead patterning process involves first attaching the bead settling layer 
(containing long straight PDMS channels perpendicular to the PET microchannel layer) to the 
PDMS microwell array layer on the bottom PMMA substrate. Then, we prepared 4 sets of a 25 µL 
bead solution at the concentration of 1 mg/mL for IL-1β, TNF-α, IL-10, and IL-6 bead respectively. 
The bead solution was loaded into four different physically separate patterning channels in the 
bead settling layer. After waiting 5 min for beads settling inside the microwells, we washed the 
patterning channels with 200 uL PBS-T (0.1% Tween20) to remove the unstrapped beads. At this 
step, we imaged the microarray under the microscope to ensure that the microwells were filled 
with the beads at a sufficient rate (typically above 50%). If not, the bead mixture solution was 
reloaded and washed again. Finally, the bead settling layer was peeled off and replaced with PET 
microchannel and top venting layer. Four layers of the cartridge were sandwiched together using 
M2 bolt screws. Note that the bonding between the PET layer and the PDMS layer was not 
permanent but through pressure-based self-sealing, which can be later easily peel off and replaced. 
We then slowly primed each sample detection channel with Superblock buffer to passivate the 
cartridge surface and incubated the whole chip for at least 1 hour before the assay to avoid non-
specific protein adsorption. The cartridge was typically prepared in batch and sealed in a moisture-
controlled petri-dish at room temperature for up to a week with no significant degradation.  
5.2.4 Design of programmed fluidic handling and low-cost optical scanning modules. 
A programmed fluid handling module was designed to allow semi-automated parallel fluid 
handling (up to 16 samples) and to improve the fidelity and sensitivity of the assay by active on-
chip mixing. The module incorporates a linear rail system (one NEMA 17 stepper motor, TB6600 
motor shield, Arduino Uno, pipette holders) to operate up to four multi-channel pipettes for assay 
reagents loading, mixing and washing (Fig. 5.2A). A multi-pin connector was designed to provide 
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good sealing for the countersink holes on the cartridge. This helps avoid leaking and bubble 
generation during sample/reagent solution loading. A liquid crystal display (LCD) screen was 
attached to inform the user of step-by-step instructions with time countdown for each assay step.  
 An optical scanning module was designed to be cost-effective and compact for high-
throughput, high-quality digital image readout. The module comprises a 2D image scanner and an 
optical unit. The scanner employs a two-axis linear rail system with two 0.9° NEMA 17 stepper 
motors, which are powered by DM542T motor shields and controlled by an Arduino MEGA 2560 
board, a lead screw/rail system, and an imaging stage made of aluminum (Fig. 5.2B). The optical 
unit (Fig. 5.2B inset) was assembled beneath the scanning unit with a 10X Nikon objective lens 
mounted on a high-precision non-rotating zoom housing, a 30mm filter cube including a dichroic 
mirror (565 nm long-path), and an excitation (545/25 nm) and emission filter (605/70 nm). The 
excitation side of the filter cube was connected to an aspherical lens (F=16 mm) that collimates an 
LED fluorescence light source (560nm) used for fluorescent excitation of beads. The bottom of 
the cage cube was connected to a sliding emission filter mount for switching between the 
brightfield and fluorescent imaging modes. The filter mount was connected to a 200mm tube lens 
(Nikon) and the light path was reflected towards the side using a 50 mm right-angle prism mirror 
mounted in a 60mm cage cube. A CMOS sensor (SONY a6100 CMOS camera) was mounted on 
the side of the 60mm cage cube and remotely controlled by a laptop to perform image scanning as 
well as data processing. Lastly, a collimated halogen lamp for bright field imaging was mounted 
above the chip to provide bright field illumination. To achieve a large field and depth of view in 
imaging as well as increase the compactness of the module, we customized the optical distance 
between the tube lens and the CMOS plane so that it lowered the magnification ratio of the whole 
optical system to 9X. To avoid high cost and complexity for the module, we did not use Köhler 
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illumination for brightfield imaging. Instead, all images were post-processed with a simple flatfield 
correction algorithm using MATLAB. The cost of the entire optical unit is less than $4000. 
 
Figure 5.2 PEdELISA assay platform comprising two modules: (A) programmed fluidic handling module 
with Arduino controlled linear rail and multi-channel pipettes. (B) customized low-cost 2-axis fluorescence 
scanning module with a consumer-grade CMOS camera. 
 
5.2.5 Control and characterization of 2D optical scanning module. 
 
Figure 5.3 (A) User-interface of the Universal Gcode Sender for automated PEdELISA assay image 
scanning (B) Characterization of the bi-directional motion control accuracy by repetitively scanning and 




To control the optical scanning module, we use the Universal Gcode Sender (UGS) that 
transmits a MATLAB-generated Gcode to the Arduino for imaging scanning (Fig. S3A). UGS 
provides a platform with manual and automated precision control of the stage and visualization of 
the scanning paths, making the whole module practical for this application. By designating each 
motor of the system through the Arduino, specific commands can be sent to each motor to move 
the stage to the desired location. A single command for moving a motor in Gcode includes the 
origin and units of movement, the shape of travel, the axis and distance of movement, and the 
motor speed. For the image scanning, an algorithm has been developed to account for any 
rotational offset in the cartridge placement to ensure that the microscope optics can capture an 
image of each microwell in the center of the view. We used a MATLAB script that generates a 
Gcode file containing line-by-line commands between two locations on the cartridge with a 5-sec 
delay for image focusing and capture. Our preliminary test showed that simultaneous x and y travel 
increases the errors of the motors. As such, we executed x and y-axis movements individually to 
improve the accuracy of the scanning. We characterized the x-y motion control accuracy by 
repeating the scanning and imaging of the on-chip microarray structures. We then used post-image 
overlay to calculate the x, y offsets which are plotted in Fig. S3B. We were able to achieve 
repeatable bi-directional scanning with a positional error of less than 5 µm and a minimum 
incremental movement of 0.31 µm.  This provided sufficient accuracy for the PEdELISA assay.  
5.2.6 Programmed PEdELISA Assay and Imaging. 
The automated pipetting system was programmed to first draw 15 µL of the sample solution 
(patient serum and assay standard) and mix with 15 µL of detection antibody (DeAb) solution in 
the 96-well tube rack for 20 cycles (25-sec), and then draw 28 µL of the mixed solution and load 
them into the PEdELISA cartridge by two steps: Step 1. Load 14 µL of the sample-DeAb mix for 
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channel buffer exchange, delay 10-sec for wiping away the original buffer solution inside the 
channel (1x PBS solution), Step 2. Load the rest of 14 µL, followed with 50-cycles of on-chip 
mixing (8-min). Then the system drew in 200 µL of washing buffer (PBS-T 0.1% Tween20) and 
slowly loaded (micro-stepping) into the chip for washing (2-min). Next, the system drew in 40 µL 
of the avidin-HRP solution and slowly loaded (micro-stepping) into the chip for enzyme labeling 
(1-min). The chip was washed again with the PBS-T solution for one cycle (200 µL) and 1x PBS 
solution for another cycle (200 µL), total to reduce the interference between Tween20 and the 
chemifluorescent HRP substrate later (total 5-min). Finally, the system drew and loaded 30 μL of 
the QuantaRed substrate solution and then sealed with 35 μL of fluorinated oil (HFE-7500, 3M) 
for the digital counting process.  
The scanning system was used to scan the image of the bead-filled microwell arrays on the 
PEdELISA cartridge right after the oil sealing step to detect the enzyme-substrate reaction activity. 
The imaging stage was pre-programmed to follow the designated path to scan the entire chip (64 
microarrays) twice: 1. Scan the QuantaRed channel (545nm/605nm, excitation/emission) 2. Scan 
the brightfield with the transmission light source on. It typically took around 6 min to scan the 
entire chip for 16 samples in 4-plex detection. 
5.2.7 Pragmatic study of rapid cytokine measurement in COVID-19. 
This study was approved by the University of Michigan Institutional Review Board 
(HUM00179668) and patients or their surrogates provided informed consent for the investigational 
use of this test. Patients with positive SARS-CoV-2 test via PCR and respiratory failure requiring 
hospitalization in the intensive care unit for heated high flow oxygen or mechanical ventilation 
were eligible for enrollment. Subjects were approached at the request of treating teams at any point 
in their disease course after intensive care unit admission. Due to restrictions on patient contact 
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during the COVID19 pandemic, samples were drawn by the subjects’ nurse with routine clinical 
labs in a serum separator tube and sent to the clinical specimen processing area, where they were 
centrifuged, aliquoted, and kept at 4°C until analysis. IL-6, TNF-α, IL-1β, and IL-10 were 
measured and results were posted to the patient’s chart the same day. Ferritin and C-reactive 
protein (CRP) measurements made during routine clinical care were recorded if available from a 
sample within 24 hours of the cytokine measurement.   
5.2.8 Statistics. 
Experiments with synthetic recombinant proteins were performed daily with 2 on-chip repeats 
averaged to calculate the patient serum cytokine levels. 10-day standard curves using 10 
microfluidic cartridges were accumulated to calculate the inter-assay coefficient of variance. The 
COVID-19 patient serum samples were performed in quadruplicate and averaged for the near-real-
time daily cytokine profile monitoring test. Conventional ELISA test was conducted 
retrospectively for IL-6 in duplicate for selected banked patient samples. Here, Pearson’s R-value 
was used to quantify the PEdELISA to ELISA correlations and the t-test was used for group 
analysis of the Tocilizumab treatment. A p-value of < 0.05 was considered to be statistically 
significant. 
5.3 Results and Discussion 
The PEdELISA microarray assay platform comprises a cartridge holding a disposable 
microfluidic chip with capture antibody (CapAb)-conjugated magnetic beads pre-settled in the 
designated microarray locations according to the antibody type, a parallel pipetting module 
controlled by Arduino for on-chip fluidic dispensing and mixing, and a 2-axis cartridge scanning 
and fluorescence imaging module (Figure 5.4A). In this setup, the disposable microfluidic 
cartridge (Figure 5.4A, inset) was designed to handle 16 samples per chip with up to 16-plex 
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maximum capacity. The chip contains two polymethyl methacrylate (PMMA) layers top (venting) 
and bottom layer (substrate) with countersink connectors that are seamlessly interfaced with fluidic 
dispensing tips, a thin polydimethylsiloxane (PDMS) layer (200 µm) which contains fL-sized 
microwell arrays for digital assay, and a polyethylene terephthalate (PET) thin (120 µm) film with 
microfluidic channels fabricated by laser cutting (see Figure 5.1 for cartridge fabrication). The use 
of the materials and processing methods significantly reduced the chip manufacturing cost (< 
$0.5/chip). 
The PEdELISA assay was carried out by the programmed pipetting module that allowed for 
microfluidic loading and handling in a consistent and repeatable manner. The module first mixed 
patient samples or assay standards with a detection antibody (DeAb) solution and then loaded them 
into the cartridge in parallel, followed by 50 automated cycles of on-chip mixing during incubation 
(8 min), washing (2 min) and enzyme labeling (1 min), washing (5 min), substrate loading, and oil 
sealing (Figure 5.4B). The chip was subsequently scanned and imaged by the compact and low-
cost (<$5000) fluorescence imaging module using a consumer-grade CMOS camera, and the data 
was analyzed by a high-throughput in-house image processing algorithm based on convolution 
neural network and parallel computing (Figure 5.4C). This algorithm performed autonomous 
classification and segmentation of image features such as microwells, beads, defects, and 
backgrounds, so that the digital assay counting results were generated without human supervision. 
The assay involved some minor manual work for assay reagent preparation and serial dilution, 
fluid waste collection, z-axis focusing, and origin/endpoint positioning to trigger the optical 
scanning.   
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Figure 5.4 PEdELISA microarray assay platform for COVID-19 patient cytokine storm profiling. (A) 
Schematic and photo image of the assay system in a biosafety cabinet. The platform comprises a cartridge 
holding a disposable microfluidic chip (inset), an automated fluidic dispensing and mixing module, and a 
2D inverted fluorescence scanning module. (B) The 4-step assay procedure includes (i) automated injection 
and subsequent on-chip mixing of serum and a detection antibody solution with capture antibody-coated 
magnetic beads pre-deposited in microwell arrays, which is accompanied by a short incubation (8-min) and 
followed by washing (2-min), (ii) HRP enzyme labeling (1-min), followed by washing (5-min), (iii) 
fluorescence substrate loading and oil sealing (2-min), and (iv) x-y optical scanning and imaging (12-min). 
(C) Data analysis using a convolutional neural network-guided image processing algorithm for high 
throughput and accurate single-molecule counting that corrects image defects and accounts for signal 
intensity variations. Both the fluorescence substrate channel (Qred CH) and brightfield channel (BF CH) 
are analyzed to calculate the average number of immune-complexes formed on each bead surface. The 
unlabeled scale bars are 25 μm. 
 
We ensured the x-y optical scanning motion control accuracy each time by repetitively 
scanning and imaging the microarray structures on the cartridge. Post-image processing was used 
to calculate the x, y offset, which may be induced by the imperfection of system alignment, lead 
screw backlash, or motor step missing. We developed a mathematical algorithm to correct these 
offsets, and the scanning module was able to achieve less than 5 µm bidirectional repeatability and 
0.31 µm minimum incremental movement (Figure 5.3). Using the programmed fluidic dispensing 
system, we optimized the assay reaction parameters (incubation time and reagent concentration) 
and achieved a limit of detection (LOD) less than 0.4 pg/mL with both assay reaction and labeling 
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incubation time in 9 min (Table 5.1). We also assessed the 4-plex assay’s specificity and signal to 
noise ratio (SNR) by spiking-in each cytokine analyte in 100% fetal bovine serum buffer (FBS) to 
mimic the patient serum detection. Figure 5.5A shows the assay results of “all-spike-in,” “single-
spike-in,” and “no-spike-in” using 200 pg/mL recombinant cytokine standards (a typical clinical 
threshold for cytokine storm). Negligible antibody cross-reactivity was observed between each 
cytokine analyte and SNR=488.0 was calculated on average (averaged assay signal over 
background signal). 
 
Figure 5.5 PEdELISA assay characterization. (A) Assay specificity test with “all-spike-in,” “single-spike-
in,” and “no-spike-in” (negative) of recombinant cytokine standard at 200 pg/mL in fetal bovine serum 
(FBS) buffer. (B) Daily COVID-19 patient assay standard curves for four cytokines from 0.32 pg/mL to 
1000 pg/mL in FBS (10 curves for each cytokine obtained over 10 workdays). The data points were fitted 
with four-parameter logistic (4PL) curves. The black dotted line represents the signal level from a blank 
solution. The blue dotted line shows 3σ above the blank signal, which is used to estimate the limit of 
detection (LOD) for each cytokine. (C) Linear correlation (R2=0.99, P<0.0001) between rapid 
measurements of fresh samples and retrospective measurements of stored samples (1 freeze-and-thaw at -
80 °C) in quadruplicate for 5 representative COVID-19 patients. (D) Good agreement (R2=0.95, P<0.0001) 
observed between single-plex IL-6 ELISA and multiplex PEdELISA measurements for 16 COVID-19 
patients. The inset shows the circled region. 
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In order to facilitate the care of patients with COVID-19 at the University of Michigan 
Hospital, we undertook a pragmatic study to rapidly return same-day cytokine levels to the clinical 
teams treating critically ill COVID-19 patients in ICU at the physicians’ request from April 9th to 
May 29th in 2020 (170).  Given the investigational nature of the assay, patients or their 
representatives provided informed consent for cytokine measurements to be provided for clinical 
use (UM IRB HUM00179668). COVID-19 Patients with respiratory failure that requires 
hospitalization in the ICU for mechanical ventilation were eligible for enrollment (see 5.2.7 for 
details). To ensure the accuracy of our data, the COVID-19 patient samples were run in 
quadruplicates with a calibrated assay standard curve every day. Figure 5.5B shows assay standard 
curves that were accumulated in 10 different workdays of the patient cytokine monitoring period.  
The multiple assay standard curves yielded excellent repeatability with the inter-assay coefficient 
of variation (CV) of ~ 10% due to the programmed fluidic handling and reaction (Table 5.1). We 
also characterized the intra-assay CV for five representative COVID-19 patient serum samples 
with cytokines at concentrations ranging from 6-600 pg/mL, each tested in quadruplicate 
measurements. We compared assay data for these five patients resulting from near-real-time 
measurements of fresh samples drawn daily and retrospective measurements of stored samples 
after one freeze-thaw cycle. We observed a good linear correlation (R2=0.99) between the two 
measurement modes except for TNF-α. This suggests that TNF-α in the stored serum could 
degrade by 20-40% after the freeze-and-thaw banking at -80 °C (Figure 5.5C). Additionally, to 
validate our PEdELISA microarray assay, we compared the assay results with those of a 
conventional single-plex ELISA method that retrospectively measured 15 banked samples from 
identical patients. Because conventional ELISA requires a much larger sample volume (>200 L 
for each measurement, in duplicate per analyte) relative to PEdELISA, it was practically difficult 
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for us to manage the acquisition of a sufficiently large blood sample volume from critically ill 
COVID-19 patients. Therefore, we only validated our assay against IL-6 detection results  (Figure 
5.5D). The data between these two methods overall matched linearly (R2=0.95, P<0.0001). The 
slight discrepancy was observed at concentrations below 50 pg/mL and may potentially due to the 
limited sensitivity and linearity of the ELISA assay (Figure 5.5D inset).  
Table 5.1 Limit of detection (LOD), limit of Quantification (LOQ), and coefficient of variation (CV) of 
PEdELISA for a panel of 4 cytokines. Here, the LOD and LOQ values were determined from the blank 
signal + 3σ and the blank signal + 10σ, respectively. The intra-assay CV was determined by quadruplicate 
measurements of five COVID-19 patient samples at the range of 6-600 pg/mL in both near-real-time and 
retrospective assay modes. The inter-assay CV was determined by taking the root-mean-square average of 






















IL-1β 0.000143 0.000347 0.191 1.188 4.68 9.98 
TNF-α 0.000179 0.000379 0.198 1.889 8.77 11.66 
IL-10 0.000136 0.000378 0.350 1.552 5.70 9.63 
IL-6 0.000189 0.000309 0.377 2.378 4.55 10.80 
 
Figure 5.6A shows a typical timeline of our daily cytokine profile measurement 
completed within 4 hours after the blood draws in the ICU. The assay itself could be 
performed with a sample-to-answer time as short as 30 min for typical non-COVID-19 
serum samples. However, in the practical operation of our test, a larger amount of time was 
spent on sample processing, transport, and team coordination, as well as biosafety and 
disinfection protocols in handling COVID-19 samples. Nevertheless, the <4-hour blood 
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draw to result turnaround is still rapid as compared to typical clinically deployed tests. This 
rapid result of the PEdELISA allows clinically meaningful time-course measurements in 
critically ill COVID-19 patients with respiratory failure during their ICU-span. Here, 
patients undergoing treatment with an expanded/emergency use of an immunomodulating 
selective cytophoretic device (SCD) were screened (first data point) and monitored with 
PEdELISA to provide <4-hour feedback on progress of therapy. Here, the SCD therapy 
was applied to temper the cytokine storm by continuously processing circulating 
neutrophils and monocytes to a less proinflammatory phenotype using an extracorporeal 
membrane cartridge integrated into a renal replacement blood circuit (171). Treatment 
details and outcomes are described in (172), and here we present serial measurements from 
two additional patients for two-week continuous monitoring. Both patients experienced 
severe cytokine storm and acute respiratory distress syndrome (ARDS) on the screening 
time point, and demonstrated decreases in IL-6 and IL-6/IL-10 ratio and clinically 
improved treatment outcome over the course of therapy (Figure 5.6B, C). With the 
successful implementation of this therapy monitored by PEdELISA, both of the patients 
were able to come off of extracorporeal membrane oxygenation (ECMO) and mechanical 
ventilator support and were eventually discharged alive from the hospital. 
Our rapid cytokine measurement also revealed significant subject-to-subject 
heterogeneity despite all patients being critically ill. As expected, interruption of IL-6/IL-
6R signaling in patients who received tocilizumab resulted in marked elevation of IL-6 
levels in the setting of ongoing illness (p<0.0001, Figure 5.6D) (173). Among patients who 
did not receive tocilizumab, we observed a large degree of variability in IL-6 levels, with a 
quarter of subjects having IL-6 <15 pg/mL, median value of 106 pg/m, and coefficient of 
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variation (CV) of 114%.  Variability of TNFα (CV 164%) and IL1β (CV 193%) was driven 
by a small number of subjects with elevated levels. However, like IL6, levels of IL10 were 
also broadly distributed in patients who had not received tocilizumab (CV 93%).   
 
Figure 5.6 (A) Timeline of daily near-real-time COVID-19 cytokine measurement. (B)-(C) Two-week 
serial monitoring of two critically ill COVID-19 patients with respiratory failure in ICU. Both patients 
experienced severe cytokine storm and were under emergency use of a selective cytophoretic device (SCD) 
by cytokine pre-screening (first data point). The patients demonstrated decreases in IL-6 and IL-6/IL-10 
ratio and clinically improved treatment outcome over the course of therapy. (D) Statistical group analysis 
of patients that were dosed/undosed with Tocilizumab. Significant elevations of IL-6 levels were observed 
after the treatment of Tocilizumab (P<0.0001). (E)-(F) Correlation of cytokine IL-6 to Ferritin and C-
Reactive Protein (CRP), standard clinical inflammatory biomarkers. Ferritin does not correlate well with 
IL-6 (R2 = 0.066, P=0.261). CRP correlates with IL-6 (R2 =0.394, P=0.0013) better, but the IL-6 levels 
were widely distributed for patients with high levels of CRP. 
 
Given the heterogeneity of cytokine levels in critically ill patients with COVID-19, we asked 
whether IL-6 levels were reflected in surrogate biomarkers. In current, rapidly evolving clinical 
practice, the presence of cytokine storm and risk of clinical deterioration is frequently judged by 
inflammatory markers such as CRP and ferritin in the absence of direct cytokine measurement.  
Ferritin did not predict IL-6 levels (Figure 5.6E, R2 = 0.01, P=0.71).  CRP was significantly 
associated with IL-6 (Figure 5.6F, R2 =0.41, P=0.018). However, this association was driven by 
low IL-6 in subjects with low levels of CRP, while IL-6 values in subjects with high CRP were 
widely distributed.  Neither CRP nor ferritin is a reliable predictor of IL-6. Note that our pragmatic 
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study of rapid cytokine measurements in patients with COVID-19 was designed to provide 
information to clinicians, rather than systematically study the biology of COVID-19. We therefore 
enrolled subjects without regard to time from the onset of infection. Furthermore, due to these 
subjects’ critical illness, many received empiric antibiotic therapy, limiting our ability to determine 
bacterial co-infection. These factors, as well as our small sample size, may have contributed to the 
heterogeneity of the cytokine response. Nevertheless, all subjects in this study were critically ill 
and had respiratory failure, underscoring the diversity of biological mechanisms that may lead to 
critical illness in COVID-19 and the importance of measuring, rather than inferring, cytokine 







AC Electroosmosis-enhanced Nano-plasmofluidic Detection of Ultra-low-
Concentration Cytokine 
 
6.1 Introduction to the Study 
The ability to detect the dynamic surface binding of biomolecules without using labeling agents 
provides a critical basis for emerging biochemical analysis. Plasmonic biosensors based on 
biologically functionalized noble metal nanoparticles enable rapid, label-free detection of proteins, 
DNA, and mRNA with ease of signal acquisition and robustness in complex biological solutions 
(174-177). These biosensors transduce biomolecular surface binding events into optical signals 
that reflect changes in the resonant behavior of conduction band electrons near the surface of 
optically excited metallic nanoparticles. Among them, gold nanorod-based plasmonic biosensors 
have been demonstrated to achieve single-molecular sensitivity (178-180) and its microarray 
enables practical protein detection at high-throughput and multiplexity (31, 181, 182). Despite 
their practicality and the intrinsic sensitivity of the individual nanoparticles, these biosensors 
exhibit performances limited by poor diffusion of the target molecules, exemplified by the 
presence of a large depletion zone near the sensor surface, especially for high-density microarrays. 
The diffusion-limited molecular binding kinetics and the resulting poor LOD prohibit the wide use 
of the nanoplasmonic biosensors in clinical diagnostics and biochemical assays.   
 112 
A miniaturized microfluidic design with effective sample mixing techniques (183-186) plays 
a key role in the detection of a wide variety of chemical/biological species. In particular, AC 
electrokinetics, including dielectrophoresis (DEP), ACEO, and electrothermal effects, have been 
widely used to preconcentrate biomolecules and enhance the analyte capture efficiency in 
microscale heterogeneous assays (187-190). For example, Gong (191) et al. monolithically 
integrated silicon nanowire field-effect transistor (FET) biosensors with micro-fabricated 
electrodes and achieved 104 times sensitivity improvement for detection of prostate specific 
antigen (PSA) in PBS buffer. Cheng (192) et al. integrated ACEO and positive DEP with an 
electrochemical impedance spectroscopy (EIS) biosensor in the detection of IgG-protein A. More 
recently, DEP was utilized to enhance surface plasmon resonance (SPR) sensing with gold 
nanohole arrays (42), and ACEO was coupled with surface-enhanced Raman spectroscopy (SERS) 
(40), in both studies, unprecedented levels of detection limit and assay speed were demonstrated. 
Among these sensing enhancement mechanisms, ACEO coupled with label-free optical biosensing 
logically offers a promising approach because it can generate strong three-dimensional (3D) 
vortices for microfluidic mixing at relatively low voltage (188), does not require any invasive, 
agitating mechanical components interfering with far-field plasmonic detection optics, and can be 
readily tuned by voltage and frequency using microfabricated electrodes of simple design which 
is integrated in a microfluidic system. The ACEO approach can improve mass transfer-enhanced 
analyte-receptor interactions, thus enhancing biosensing performance.   
In this study, we report synergistic integration of plasmonics and microfluidics to develop a 
label-free plasmonic gold nanorod (AuNR) optofluidic device coupled with ACEO analyte flow 
to overcome the barrier for diffusion-limited nanoparticle biosensing performance. The 
plasmofluidic integration has recently attracted much attention as an emerging approach to 
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advancing plasmonic device technology (193). Our device consists of a glass substrate coated with 
gold nanorods between two coplanar rectangular Pt microelectrodes and another 
polydimethylsiloxane (PDMS) microfluidic channel layer (Figure 6.1A). The ACE-LSPR 
biofunctional nanoparticle imaging process starts by applying an 180 out-of-phase AC voltage 
across the microelectrodes of the device. The movement of ion charges in the electrical double 
layer induced on the electrode surfaces (Figure 6.1A) generates a rotational fluid motion.  This 
fluid motion causes microfluidic agitation, facilitating the transport of analytes down to the sensing 
surface of AuNR to break the depletion zone (depicted by the blue arrows in Figure 6.1B, C). The 
sensor response is therefore enhanced by the increased molecular collision events. The binding of 
target analytes onto the antibody-conjugated AuNRs causes a spectral shift of the scattering light 
from the AuNR surfaces, which translates into a far-field intensity increase of the optical signal 
detected by optics using a bandpass filter (Figure 6.1D). Patterned AuNR arrays on the device 
were imaged by darkfield microscopy coupled with an Electron Multiplying Charge Coupled 
Device (EMCCD) with high sensitivity. As shown by the darkfield image (Figure 6.1E), the glass 
substrate contains a 25 µm-wide patterned area of AuNRs between 50 µm-wide microelectrodes 
and two additional reference AuNR sensor patterns of the same shape placed sufficiently (200 m) 
away from the microelectrodes. Three sets of such patterns were constructed on the same chip for 
triplicate measurements. The PDMS layer was attached to the glass substrate with the sample 
detection channels (400 m in width and 80 m in height) running orthogonal to the line-shaped 
AuNR sensor patterns and the microelectrodes (depicted by the dotted line in orange). A scanning 
electron microscope (SEM) image (Figure 6.1F) shows the distribution of nanorods and the 





Figure 6.1 (A) Schematic and principle of AC electroosmosis-enhanced localized surface plasmon 
resonance (ACE-LSPR) biofunctional nanoparticle imaging. Pt microelectrodes were first patterned on a 
glass substrate by photolithography and metal lift-off. AuNRs were then deposited to form line-shaped 
sensor pattern between the microelectrodes using a microfluidic patterning technique. With 180 out-of-
phase AC bias applied to the Pt electrodes, the electrical double layer horizontally moves along the electrode 
surfaces.  The electrical double layer movement generates a hydrodynamic rotational flow within the 
microfluidic channel.  The hydrodynamic flow facilitates the transport of the target biomolecules down to 
the sensing surface and their surface binding reaction. (B)-(C) Close views of the analyte-receptor 
interactions with/without ACEO. A large depletion zone is formed and slows down the surface reaction 
under diffusion-limited operation. (D) The binding results in an increase of scattering cross-section and a 
red shift of the plasmon resonance which is converted into the scattering intensity increase by a band-pass 
filter (680/13 nm, shown by the shade). (E) Darkfield image of AuNR line-shaped patterns (shown in red) 
and microelectrodes (black strips in the middle) with a microfluidic flow channel perpendicular to them 
(400 μm, orange dotted line). (F) SEM image showing the zoomed-in view of the isolated AuNRs patterned 
on the glass substrate between the microelectrodes. The size of the AuNRs was measured to be ~40 nm in 
diameter and ~84 nm in length. After the assay, the formation of a dense dielectric layer surrounding each 
AuNR was observed, suggesting the binding of antibodies and analytes onto the sensor surface (Inset). 
 
6.2 Materials and Methods 
6.2.1 Materials.  
The AuNRs were purchased from NanoSeedzTM, Hong Kong (product # NR-40-650). Each 
AuNR is 40 nm in diameter and 84nm in length. The particle shape and size were chosen to yield 
high sensitivity and sufficient binding sites (31, 194). The AuNRs were synthesized by a seed-
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mediated method and were stabilized by cetyltrimethylammonium bromide (CTAB). The 
measured ensemble-average scattering longitudinal plasmon resonance of these particles in water 
is at  = 655 nm. Human IL-1β capture and antibody was purchased from BioLegend. Human IL-
1β uncoated ELISA kit was purchased from Invitrogen. EDC (1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride), Sulfo-NHS (Sulfo-N-hydroxysulfosuccinimide), MES (2-(N-
morpholino)ethanesulfonic acid) buffered saline, and PBS SuperBlock blocking buffer were 
obtained from Thermo Fisher Scientific. 16-Mercaptohexadecanoic acid (MHA) was purchased 
from Sigma-Aldrich. Charcoal stripped human serum matrix was obtained from EMD Millipore. 
6.2.2 Device Layout and Fabrication. 
 
Figure 6.2 ACE-LSPR optofluidic device layout. (a) Photo image of the ACE-LSPR optofluidic device 
chip. The scale bar is 1 cm.  (b) Device layout showing the design incorporating three parallel meandering 
AuNR patterns (yellow) and six parallel sample loading/detection channels made of PDMS (blue). Inset: 
x10 darkfield image of the sensing spot formed at the intersection between the AuNR lines and the PDMS 
channels. Ref: ACEO-Decoupled LSPR Biosensor. 
Figure 6.2 shows the detailed device layout, which consists of coplanar rectangular Pt 
microelectrodes, three parallel meandering lines of gold nanorods (AuNRs) (depicted in yellow), 
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and six parallel sample loading/detection channels of PDMS (depicted in blue) on the same glass 
substrate. Each intersection between the AuNR lines and the horizontal sample loading/detection 
channels yields a sensing spot, which has an ACEO-coupled LSPR biosensor region between the 
microelectrodes and two ACEO-decoupled LSPR biosensor regions 200 m away from the 
microelectrodes. The ACEO-decoupled LSPR biosensor regions are used as references in control 
experiment (depict as Ref in Figure 6.2B inset). Three identical sets of the sensing spot were 
constructed within each sample loading/detection channel on the same chip for triplicate 
measurements.  
 
Figure 6.3 Schematic of the device fabrication process which includes: (A) Pt/Cr microelectrode patterning 
by sputtering and liftoff processes; (B) AuNRs deposition by O2 plasma treatment, microfluidic patterning, 
and thermal annealing; (C) Bioconjugation of AuNR sensor sites with anti-IL-1β with EDC/sulfo-NHS 
linking using 16-Mercaptohexadecanoic acid. 
Figure 6.3 shows the schematic of the ACE-LSPR device fabrication process. It started with 
deposition of parallel coplanar Cr/Pt (60nm) plate microelectrodes (50um wide, 25 um gap) on 
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glass substrates (Figure 6.3A). A glass substrate was first treated with Piranha solution 
((H2SO4:H2O2 = 3:1 v/v), rinsed thoroughly with DI water, and air dried before use. A layer of 
positive photoresist (SPR 220 3.0) was spin-coated on the glass substrate and photolithographically 
patterned using a darkfield photomask. An E-beam evaporation method (EnerJet Evaporator) was 
used to deposit a 10 nm-thick layer of chromium as the adhesion layer and then a 50 nm-thick 
layer of platinum on top of it. The Cr/Pt layer was subsequently lifted off using acetone and 
ultrasonication, which formed the microelectrode patterns. The Cr/Pt microelectrode-patterned 
glass substrate was then thoroughly rinsed with D.I. water and dried with N2. 
The next step involved deposition and patterning of gold nanorods (AuNRs) to form the three 
parallel sensor lines on the glass substrate using a microfluidic patterning technique (Figure 6.3B). 
The substrate was again Piranha cleaned (10 min) and then treated with O2 plasma. The O2 plasma 
treatment generates a negatively charged surface as a result of the dissociation of hydroxyl groups, 
which enables the glass substrate to attract the positively charged, CTAB stabilized AuNRs 
suspended in a colloidal solution onto its surface. Immediately after plasma treating, a soft-
lithographically molded PDMS microfluidic channel layer was placed on the substrate with the 
straight-line segments of its meandering-shaped channels aligned to the microelectrodes under a 
long working-distance stereomicroscope. The AuNR containing colloidal solution with a carefully 
determined particle concentration was loaded into the microfluidic channels from their inlets in 
both directions. A uniform monolayer of AnNR with an average inter-particle distance > 200 nm 
was settled on the substrate (Figure 6.1F), which was followed by a thermal annealing step (195) 
(120 ̊C, 1h) to increase the binding strength between the AuNRs and the substrate.  The straight-
line segments of the meandering channels formed the AuNR sensor lines. 
 118 
The third step was biofunctionalization of the AuNR patters with antibodies (Figure 6.3C). 
After removing the aforementioned PDMS layer, the ACE-LSPR biosensor glass substrate was 
rinsed with pure ethanol. An O2 plasma descum process was used to clean the substrate surface 
and to remove the excess CTAB. The substrate was then immersed in 0.5mM of 16-
Mercaptohexadecanoic acid (MHA) dissolved in ethanol overnight to form a uniformly coated 
self-assemble monolayer (SAM). Finally, the substrate was rinsed with ethanol and DI water, and 
the chip was covered with another soft-lithographically molded PDMS layer with straight sample 
loading/detection channels (400 m in width and 80 m in height). These channels were aligned 
orthogonal to the directions of the microelectrodes and the AuNR sensor lines. A solution of 0.4M 
EDC and 0.1M sulfo-NHS was loaded into the microchannel and incubated for 40min to activate 
the carboxylic acid groups of MHA. Rinsed with DI water, the chip was incubated for 1.5 hr by 
loading 50 µg/ml anti-IL1β solution and then passivated by SuperBlock™ (PBS) Blocking Buffer 
for 30 min, and finally became ready for the real-time LSPR biofunctional nanoparticle imaging 
study.  
6.2.3 Experimental Setup and ACE-LSPR Imaging Technique. 
Figure 6.4 shows the dark-field microscopy setup used for ACE-LSPR biofunctional 
nanoparticle imaging and signal detection. The molecular binding on the AuNR surface induces a 
red-shift of scattering spectrum due to the change of local refractive index as well as an increase 
of the particle scattering cross-section. The electron multiplying charge coupled device (EMCCD) 
was implemented to quantify the signal intensity enhancement here by coupling with a proper 
band-pass filter (680nm/13nm). We also used a fiber spectrometer to check the extinction spectrum 
of the entire AuNR substrate and roughly monitored the spectral shift at each bio-conjugation step. 
The ACE-LSPR biofunctional nanoparticle imaging process involved mounting the ACE-LSPR 
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device chip on a motorized X-Y stage (ProScanIII, Prior Scientific, Rockland, MA), loading a 
sample of 5 μL into each microfluidic channel by a syringe pump, and then performing time-lapse 
recording and automated image scanning across the entire sensing spots within the same channel. 
The optical intensity signal was averaged over the sensor surfaces, each holding a large number of 
AuNR biosensor nanoparticles, using a customized MATLAB code developed in our lab.  
 
Figure 6.4 (A) Schematic of the dark-field microscopy setup used in this study. (B) Illustration of the 
ACE-LSPR biofunctional nanoparticle imaging process. (C) Photo image of the ACE-LSPR device 
mounted on the motorized X-Y stage of the dark-field microscopy setup.  
 
6.2.4 Modeling of Electrical Double Layer. 
Modeling the ACEO effect accompanying our device operation is a key task of the theoretical 
part of this study. First, the long coplanar plate electrodes immersed in aqueous electrolyte were 
modeled as a series of distributed capacitors associated with the electrical double layer and 
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semicircular resistors due to the electrolyte.  The potential drop across the electrical double layer 





where 𝑉0 and  are the peak value and frequency of the applied AC bias, respectively, 𝜀 and 𝜎 are 
the permittivity and conductivity of the electrolyte, respectively,  𝜅 is the reciprocal Debye length, 
which is the function of the ionic strength of the solution, and x is the distance from the center 
between the two coplanar microelectrodes. This equation is valid when 𝑉0 is small enough to avoid 
an additional electrochemical effect and 𝜔 is much smaller than the relaxation frequency of the 
solution. Since the thickness of the electrical double layer is small compared to the microfluidic 
channel height, a linear relationship was assumed between the surface ion charge density s and 
the potential drop across the diffuse layer ∆𝜙𝐸𝐷𝐿 as 𝜎𝑠 = 𝜀𝜅∆𝜙𝐸𝐷𝐿. The electrical force acting on 
the fluid was derived by Coulomb’s law, which is opposed by the viscous force of the fluid as 




where 𝐸𝑡  is the tangential component of the electric field, 𝜌𝑒  is the charge density, 𝜇  is the 
dynamic viscosity of the solution. Integrating Equation (2) from infinity (y = ∞) to the electrode 
surface (y = 0) and combine the surface charge expression, we derived the AC electroosmosis 
velocity 𝑢𝐴𝐶𝐸𝑂 as shown in the main text. It should be noted that although a more complicated 
electrical double layer modeling may be needed especially for high ion concentration conditions, 
this simple circuit model fairly well predicts the experimentally observed flow velocity fields in 
the solution, and thus is sufficient for providing insights into the physical phenomena governing 
the ACE-LSPR device performance.  
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6.2.5 ACEO Flow Visualization and Particle Image Velocimetry (μ-PIV) Analysis. 
AuNRs (l=84 nm, d=40 nm) were used as tracer particles to visualize the flow patterns within 
the fabricated device. The particle motions were observed using the above-described darkfield 
microscope (Figure 6.4) and recorded by the EMCCD camera. We selected the operating voltage 
and frequency in a buffer solution with varying ion concentration such that the fastest particle 
motions were visually observed from the dark-field image. The buffer solution we used were 
0.001x phosphate-buffered saline (PBS) and 50% DI diluted human serum matrix (HSM). The 
colloidal medium suspending gold nanoparticles was first centrifuged in a tube. The original 
medium was collected from the tube using a pipette and replaced by the PBS solution.  The gold 
nanoparticles in the PBS solution were loaded into the microfluidic channels of the ACE-LSPR 
device. The gold nanopartilces are much smaller than fluorescent latex spheres normally used in 
conventional particle image velocimetry for flow visualization. The small mass of the 
nanoparticles together with the non-fluorescence detection approach has the potential to visualize 
even weak flow patterns in a nanofludic environment without photobleaching. We took videos that 
showed nanoparticle motions resulting from a vortex flow pattern whose center of circulation was 
close to the electrode edge as predicted by our theoretical calculation. As the buffer was switched 
from PBS to HSM, the speed of the nanoparticle motions significantly decreased due to an increase 
of the ion concentration in the medium. The video also showed flow patterns at different 
frequencies. The fastest nanoparticle motions were observed at 1kHz in HSM, thus suggesting that 
it is close to the optimum ACEO bias frequency.  Note that some aggregation of nanoparticles due 
to the positive dielectrophoretic effect was visualized at the edge of the electrodes under condition 
𝑉0 = 2𝑉  at f=1kHz. This dielectrophoretic effect could cause non-specific adsorption of free 
background proteins occurred in serum.  
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This study developed a flow visualization technique to characterize ACEO velocity fields 
experimentally within the ACE-LSPR device based on 2D micron resolution particle image 
velocimetry (μ-PIV) analysis. An open source MATLAB toolbox (197) was utilized to perform 
image processing and fluid velocity field measurement. We captured a video series of the gold 
nanorods moving in the 0.001x PBS buffer ( = 1.59 mS/m) at 𝑉0 = 1V and 16.67 frame/s with 
the frequency varied using darkfield microscopy. Since the video were taken from the top view, 
the focal plane was fixed at 40 μm above the microelectrode surface to ensure the image quality 
and unidirectional flow. Some image preprocessings were first applied to enhance the image 
contrast, filter the background noise, and remove the very bright particle spots. A region of interest 
(ROI) was then selected around the electrode surface as depicted by the blue dotted line in Figure 
6.5A. A mask image was placed at the center of the microelctrodes so that the out of plane flow 
will not be quantified. Cross-correlation functions were built up based on a fast Fourier transform 
(FFT) algorithm. Lastly, the velocity field at the frame rate was visualized with arrows as shown 
in Figure 6.5A. Figure 6.5B shows the theoretical and experimental ACEO velocity values at x 
=17.5 μm from the center of the microelectrodes at frequency 200Hz. The scattered dots represent 
experimental values obtained by averaging the tracing particles’ x-direction velocity along the red 
dotted line (shown in Figure 6.5A) at 𝑉0 = 1V while the curve represents an simulation obtained 
at 𝑉0 = 0.613V. Here, anticipating experimental uncertainties associated with our electronics setup, 
the value of V0 in the simulation was slightly corrected to be lower to match the theoretical ACEO 
velocity value with the one measured at the operational frequency of 200Hz. Note that the bell-
shaped simulation velocity is slightly narrower than the experimental results. A similar 
discrepancy was also found by N.G. Green et al. (198),  which is likely to be caused by the 
simplified linear assumption in the electrical double layer model as mentioned above and the 
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deviation of the relaxation time 𝜏 =  𝜀 𝜎⁄  associated with the fabricated electrodes from the 
theoretical value. Nonetheless, combining the μ-PIV measurement and the theoretical mass 
transfer calculation allows us to accurately estimate the upper bound for the ACEO enhancement 
of biosensing.  
 
Figure 6.5 (A) Fluid velocity field measured by 2D micron resolution particle image velocimetry (μ-PIV) 
analysis. Images of the gold nanorods moving in the 0.001x PBS buffer (  = 1.59 mS/m) were captured at 
16.67 frame/s using darkfield microscopy with a focal plane at 40 μm above the microelectrode surface. 
(B) Theoretical and experimental ACEO velocity at x =17.5 μm from the center of the microelectrodes at 
200Hz. The scattered dots represent experimental values obtained by averaging the tracing particles’ x-
direction velocity values along the red dotted line in (a) at 𝑉0 = 1V. The curve represents simulation results 
at a corrected value of 𝑉0 = 0.613V.  
 
6.2.6 ELISA Correlation Test. 
The Invitrogen™ 96-well Human IL-1β ELISA Kit was used to quantify the level of human 
IL-1β in the same patient serum sample as we used for our ACE-LSPR assay. For the both tests, 
two identical sets of serum sample were prepared during each freeze-thaw cycle. The patient serum 
samples were diluted two times by DI water, and the standard curves were obtained using 50% 
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diluted heat inactivated and charcoal stripped human serum matrix (EMD Millipore) spiked by 
known concentrations of IL-1β.  
6.2.7 T-Test for 5min Initial Slope Analysis. 
The initial slope analysis for analyte binding curves under ACEO operation (ACE-LSPR 
binding curves) provides an effective and advantageous way to reduce the sampling-to-answer 
time for assays using label-free biosensors (35). Plotting the initial slope value as a function of the 
IL-1 concentration yielded a calibration curve showing a similar trend to the conventional method 
analyzing the signal intensity at the end point of the analyte biding assay. We found out that the 
selection of the time period from the starting point of the ACE-LSPR binding curve for which the 
initial slope value was extracted (initial slope extraction time) strongly affected the extraction of 
the calibration curve. To determine the minimum initial slope extraction time required for reliable 
calibration curve extraction, we performed a two-tailed heteroscedastic t-test. This analysis 
involved comparing the initial slope values obtained for the extraction time of 1, 2, 3, …, 7 min 
with the one obtained for the extraction time of 8 min, as shown by Figure 6.6. Here, fitting to the 
ACE-LSPR binding curve data within the first 8 min was found to yield the same initial slope 
value as fitting to the whole binding curve covering the entire incubation period of 15 min. Thus, 
the analysis took the value for the initial slope extraction time of 8 min as the reference. All the 
initial slope values obtained for time periods longer than 5 min show statistically insignificant 
differences (P>0.2) while these values were distinct from those obtained for time periods shorter 
than 3 min (P<0.05). Thus, we concluded that the incubation time of 5 min was long enough to 
yield an ACE-LSPR binding curve for which we can obtain consistent standard curve data. The 
initial slope analysis for the 5 min incubation allows us to perform the rapid analyte quantification 
for patient samples. 
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Figure 6.6 Initial slope values obtained from analyte binding curves under ACEO for the initial slope 
extraction time of 1 to 8 min. The time period of 5 min was determined as the minimum period to obtain 
the calibration curve. P values were calculated between the initial slope values for 1 to 7 min and the value 
for 8 min for the IL-1 concentration at 100 pg/mL, 500 pg/mL, and 1 ng/mL. *, p-value < 0.05; **, p-
value < 0.01; NS, no significant difference. 
 
 
6.3 Results and Discussion 
6.3.1 Theoretical Study of ACE-LSPR. 
Figure 6.7A provides a schematic illustration of the theoretical model for the ACEO-enhanced 
analyte transport and surface reaction during the ACE-LSPR optofluidic device operation. Using 
a simplified two-dimensional model, AC electroosmosis velocity 𝑢𝐴𝐶𝐸𝑂 was first calculated from 
the movement of the electrical double layer in the presence of an alternating tangential electric 









  (3) 
where Ω is the non-dimensional frequency defined as Ω = 𝜋2𝜅𝑥(𝜀𝑚 𝜎𝑚)𝑓⁄ , in which 𝜅  is the 
reciprocal of the Debye length, and 𝜀𝑚  and 𝜎𝑚  are medium electrical permittivity and 
conductivity, respectively, 𝜇 is the dynamic viscosity of the solution, 𝐶𝑆 is the capacitance of the 
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Stern layer, or the thin layer of tightly associated counter ions near the electrode surface, 𝐶𝐷 is the 
capacitance of the Diffuse layer, or the layer behind the Stern layer in which the electric potential 
exponentially decays, and 𝑉0 is the peak value of the applied potential. The AC electroosmosis 
velocity 𝑢𝐴𝐶𝐸𝑂  was then included into the slip boundary condition when solving the 
incompressible Navier-Stokes (N-S) equation to obtain the velocity field (𝑢, 𝑣) of the solution.   
The transient local analyte concentration c = c(x, y, t) was then calculated by solving the mass 















)    (4) 
where 𝐷 is the diffusion coefficient. At the sensor surface (y = 0), the boundary condition was set 
up such that the analyte mass flux is balanced with the surface binding reaction rate based on the 




= 𝑘𝑜𝑛𝑐|𝑦=0(𝐵0 − 𝐵) − 𝑘𝑜𝑓𝑓𝐵 (5) 
where 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 are association/dissociation constants, 𝐵0 is the initial binding site density, 
and 𝐵 is the immobilized antigen concentration. Here, the key parameters to be optimized are the 
applied voltage, frequency, and microfluidic chamber height under different ionic concentrations 
in solution. Both the applied voltage and frequency determine 𝑢𝐴𝐶𝐸𝑂  while the microfluidic 
chamber height affects the entire mass transport process. The inlet and outlet were set as an “open 
boundary”, where the local concentration is equal to the bulk solution concentration under zero 
normal stress. Table 6.1 summarizes key parameters used for our simulation and device design. 
The dissociation constant 𝑘𝐷  was estimated based on published cytokine binding kinetics (93, 
199). Note that the electrode thickness was carefully selected to be 60 nm in our device, higher 
than AuNR’s diameter (40nm) to ensure the binding is well-protected from the movement of the 
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electrical double layer. Previous study (200) suggests that too high a flow velocity on the electrode 
surface at a high voltage may pull the antigen out of the bond, thus causing a negative effect.  
Table 6.1 Simulation and design parameters selected for the ACE-LSPR device. 
Simulation Parameter Design Parameter 
𝑘𝐷 (M)
10-11 10-11 𝑤𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑑𝑒 (μm) 50 
𝑘𝑜𝑛 (M
-1s-1) 3×107 ℎ𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑑𝑒 (nm) 10 (Cr)+50 (Pt) 
𝑘𝑜𝑓𝑓 (s
-1) 3×10-4 𝑤𝑔𝑎𝑝 (μm) 25 
𝐶0 (ng/ml) 1.0 𝑤𝑐ℎ𝑎𝑛𝑛𝑒𝑙  (μm) 400 
𝐷 (m2s-1) 10-11 ℎ𝑐ℎ𝑎𝑛𝑛𝑒𝑙 (μm) 80 
ℎ𝑐ℎ𝑎𝑛𝑛𝑒𝑙  (μm) 60-140 𝑙𝑐ℎ𝑎𝑛𝑛𝑒𝑙 (cm) 2 
𝑤𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑑𝑒 (μm) 50   
𝑉0 (V) 1-4   
𝑓 (Hz) 50-100000   
σ (mS/m) 1.590   
 
In order to accurately predict the enhancement of the ACEO-facilitated analyte transport and 
surface reaction, we experimentally verified the ACEO velocity calculated above using a flow 
visualization technique developed in this study (see 6.2.5). This technique employed AuNRs 
suspended in a testing buffer solution as tracing particles. Real-time imaging of particle trajectories 
with a darkfield microscopy setup allowed us to measure the flow velocity field within the device 
under ACEO operation by two-dimensional (2D) micron resolution particle image velocimetry (μ-
PIV) analysis. We quantitatively observed a good match between our theory and experiment for 
frequency-dependent ACEO flow behaviors and determined the best operating frequency to be f = 
200Hz for the testing buffer (conductivity: 1.59 mS/m), as shown in Figure 6.5.  
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Figure 6.7 2D Finite-element analysis (FEA) simulations on the mass transport and surface reaction in the 
ACE-LSPR optofluidic device. (A) Simulation setup and boundary conditions. The ACEO velocity was 
first characterized by calculating the movement of the electrical double layer driven by the tangential 
component of the electric field using Coulomb’s law. This velocity was then coupled with incompressible 
N-S equation to solve for the flow field, which was subsequently integrated with Fick’s law to derive the 
concentration profile. Finally, the first order Langmuir Absorption was adopted as a boundary condition 
accounting for the surface reaction at the sensor surface. (B)-(D) Analyte concentration profiles within 
microfluidic channel of the device operated under ACEO at 𝑉0 = 2𝑉 𝑓 = 200𝐻𝑧, with diffusion only, and 
with convection flow at 25 μm/s, respectively. The ACEO velocity direction and magnitude are shown by 
the blue arrows. The initial concentration for all three cases was set to be 𝑐 𝑐0⁄ = 1. The inlet (left edges) 
and the outlet (right edges) for ACEO and diffusion only cases were defined as open boundaries with no 
analyte replenishment (𝑐 𝑐0⁄ = 1 𝑎𝑡 𝑥 = ∞). (E) Time-course change of binding ratio (BR) for different 
operating conditions. The BR is defined as the ratio of analyte occupations over the entire available binding 
sites. (F) Time-course change of enhancement factor for different channel heights under ACEO operation 
at 𝑉𝑝−𝑝 = 2𝑉 𝑓 = 200𝐻𝑧. Here, the enhancement factor is defined as the BR under ACEO over the BR 
under the condition of diffusion only.   
 
Using the experimentally verified model, we calculated the binding ratio 𝐵𝑅 = 𝐵 𝐵0⁄  (the 
fraction of binding sites occupied by analyte molecules over the total sensor surface area) after an 
incubation period of 20 min for three assay conditions: (1) ACEO agitated incubation without 
forced convection at 𝑉0 = 2V and f = 200Hz (Figure 6.7B), (2) static incubation driven by pure 
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diffusion without forced convection or ACEO (Figure 6.7C), and (3) forced convection without 
ACEO (Figure 6.7D). The ACEO operation at 2V/200Hz was later determined to yield the optimal 
biosensing condition. The value of BR was assumed to be proportional to the LSPR scattering light 
intensity. Figure 6.7B shows that the circular flow generated by ACEO can significantly suppress 
the depletion zone as compared to the static incubation condition in which sample solution is not 
replenished at the sensor surface. Figure 6.7E shows numerical results of BR over time for human 
cytokine IL-1β at 1 ng/mL in 1000 times diluted (0.001x) PBS (conductivity: 1.59 mS/m) with an 
ionic strength of 0.2105 mol/m3. Here, we chose IL-1β, a proinflammatory cytokine (cell signaling 
protein) produced by monocytes and macrophages, as the model analyte in our study. IL-1β has a 
relatively low molecular weight (17 kDa) and a small dissociation constant (10-10-10-11M), and is 
responsible for systemic inflammatory responses of the host, activation of phagocytes, and 
production of acute phase proteins by the liver (201).  
With the optimum frequency fixed at f = 200Hz, we further varied the applied voltage and 
channel heights. Since 𝑢𝐴𝐶𝐸𝑂  scales with 𝑉0
2 (see Equation (3)), our simulation in Figure 6.7E 
shows that BR is significantly enhanced as 𝑉0  increases from 1V to 4V. Now, we define the 
enhancement factor as 𝐵𝑅𝐴𝐶𝐸𝑂 𝐵𝑅𝐷𝑖𝑓𝑓⁄ , where 𝐵𝑅𝐴𝐶𝐸𝑂 and 𝐵𝑅𝐷𝑖𝑓𝑓 are the binding ratios under 
ACEO agitated incubation (Figure 6.7B) and the diffusion-driven static incubation (Figure 6.7C), 
respectively. The enhancement factor thus quantifies the ACEO-driven enhancement of the analyte 
binding at the sensor surface. Figure 6.7F shows the enhancement factor as a function of time and 
channel height, with its maximum 5-7 fold reached within the first 3-5 min of device operation. 
When the channel height is small, the confinement of fluid by the channel ceiling suppresses 
ACEO-induced fluid mixing. Without forced convection of the sample fluid, the analyte depletion 
zone quickly grows over time since no analytes are replenished at the sensor surface. A larger 
 130 
channel height prevents the depletion region from reaching the channel ceiling, effectively 
increasing the enhancement factor. However, the enhancement starts to taper off with the channel 
height exceeding ~140 m as ACEO-induced fluid mixing decreases with the distance from the 
electrode. To keep the fabrication practically easy, we selected a channel height of 80 m.  
6.3.2 Experimental Validation of ACE-LSPR. 
We next experimentally demonstrated detection of low-concentration IL-1β using the AuNR 
optofluidic device and ACEO-induced fluid mixing operation. To this end, we first conjugated 
anti-IL-1β to AuNR surfaces using a two-step EDC/sulfo-NHS protocol (see 6.2.2). The use of a 
low conductivity medium, 0.001x PBS buffer (1.59 mS/m), was expected to achieve high ACEO 
velocity without undesired heat generation and electrolysis. To monitor the real-time binding of 
IL-1β on the sensor surface, we recorded the scattering intensity change of the line-shaped AuNR 
sensor patterns every 5s. Figure 6.8 shows time-resolved intensity change upon analyte binding, 
corresponding to the IL-1β concentration from 50 fg/mL to 100 pg/mL in PBS (0.001x) buffer 
along with a negative control. The assay started with sample loading for 5 min and incubation for 
another 5-6 min, followed by applying an AC bias of 180 phase difference for around 15 min. 
We observed a significantly enhanced intensity shift and a much faster binding speed towards 
equilibrium after introducing the ACEO flow (indicated by the dashed blue line in Figure 6.8).  
As a result, we were able to distinguish the signal indicating the presence of IL-1β in PBS 
down to 50 fg/mL (2.9 fM) from the signal of the negative control (purple line, Figure 6.8) within 
10 min after turning on ACEO. In Figure 6.8B, the end-point intensity increases of the triplicated 
AuNR line-shaped sensor patterns are mapped at different analyte concentrations with and without 
ACEO. Figure 6.8C shows a close comparison of sensor responses as a function of IL-1β 
concentration with and without ACEO. Here, we define the LOD as the analyte concentration 
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which generates a signal corresponding to 3 standard deviations above the mean of the noise level 
in the negative control (107). The LOD of the ACE-LSPR device is thus 158.5 fg/mL (9.1 fM) in 
0.001x PBS, 100 fold more sensitive than that without ACEO (Figure 6.8C). In addition, enhanced 
analyte-antibody interaction by ACEO yields a larger number of binding events occurring at the 
sensor surface, as indicated by the ~2.5 times increase of scattering signal with ACEO (Figure 
6.8). This is the key reason for the ACE-LSPR device to achieve such a low LOD value and short 
assay time. It should be noted that the signal enhancement ratio is around 40% smaller than the 
theoretical predictions. This discrepancy is acceptable, considering (i) the assumption made to 
simplify our model, in which the ion charge density on the microelectrode surface induced by the 
applied AC bias is linearly proportional a potential drop in the electrical double layer, and (ii) 
uncertainties in model parameters (see 6.2.4 for simulation details). 
 
Figure 6.8 Detection of purified IL-1β in 0.001x PBS buffer. (A) Real-time scattering light intensity 
profiles of the line-shaped ACE-LSPR AuNR sensor patterns at various IL-1β concentrations (50 fg/mL to 
100 pg/mL). Here, the operation condition at 𝑉𝑝−𝑝 = 4𝑉 𝑓 = 200𝐻𝑧  was applied after 10-11 min of 
incubation. (B) Darkfield images showing the mapping of the scattering intensities of triplicated sensing 
patters under conditions with/without ACEO. (C) Calibration curves obtained from the intensity mapping 
in b (left y axis). The LOD was determined by the intersection of the fitted calibration curve with 3 standard 
deviations (3σ) above the mean of the background noise. The LOD was calculated to be 158.5 fg/mL (9.1 
fM) for “with ACEO” and 15.2pg/mL for “without ACEO”. A reduction of LOD by two orders of 
magnitude was achieved. The signal enhancement ratio (right y axis) was calculated by the scattering 
intensity change for the “with ACEO” condition over the “without ACEO” condition. The “without ACEO” 
condition data were obtained from the intensity change of the Ref bar shown in Figure 6.1E. 
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To explore the practical utility of the ACE-LSPR device for clinical diagnosis, we further 
sought to detect human IL-1β in complex human serum, which has a greater ionic strength and 
contains a wide spectrum of background proteins. From Equation (3), it is known that ACEO flow 
velocity decreases with ion concentration, which causes the optimum operating frequency to shift 
to a higher value. A higher ion concentration also potentially introduces other undesirable effects, 
such as Joule heating, DEP concentrating, and electrolysis. These additional effects can adversely 
affect the stability of the sensor performance (184) and are difficult to predict by theory. Therefore, 
we empirically chose a 50% DI water diluted, cytokine-free heat inactivated and charcoal stripped 
human serum matrix (HSM, EMD Millipore) as the testing buffer. And we determined the 
optimum device operation condition to be 𝑉𝑝−𝑝 = 1.5𝑉 at f = 1kHz based on the flow visualization. 
Following the same protocol described previously, we obtained real-time analyte binding curves 
from 1 pg/mL to 10 ng/mL of IL-1β spiked-in human serum and the corresponding calibration 
curves, as shown in Figure 6.9A and B, respectively. A strong binding enhancement was observed 
immediately at 6 min, which is the time point when the bias was applied. This strong binding 
enhancement is similar to what we observed in the test using PBS buffer but may not entirely due 
to the ACEO fluid transport. It should be noted that even for the negative control (human serum 
without IL-1β spiked), we observed a noticeable enhancement of binding by implementing ACEO. 
This could be attributed to the non-specific adsorption of free background proteins in serum 
promoted by the positive DEP effect at the electrode edges, as discussed in previous studies (192). 
Therefore, we incorporated a washing step with deionized (DI) water at 20 min after the assay, in 
order to remove the non-specifically adsorbed proteins and to eliminate false signals. Based on the 
calibration curves, we determined the LOD of the ACE-LSPR device for human serum samples to 
be <1 pg/mL (58 fM), which is about one order of magnitude higher than the LOD in PBS buffer.  
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This higher LOD for human serum samples is likely due to the nonspecific binding of the complex 
human serum background that still partially remains after the washing step.  
 
Figure 6.9 Detection of IL-1β in human serum. (A) Real-time scattering light intensity profiles of the line-
shaped ACE-LSPR AuNR sensor patterns presenting enhanced signals for 50% human serum matrix 
(HSM) spiked by IL-1β at concentrations of 1 pg/mL to 10 ng/mL. Here, the operation condition at 𝑉𝑝−𝑝 =
1.5𝑉 𝑓 = 1𝑘𝐻𝑧 was applied after an incubation period of 5 min. (B) Calibration curves obtained from 
intensity mapping and 5 min initial slope analysis (shown by the inset). The raw data were fitted by a 5-
parameter logistic function. (C) Serum IL-1β concentrations measured by three different methods for 6 
pediatric sepsis patients stratified into hyper-inflammatory and mild-inflammatory subgroups. The labels 
of “ACE-LSPR,” “ELISA,” and “5-min Slope” indicate data obtained for the clinical samples by ACE-
LSPR signal intensity analysis after an incubation period of ~15 min, conventional 96-well plate ELISA, 
and 5-min initial slope-based analysis, respectively. (D) One-tailed paired difference t-test performed for 
5-min initial slope measurement between the two patient subgroups. The p-value calculated between the 
two patient subgroups is < 0.01. 
 
 134 
We were able to extract the initial slope values of the binding curves within the first 5 min of 
sample incubation in the presence of ACEO. As shown by red bold lines in Figure 6.9A, a linear 
regression was utilized to fit the initial real-time binding curves. Here, we found good linear fits 
to the initial 5-min regions of the binding curves for IL-1β concentrations from 10 pg/mL to 1000 
pg/mL (R2>0.95) as the Langmuir model predicts. By plotting the initial slopes as a function of 
IL-1β concentration, a calibration curve with a similar trend to the scattering intensity-based 
analysis was obtained (Figure 6.9B inset). The selection of the incubation time for initial slope 
fitting would undoubtedly affect the shape of the calibration curve and the subsequent analysis of 
the biosensing performance. Here, we decided to use the first 5 min real-time binding data based 
on a variance analysis after carefully comparing the fitted data at different incubation time periods 
over the entire real-time dataset. (See 6.2.7). By correlating the analyte concentration with the 
initial slope of the sensor response curve, we could reduce the assay time down to ~5 min while 
most of other analyte diffusion-limited biosensor operations require much longer time for the 
system to reach its equilibrium. 
6.3.3 Clinical Demonstration of ACE-LSPR. 
Finally, we further measured IL-1β concentrations in serum samples extracted from six sepsis 
patients. Three of these patients were stratified into a hyper-inflammatory subgroup, and the other 
three are into a mild-inflammatory subgroup (49). All studies were approved by the University of 
Michigan Institutional Review Board (IRB) and conducted with informed parental consent. Blood 
samples were collected from patients younger than 18 years old, meeting criteria for septic shock 
admitted to the pediatric intensive care unit at the C.S. Mott Children’s Hospital within 24 hours 
of admission. The tests were simultaneously performed using both ELISA and the ACE-LSPR 
device with 3 to 4 repeats in the same freeze-thaw cycle. Using the ACE-LSPR device, we 
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measured serum IL-1β across the patient samples from both the scattering intensity images 
obtained after the entire assay process and the 5-min initial binding curve slopes. These intensity 
and slope values were converted to IL-1β concentration values by 5-parameter logistic fitting 
(202), which is a standard fitting method in commercialized immunoassay (203) for plotting a 
sigmoidal shape calibration curve on the semi-log axes, as shown in Figure 6.9B. Figure 6.9C 
shows that the data obtained from the three different assay methods are consistent for all the patient 
samples. An excellent linear correlation (R2 = 0.947) was obtained between the results from ACE-
LSPR intensity imaging-based analysis and ELISA measurements across both the spiked-in and 
patient samples for the IL-1 concentration ranging from 1pg/ml to 1000pg/ml (Figure 6.10).  
 
Figure 6.10 Correlation between data obtained from the ACE-LSPR and ELISA for both the spiked-in 
serum samples and patient samples with the IL-1β concentration ranging from 1 to 1000 pg/mL. 
 
We performed one-tailed paired difference t-tests between the two patient subgroups using the 
5-min initial slope data (Figure 6.9D). The result shows a significantly higher level of IL-1β 
(P<0.01) for the hyper-inflammatory subgroup as compared to the mild-inflammatory subgroup. 
This proves that the 5 min initial-slope assay can reliably distinguish the sepsis patients with either 
hyper-inflammatory or mild-inflammatory conditions. Although this initial-slope method could 
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potentially introduce some errors, the ultrafast assay time within 5 min offers unprecedented 
opportunities in clinical diagnosis to quickly determine the patients’ immune conditions and to 















Conclusions and Future Work 
 
7.1 Thesis Summary 
This thesis has developed two ultrafast novel cytokine immunoassay platforms: the PEdELISA 
platform and the label-free ACE-LSPR platform to advance precision medicine of life-threatening 
acute illnesses in critical care. We have successfully demonstrated their applications towards near-
realtime intervention of cancer immunotherapy, COVID-19, and sepsis-induced cytokine storm, 
which potentially allow clinicians to tailor the timing, frequency, and dose of the treatment 
specifically targeting the pathological origin. As a concluding remark, the PEdELISA platform 
holds great potential in the low-abundance protein profiling scenarios (121, 172) which require 
rapid turn-around, fine-time resolution, and low-sample volume by providing the combination of 
high speed, sensitivity, specificity, and multiplexity. Its low-cost and great inter-assay precision 
enable its application in daily monitoring of patient’s biomarker status near the bedside. But 
meanwhile, we also note that comparing to the plate-based multiplex platforms (e.g. Luminex), 
the throughput of the assay for retrospective analysis may still need to be further improved. As a 
label-free immunoassay, the ACE-LSPR platform holds great potential in the application that 
requires real-time monitoring of molecular binding event, such as cellular immune-phenotyping 
and cell-to-cell communication mapping (182, 204, 205), or the scenarios for rapid, simple-step 
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high abundance proteins (e.g. Human Immunoglobulins) screening test, such as the COVID-19 
antibody testing (206). The inherited limitation for assay’s specificity and the practical viability 
for mass production are still challenges to be addressed in future clinical translations. The 
accomplishments of the thesis are summarized in the following sections respectively. 
7.1.1 Rapid Single-molecule Digital Detection of Protein Biomarkers for Near-real-time 
Monitoring of Systemic Immune Disorders 
In this study, we have introduced a “quench and snapshot” digital immunoassay approach, 
PEdELISA, that achieved fast, sensitive, cost-effective, and sample-sparing multiplex protein 
biomarker detection. We envision that future implementation of the PEdELISA platform will 
enable point-of-care cytokine profile measurements to guide biomarker data-driven management 
of CRS and other acute immunological diseases. It can also enable analysis of protein biomarkers 
in mouse blood samples in a longitudinal fashion within the same animal, which has broad 
application in studies of animal models of disease.  
Digital protein assays have great potential to advance immunodiagnostics because of their 
single-molecule sensitivity, high precision, and robustness of the measurements. However, 
translating digital protein assays to acute clinical care has been challenging because existing 
technologies have a long turnaround time. Herein, we present a technology platform for ultra-fast 
digital protein biomarker detection by employing single-molecule counting of immune-complex 
formation events at an early, pre-equilibrium state. This method, which we term “pre-equilibrium 
digital enzyme-linked immunosorbent assay” (PEdELISA), can quantify a multiplexed panel of 
protein biomarkers in 10 µL serum within an unprecedented assay incubation time of 15-300 sec 
over a 104 dynamic range. PEdELISA allowed us to perform near-real-time monitoring of protein 
biomarkers in patients manifesting post-chimeric antigen receptor (CAR) T-cell therapy cytokine 
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release syndrome (CRS) with ~30 min serum sample to answer time and a ~1pg/mL limit of 
detection (LOD). The low input volume requirement also enabled high time-resolution, 
longitudinal serum cytokine measurement in a mouse model of sepsis. The rapid, sensitive and 
low input volume biomarker quantification enabled by PEdELISA is broadly applicable to timely, 
personalized management of acute disease in humans, as well as to longitudinal blood biomarker 
studies in various mouse models of disease. 
Early intervention in evolving critical illness requires “real-time” data with high sensitivity. 
We developed a near-bedside ultrafast multiplex digital immunoassay to quantify serum protein 
biomarkers in evolving systemic immune disorders. Our study indicates that single-molecule 
digital counting of antigen-antibody complex reaction quenched at its early pre-equilibrium stage 
can achieve unprecedented incubation times that are >1000x shorter than gold-standard ELISA 
with a clinically relevant dynamic range of 104 and a sample volume < 5 L. We applied the assay 
for real-time monitoring of sepsis biomarkers in mice and cytokines in leukemia patients with CRS 
due to CAR-T therapy. The captured biomarker dynamics manifest rapid feedback to drug 
treatment, which may guide individualized management with the optimal dose and timing of 
immunomodulatory interventions. 
7.1.2 Machine Learning-Based Cytokine Microarray Digital Immunoassay Analysis 
We expect that extending the multiplex capacity of digital immunoassay would greatly broaden 
its utility in the continuous monitoring of protein biomarkers for critically ill patients. However, 
multiplexing the assay becomes enormously difficult with an increasing number of target 
biomarkers. Multiplexed digital signal counting required over more than a few millions of fL-sized 
reactors with conventional methods experiences poor sample/reagent handling and declined 
accuracy due to various error sources. In this study, we developed a highly multiplexed digital 
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immunoassay platform, namely the PEdELISA microarray, to provide a promising solution for 
these challenges. The assay platform employs a unique combination of spatial-spectral encoding 
and machine learning-based image processing on a microfluidic chip. The positional registration 
of on-chip biosensing patterns, each with more than 40,000 microwell reactors confining sample 
sub-volumes, fluorescence-encoded analyte-capturing beads, and assay reagents, enabled 14-plex 
cytokine detection for 10 L of serum with high sample handling efficiency, small reagent loss, 
and negligible sensor cross talk. The signal processing and analysis of the 14-plexed PEdELISA 
microarray analysis employed a novel parallel computing CNN-based machine-learning 
algorithm. This algorithm achieved autonomous classification and segmentation of image features 
(e.g. microwells, beads, defects, backgrounds) at high throughput (1 min/analyte). Notably, it 
yielded 8-10 fold higher accuracy than the conventional GTS-based algorithm without any human-
supervised error correction.  
We ran the PEdELISA microarray measurement of human serum samples from patients who 
received CAR-T cancer therapy with an incubation time as short as 5 min. The assay 
simultaneously detected 14 cytokine biomarkers per sample with a clinically relevant dynamic 
range of pM-nM, and the entire assay process from sample loading to data delivery was completed 
within 30 min. We tested blood samples obtained from a CAR-T patient at different time points 
during the course of the therapy with the short assay turnaround. The longitudinal measurement 
proved the ability of our assay platform to continuously monitor a large number of cytokine 
profiles that were rapidly evolving in the circulatory system of a patient manifesting CRS. With 
its speed, sensitivity, multiplexing capacity, and sample-sparing capability, the PEdELISA 
microarray is poised for future translation to critical care medicine. This technology could be 
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applied for guiding the treatment of life-threatening illnesses caused by COVID-19 global 
pandemic to be timely and tailored with the patient’s comprehensive biomarker profiles.   
7.1.3 A Digital Protein Microarray for COVID-19 Cytokine Storm Monitoring 
Timely intervention of cytokine storm guided by rapid cytokine measurement is critical for the 
management of severe COVID-19 infections resulting in respiratory failure. To this end, we have 
developed a microfluidic digital immunoassay platform that enables rapid 4-plex measurement of 
cytokines in COVID-19 patient serum. Our assay employed single-molecule counting for an 
antibody sandwich immune-complex formation quenched at an early pre-equilibrium state. The 
pre-equilibrium approach resulted in a detection limit < 0.4 pg/mL and a linear dynamic range of 
103 while requiring a total assay incubation time as short as 10 min. The platform incorporates a 
programmed fluidic dispensing and mixing module and a compact optical reader module for 
microfluidic analysis using low-cost disposable chips manufacturable at a large scale. Each chip 
contains spatially encoded microwell array patterns with capture antibody-coated magnetic beads 
pre-deposited for multiplex cytokine detection. The 4-plex on-chip measurement with a 15 µL 
sample volume showed negligible sensor cross-talk. The programmed fluidic handling and mixing 
module permitted high inter-assay repeatability (~10% CV). Our assay platform with the 
combination of high sensitivity, speed, and fidelity allowed us to complete a whole cytokine 
profiling test from initial blood draw with critically ill COVID-19 patients to data delivery to 
physicians within 4 hours.  
This rapid cytokine assay was successfully implemented in real-time serial monitoring of two 
critically ill COVID-19 patients with severe cytokine storm and ARDS, and support their 
immunomodulatory therapies using the Selective Cytopheretic Device. Meanwhile, anti-IL6 
therapy in COVID-19 is under investigation in multiple clinical trials and has been employed in 
 142 
clinical practice as an off-label use. Preliminary results from trials of the anti-IL6 receptor antibody 
sarilumab have not demonstrated efficacy in moderately ill patients and trials continue in critically 
ill patients (207). Notably, our results here highlight the heterogeneity of cytokine response even 
among critically ill COVID-19 patients and the poor ability of surrogate inflammatory markers to 
predict an IL-6 response. These results confirm that rapid, reliable and repeatable direct cytokine 
measurement is needed to facilitate precision administration of anti-cytokine therapies only in 
patients who are experiencing cytokine storm. Our digital immunoassay platform may provide a 
promising means to enable such a precision medicine strategy in the pharmacotherapeutic 
management of life-threatening cytokine storm in COVID-19.  
7.1.4 AC Electroosmosis-enhanced Nano-plasmofluidic Detection of Ultra-low-
Concentration Cytokine 
In this study, we have uniquely integrated AC electroosmosis with nanoplasmonic microfluidic 
biosensors and demonstrated that effective electrohydrodynamic agitation in bulk solution can 
significantly improve the label-free sensing performance of the nanoplasmonic biosensors. The 
ACE-LSPR biofunctional nanoparticle imaging technique applied to our device has achieved 
femtomolar-level detection of IL-1β, a pro-inflammatory cytokine, in PBS buffer with assay time 
less than 15 min using a sample volume as small as 5 L. To the best of our knowledge, it is the 
most sensitive label-free nanoparticle-based plasmonic cytokine sensor reported so far. A 
compromised sensing performance is observed for the ACE-LSPR device when operating with 
high ion-concentration biological medium due to the augmented electrical screening effect. 
Nonetheless, we have successfully shown that 50% serum dilution still enables the ACE-LSPR 
device to retain its capability of enhancing the sensing speed and sensitivity even for complex 
human serum samples. Analyzing initial analyte binding curve slopes obtained from the ACE-
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LSPR measurements, we have successfully demonstrated a 5-min cytokine immunoassay for 
stratifying sepsis patients into statistically distinct inflammatory status groups. The significantly 
improved sensitivity and shortened assay time clearly indicate the promising potential of the ACE-
LSPR device for rapid screening and stratification of acute inflammatory diseases. Using micro-
inkjet printing and 3D-stage controlled micro-brush patterning for AuNR patterning and antibody 
conjugation, we may potentially scale up the manufacturing throughput of the current device. Our 
future development of a faster, cheaper and smaller CMOS photon detector together with a high 
NA air condenser would allow our ACE-LSPR devices to be integrated in a handheld system, 
which would enable point-of-care personalized treatment with timely, precise immunomodulatory 
drug delivery.  
7.2 Future Work 
My doctoral research aims to provide a technology-based solution to enable near real-time 
monitoring of the patient’s immune status and early interventions for severe cytokine storm. This 
thesis has proved the concept of the PEdELISA approach and demonstrated the preliminary setup 
of the platform for near-realtime monitoring the cytokine profiles of COVID-19 and CAR-T 
patients. The next critical steps toward the dissemination of PEdELISA to clinical research 
communities are to develop a fully automated, compact prototype instrument that can potentially 
be operated in a clinical lab using whole blood or even near the patient bedside. A low-cost mass-
producible PEdELISA cartridge will also be explored using hot embossing and laser cutting 
microfluidic methods. The future direction on the clinical side will be focused on utilizing the 
developed high-throughput instrumentation to massively collect fine-time resolution cytokine 
profile data from CAR-T patients and mouse model. The data, together with mRNA sequencing 
will be used to statistically identify time-series cytokine profile signatures that determine the early 
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onset of severe CRS and predict the trajectory of the illness for biomarker-guided therapeutic 
interventions, such as IL-6R antagonist (tocilizumab) and other immunomodulatory approaches.   
7.2.1 System Automation and Platform Translation.  
 
Figure 7.1 Preliminary test of the microwell fabrication on clear PMMA sheet using hot embossing method. 
The embossed the microwell diameter is 40 µm.   
Future work should be performed to design and manufacture a mass-producible low-cost 
microfluidic cartridge with interfaces for automated microfluidic handling. The PDMS-based 
fabrication is a standard technique in the microfluidic research field for fast-prototyping with 
advantages of low-cost and sub-micrometer molding resolution. However, the soft nature of this 
silicone-based material and the slow curing process made the PDMS unsuitable for mass 
production and interfacing with automated fluidic pumping instrument. Here, I will explore the 
fabrication of the microwell structure using PMMA sheet by hot embossing and microfluidic 
channels by laser cutting. Our preliminary results have shown the success of transferring a 2cm-
by-2cm microwell structure (d=40 µm) to the PMMA surface using a PDMS pillar array as the 
mold by heating to 125 °C for 10 min (Figure 7.1). Further in-depth tests will be performed to 
explore larger area pattern transfer (4-inch wafer) with smaller microwell sizes (e.g. d=4 µm) by 
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optimizing the embossing temperature, pressure, and mold type (e.g. PDMS, SU-8). Other 
materials like cyclic olefin copolymer will also be tested.  
 
Figure 7.2 (A) Illustration of PEdELISA microarray disk design for integrated blood plasma separation, 
collection, metering and downstream multiplex PEdELISA analysis. The fabricated PEdELISA microarray 
disk has a multilayer structure consisting of a top vent layer (PMMA), top pressure sensitive adhesive layer 
with microfluidic channels (PSA), middle micro-chamber layer for sample storage (PMMA), bottom 
adhesive layer with microfluidic channels (PSA) and, bottom microwell array layer (PMMA). (b) 
Illustration of integrated laser scanning optics for high-throughput PEdELISA fluorescence digital counting 
analysis. The scanning principle is similar to that of a conventional CD-type read head. 
Another direction of our future work is to further develop a fully automated, compact prototype 
instrument that can potentially be operated near-bedside. Lab-on-a-disk or centrifugal 
microfluidics has been proved to be promising for the development of commercial products for 
automated biochemical analysis (208-210). Although in Chapter 5, we have developed a 2-part 
semi-automated system for the COVID-19 study, the system’s automation and integration level 
are still quite limited with bulky fluidic pipetting required. Here, I propose to develop a 
microfluidic compact disk (CD) device, the “PEdELISA Microarray Disk”, which permits the 
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automated operations of blood plasma separation, reagent metering, PEdELISA assay on a 4-inch-
diameter CD cartridge (Figure 7.2A). The device will have primarily three functional components: 
(i) a blood plasma separator (ii) a PEdELISA assay reactor and (iii) a laser scanning disk reader. 
The plasma separator will allow for plasma (supernatant of whole blood) processing steps, 
including sample inlet, blood cell sedimentation and plasma separation in a separation chamber, 
and plasma transfer into a collection chamber. We will optimize the microfluidic chamber/channel, 
valve design and operational conditions of our plasma separator according to the sample volume 
and purity needed for our downstream analysis. The separated plasma will be metered and 
transferred to the PEdELISA assay reactor which permits multiplex cytokine detection. The 
programmable fluid transfer on the disk will be activated using passive control valves. More 
specifically, siphon valves and a series of Teflon coated hydrophobic valves (activation frequency 
frot 1< frot 2 <··,frot n) will be designed and tested. Finally, the digital signal counting will be achieved 
by the high-speed laser scanner with a feedback position tracking mechanism for the rotating disk 
(Figure 7.2B). The “0” and “1” nature of digital immunoassay and the small microwell size make 
the PEdELISA suitable for a high-throughput laser scanning readout like a CD, except that the 
readout has to be fluorescence-based scanning. Therefore, we will develop a customized 
fluorescence laser scanning optics for high-throughput PEdELISA digital counting. With a 
moderate disk rotation speed at 200 rpm, the estimated reading rate will be ~5000 well/sec which 
will allow us to complete the entire digital counting within 1-min. The anticipated cost for the 
instrumentation of the new system is much less than that of a bulky high-end system incorporating 
a fully automated robotic machine for sample/reagent handling (51). I also anticipate this generic 
platform will have broader applications not only for cytokine storm, but also for a variety of time-
sensitive critical illnesses, such as sepsis, systemic inflammatory response syndrome (SIRS), and 
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acute respiratory distress syndrome (ARDS). By designing and constructing a novel, compact, and 
mass-producible prototype instrument with a wide spectrum of potential applications will serve as 
the first step towards the future commercialization process. 
7.2.2 Biomarker-guided Clinical Study.  
For the CAR-T patient cytokine storm study, I will perform the multiplex analysis of 16 
cytokine biomarkers in serum specimens longitudinally collected from >30 CAR-T patients (~400 
samples) using the prototype instrument developed in the previous sections. This clinical study, 
which has already been IRB-approved (HUM00092161) and successfully initiated, collects serum 
longitudinally up to 5 times a week during pre-treatment, lymphodepleting chemotherapy, and 
CAR-T cell infusion stages, and the remainder of hospitalization (~2 weeks after CAR-T infusion). 
This is an on-going collaboration with the department of internal medicine which will focus on 
biomarker development for near-term prediction of severe CRS, enabling clinical trials for earlier 
interventions with IL-6R antagonist (tocilizumab) and other immunomodulatory therapeutic 
approaches. 
For the mouse septic model study, I will first verify a novel sepsis biomarker, Citrullination of 
histone H3 (CitH3), in mouse cecal ligation and puncture (CLP) model and then demonstrate a 
novel strategy of sepsis treatment guided by real-time biomarker profile data. Previous studies 
(134, 138) indicates that blood CitH3 shows high specificity and selectivity that can distinguish 
sepsis from noninfectious conditions and predict sepsis outcomes. The pathological link between 
CitH3 and sepsis opens up a promising opportunity to establish a precise sepsis screening 
technique. Here, our treatment strategy is the double blockade of PAD-CitH3 pathway by blocking 
both intracellular PAD activity and extracellular circulating CitH3 with the hypothesis that this 
strategy will synergistically improve outcomes of sepsis (Figure 7.3) 
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Figure 7.3 Double blockade of PAD-CitH3 pathway for the treatment of sepsis. PAD citrullinates H3 to 
produce CitH3; CitH3 triggers neutrophil extracellular traps (NETs) cell death (NETosis) to release nuclear 
contents, which forms a “vicious cycle” (left panel). PAD inhibitor with specific monoclonal anti-CitH3 
antibody (Ab) for neutralization of circulating CitH3 (double block, right panel) can suppress PAD-CitH3 
pathway and promote survival. TLR: Toll-like receptor; MPO: Myeloperoxidase; MyD88: Myeloid 
differentiation primary response gene 88; WT: wild type; KO: Knockout. 
 
Briefly, we will first develop a 6-plex mouse biomarker panel which includes four cytokines: 
IL-6, TNF-α, IL-1β and IL-10, a widely used sepsis clinical marker procalcitonin (PCT) and the 
novel marker CitH3. We will then perform multi-time-point PEdELISA measurements of the 6 
biomarkers from two groups of mice: 1) sham; 2) CLP (septic shock; ligated at 50%, 75%, and 
100% of the total cecum length) mice and obtain high-resolution temporal biomarker profiles. 
Lastly, we will carry out the “double blockade of PAD-CitH3 pathway” study. Mice will be subject 
to various groups treated with different drugs, such as PAD inhibitor, Anti-CitH3 monoclonal 
antibody, or both etc. The drug(s) in each group will be administered at any measurement time 
point if the real-time CitH3 profile measured by PEdELISA reaches or exceeds the threshold value 
(in human patients it is 79 pg/mL for circulating CitH3) determined for each time point and the 
results represent novel CitH3-guided real-time interventions. We will monitor the survival rate and 
compare the therapeutic outcomes among them. The mice treated with vehicle serve as a control. 
Successful completion of this study will provide evidence that identifies biomarker-guided CitH3 
blocking as a novel therapy for sepsis in a critical care setting which potentially supports a future 






Appendix A.   CAR-T patient clinical information  
Patient A: Blood collection summary. 
Subject ID Day # Serum Clot 
Time (min) 
SC06 Baseline 42 
SC06 -2 90 
SC06 0 51 
SC06 1 80 
SC06 2 33 
SC06 5 35 
SC06 6 31 
SC06 7 31 
SC06 8 40 
SC06 9 30 
SC06 13 47 
SC06 14 38 
SC06 15 40 
SC06 16 58 
 
Patient A: Clinical intervention summary. 




Tocilizumab (ACTEMRA) 1 - 720 mg Intravenous 
Tocilizumab (ACTEMRA) 7 - 800 mg Intravenous 
Tocilizumab (ACTEMRA) 7 - 800 mg Intravenous 
     
Infliximab (REMICADE) 8 - 1100 mg Intravenous 
Infliximab (REMICADE) 11 - 500 mg Intravenous 
     
Methylprednisone 7 - 1000 mg Intravenous 
Methylprednisone 8 - 1000 mg Intravenous 
Methylprednisone 9 - 1000 mg Intravenous 
Dexamethasone (DECADRON) 11-16 Every 6 hrs 10 mg Intravenous 
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Patient B: Blood collection summary                    Patient C: Blood collection summary 
Subject ID Day # 
Serum Clot 
Time (min) 
SC02 Baseline 52 
SC02 0 121 
SC02 1 47 
SC02 3 60 
SC02 9 45 
SC02 11 33 
SC02 14 36 
SC02 15 36 
SC02 17 68 
SC02 24 60 
SC02 31 57 




Patient B: Clinical intervention summary 




Tocilizumab (ACTEMRA) 2 - 800 mg Intravenous 
Tocilizumab (ACTEMRA) 4 - 800 mg Intravenous 
Tocilizumab (ACTEMRA) 5 - 800 mg Intravenous 
          
Dexamethasone (DECADRON) 6 Every 6 hrs 8 mg Intravenous 
Dexamethasone (DECADRON) 7-11 Every 6 hrs 10 mg Intravenous 
 
Patient C: Clinical intervention summary 
Patient C Day # 
Administer 
Time 
Dose Administer Type 
Dexamethasone (DECADRON) 9-32 Every 6 hrs 10 mg Intravenous 
  
Subject ID Day # 
Serum Clot 
Time (min) 
SC05 Baseline 42 
SC05 0 50 
SC05 1 50 
SC05 3 46 
SC05 7 55 
SC05 9 35 
SC05 11 45 
SC05 14 30 
SC05 21 32 
SC05 23 32 
SC05 28 51 
SC05 35 50 
SC05 38 40 
SC05 43 33 
SC05 50 45 
 151 
Appendix B.   Procedures of PEdELISA Cytokine Measurement for COVID-19 Patients 
 
Section 1. Multiplex Chip Patterning 
Safety Protection: 
 PPE: Lab coat, single layer surgical face mask, safety glasses, single layer nitrile exam gloves 
 Only 1 person is needed (the other person stay 6-feet away for emergency help) 
 Perform all the procedures on the wet bench 
 No biohazard is generated for this section, standard waste collection. 
Reagent Prep: 
 EtOH – 1.5 mL in Eppendorf Tube 
 Reagent PBST – 2 mL in Eppendorf Tube 
 Superblock – 1.5 mL in Eppendorf Tube 
 Capture Ab Beads. Stock is in 4C glass door fridge in COVID-19 box. 
 IL-1B, TNF-a, IL-10, IL-6 BEADS – Dilute beads in 0.6mL Tube.  
o All:  4uL stock +21uL PBST 
Procedure: 
1. Clean and attach a multiplex loading channel to a NEW multiplex chip.  
2. Wet the channels with PBST 
3. Load Beads 





b. Check beads quality on microscope 
c. If loading is good, gently wash each channel with 200uL PBST changing tip each time 
4. Change to sample loading channel and seal 
a. Load PBST into each loading channel slowly 
5. Load 100uL superblock into each channel. Cover inlet and outlet with a cap. No need to change 
tip. 
6. Incubate for at least 1 hour (or 4C over-night for the next day assay) 
 
Section 2. Assay Preparation 
Safety Protection: 
 PPE: Lab coat, single layer surgical face mask, safety glasses, single layer nitrile exam gloves, 
protection disposable bouffant caps 
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 Two people are needed: stay 6-feet away from each other 
 Perform all the procedures on the wet bench 
 No biohazard is generated for this section, standard waste collection. 
 Turn on the UV light in the biosafety cabinet at least 1hr before the assay for sterilization 
Transfer COVID-19 Patient Sample to the biocabinet (right after received!):  
 Wear all the PPE required plus double gloves 
 Spray 75% EtOH on the biosafety cabinet surface, and sample bag/box surface (unopened) 
 Place the unopened sample bag/box into the cabinet on Wet ice (0C) 
  Change gloves! Do not open the sample bag/box during this entire section!!! 
Reagents Needed: 
 100uL 100% FBS Aliquot (Frozen, -20C) 
 Detection antibody cocktail stock (4-plex, 4C) 
 Antigen cocktail stock (10ng/mL, 4-plex, -80C) 
 HRP Stock (4C) 
 Superblock (4C) 
 0.1% BSA Buffer (4C) 
Procedure: 
1. Label a 4x8 tube rack: assay standard unit: pg/mL 
1         
2         









4         
 
2. Add 20uL sterilized FBS from FBS COV aliquots to each standard in row 3 
3. Perform serial dilution: (Mix 30x with pipette each time, do not change tip) 
a. Add 5uL antigen cocktail to 1000 pg/mL standard 
b. Take 5uL from 1ng and add to 200 pg/mL 
c. Take 5uL from 200 and add to 40 pg/mL 
d. Take 5 uL from 40 ng and add to 8 pg/mL 
4. Add 15 uL Detection antibody cocktail stock to each tube in row 4 
5. Dilute HRP 2.5uL stock + 372.5uL Superblock. Add 45uL to each tube. 
6. Leave the Sample 1-4 empty for the next section 







Section 3. Assay 
Safety Protection: 
 PPE: Disposable Lab coat, Double-layer surgical face mask (N95 mask is strongly suggested 
for this section if available), safety glasses, face shield, nitrile exam glove (as an inner layer), 
long latex gloves (as the outer layer, seal the lab coat cuff), protection disposable bouffant 
caps, Protective Polyethylene Sleeve Covers, Shoe cover (if available) 
 Two people are needed! Later referred as USER and HELPER 
 Perform all the procedures inside the biosafety cabinet 
 COVID-19 patient biohazards are generated in this section, biohazard waste collection. 
Biocabinet Prep: 
 Check all the reagents, washing buffer tray, and patient samples stored in the biosafety 
cabinet 
 Biowaste disposal bag in hood with enough room 
 Paper towels in hood 
 Hospital-grade disinfectant wash beaker in hood 
 Plastic cup for wash lines 
 A single 20uL pipette and three multi-pipettes in hood 
 Prepare automated PEdELISA system:  
1. Motor power OFF, Arduino power (USB) OFF  
2. MultiCH-pipette set to 28.5uL.  
3. Reset motor starting location to the pipette plunger.  
4. Motor power ON 
5. Attaches sample loading lines. 
Procedure: 
1. Add 15uL patient samples (determine dilution ratio here!) to tube rack using 20uL gray pipette 
2. Use a multichannel pipette to take 15uL from sample row and add to DeAb row. Mix 20x. 
3. Start the automated system Arduino. 
4. 10 second delay, then the system presses multichannel pipette plunger down 
5. Plugin mixer lines to tube rack. The system draws up sample. 
6. Plug into the chip. 
7. Samples are dispensed into the chip. WIPE AWAY caps at the outlet side. IMMEDIATELY 
Spray EtOH on it and discard it into the biowaste bag. 
8. Samples are mixed on-chip (for 8 minutes).  
9. Mixer pushes the plunger halfway when done. Unplug mixer lines. 
10. Insert washing lines. 
11. 2 min washing start 
12. After washing the system pusher will move back. USER adjusts the multichannel pipette to 40uL 
and ejects sample lines. (5 min) 
a. Immediately immerse the sample lines in a disinfectant beaker (75% EtOH) 
b. Install HRP lines to mixer 
13. The system pushes down on pipette.  
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14. Plugin HRP lines into HRP tube row. The system draws up HRP. 
15. DISCARD tube rack and plugin HRP lines to chip 
16. The system quickly dispenses enough volume to displace PBST. Wipe away caps. 
17. The system microsteps HRP into the device.  
18. Microstepping is done after 1 min. Remove HRP lines and insert washing lines 
19. Wash for 5 min.  
20. During the wash, remove HRP lines and wash in disinfectant. Give both lines to HELPER to 
wash 5x in EtOH and DI water. Clean up the rest of the biosafety hood. HELPER leaves to turn 
on the PEdELISA reader and begin quanta red prep. 
21. After the wash is done, leave the chip inside the hood, and wait for the QuantaRed reagent 
loading (prepared by the HELPER in the next section)   
 
Section 4. Reagents Preparation for Imaging 
Safety Protection: 
 PPE: Continue the PPE from the previous section!  
 Two people are needed: stay 6-feet away from each other 
 Perform all the procedures on the wet bench 
 No biohazard is generated for this section, standard waste collection. 
Reagent Prep: 
 QuantaRed Kit 
 1x PBS (not PBST!) 
 HFE Oil 
Equipment Prep: 
 Turn on the PEdELISA reader, including light source, cameras, the scanning stage (UGS) and 
creating file path 
Procedure 
Done by HELPER during final assay wash (wet bench): 
1. Add 100uL PBS to a 1.5mL tube 
2. From Quanta Red Kit: 
a. Add 100uL H2O2 from glass bottle aliquot 
b. Add 100uL QRED enhancer from foil-covered aliquot 
c. Add 2uL QRED ADHP from foil-covered aliquot 
3. Vortex well 
4. Bring the QuantaRed solution and HFE Oil to the biosafety hood for the USER 
The following will be Done by the USER (biosafety cabinet!) 
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At quick but controlled speed: 
1. Add 30uL Quanta Red Solution to each channel (the chip) in order of imaging 
2. Seal with 35uL oil into each channel in order of imaging 
3. Cover inlets and outlets  
4. Place the chip inside a petri dish and transfer it to the optics room. 
Done by HELPER: while the USER is doing the imaging 
1.  Clean remaining surfaces in biosafety hood and turn on UV for >1 hour. 
2. Spray 75% EtOH on all the biohazard’s waste, seal the bag carefully and took them outside the 
biocabinet for autoclave. 
3. Change gloves, take off the face shield but keep all the other PPE on!  
4. Go and check if the USER need any help 
 
 
Section 5. Image and Data Analysis 
Safety Protection: 
 PPE: Continue the PPE from the previous section! Except for no face shield 
 Two people are needed: stay 6-feet away from each other 
 Perform all the procedures on the wet bench 
 The assay chip is the only biohazard that needs to be collected.  
Procedure: 
1. Set camera parameters: ISO 3200, Large, 1/8 sec EXP 
2. Create a new file folder with assay date labeled on google drive 
3. Save sensor spot positions: MATLAB code and UGS 
4. Acquire fluorescence images 
5. Acquire bright-field images 
6. Run convolutional neural networks on the data (stored in the cloud) 
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